{"title":"Farmaci e Pastiglie per il Mal di Gola","description":"\u003cp\u003ePer la gola infiammata e il dolore quando si deglutisce: spray e collutori antinfiammatori con flurbiprofene e benzidamina, pastiglie da sciogliere in bocca con antisettici o principi vegetali, propoli in spray. Formati anche senza zucchero. Spedizione veloce in 24\/48 ore.\u003c\/p\u003e","products":[{"product_id":"propoli-spray-forte-tintura-madre-propoli-30ml-dr-tili","title":"Propolis Spray Strong propolis mother tincture 30ml Dr.Tili","description":"\u003cp data-mce-fragment=\"1\"\u003e\u003cimg height=\"125\" width=\"125\" alt=\"Supplement made in Italy\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\" style=\"float: none;\" data-mce-style=\"float: none;\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_glutine_480x480.png?v=1668012159\" alt=\"gluten-free supplement\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_glutine_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_lattosio_480x480.png?v=1668012159\" alt=\"lactose-free supplement\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_lattosio_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ingredienti_vegani_480x480.png?v=1668012159\" alt=\"vegan supplement\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ingredienti_vegani_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e  \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003ePropolis spray Forte is a highly titrated phytotherapeutic extract obtained from \u003cstrong\u003efresh mother tincture of propolis\u003c\/strong\u003e with the addition of \u003cstrong\u003eeucalyptus essential oil\u003c\/strong\u003e which enhances its activity. Useful in case of \u003cstrong\u003esore throat\u003c\/strong\u003e, \u003cstrong\u003ecold\u003c\/strong\u003e, \u003cstrong\u003eseasonal flu and inflammation of the oral cavity\u003c\/strong\u003e. The particular formulation of Propoli Spray Forte guarantees the stability of the active ingredient over time. His \u003cstrong\u003eparticular density\u003c\/strong\u003e \u003cstrong\u003eimproves adhesion\u003c\/strong\u003e of the substance \u003cstrong\u003eto the mucous membranes\u003c\/strong\u003e for a prolonged action. Propolis strong spray contains alcohol and eucalyptus essential oil, which make it \u003cstrong\u003ealso useful in case of canker sores, gingivitis and abscesses\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003epropolis\u003c\/strong\u003e it is a natural substance produced by bees to insulate hive cells. It thus limits the entry of air, water, bacteria, viruses and pathogens. It appears as a gummy, sticky and water-insoluble resin. It can be made up of over 200 different compounds including resins, wax, essential oils, pollen, flavonoids, organic compounds, mineral salts, vitamins and other elements. Its composition depends on the type of vegetation from which the bees obtain the starting material to synthesize it.\u003c\/p\u003e\n\u003cp\u003eProperties are attributed to propolis \u003cstrong\u003enatural antiviral and antibacterial\u003c\/strong\u003e, anti-inflammatory and immunostimulant. These are due in particular to the presence of \u003cstrong\u003eflavonoids\u003c\/strong\u003e (Galangina and Pinocembrina). Propolis is traditionally \u003cstrong\u003econsidered a natural antibiotic\u003c\/strong\u003e. It can inhibit the ability of bacteria to reproduce and naturally disinfect the mucous membranes and oral cavity. It is useful in case of burning throat and inflammation of the upper respiratory tract such as pharyngitis, laryngitis. Propolis is also a natural antiviral useful against \u003cstrong\u003eviruses that cause the common flu\u003c\/strong\u003e seasonal.\u003cbr\u003eIndicated in case of: sore throat, flu, cold, canker sores, abscesses, gingivitis, pharyngitis, laryngitis, burning throat.\u003c\/p\u003e\n\u003cp\u003eThe\u003cstrong\u003eeucalyptus essential oil\u003c\/strong\u003e extracted from eucalyptus leaves it is rich in \u003cstrong\u003eeucalyptol\u003c\/strong\u003e, to which strong natural germicidal properties are attributed. Eucalyptol helps in case of pain and inflammation of the mucous membranes of the oral cavity with its \u003cstrong\u003ebalsamic power,\u003c\/strong\u003e also due to \u003cstrong\u003ecanker sores and abscesses\u003c\/strong\u003e. Thanks to its balsamic and antiseptic properties, eucalyptus essential oil is an excellent ally for dealing with sore throats. In fact, when the first symptoms of pharyngitis or laryngitis appear, eucalyptus takes advantage of its \u003cstrong\u003edecongestant and emollient power\u003c\/strong\u003e to counteract infection by viruses or bacteria.\u003cbr\u003eIndicated in case of: fever, flu, aphthous stomatitis, bronchitis, sinusitis\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy do you use Propoli Spray Forte propolis mother tincture 30ml Dr.Tili? What is it for?\u003c\/h3\u003e\u003cp\u003eHighly titrated phytotherapeutic extract from the propolis mother tincture with eucalyptus essential oil, useful in case of sore throat, colds, seasonal flu and inflammation of the oral cavity, including canker sores and gingivitis.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Propolis Spray Forte propolis mother tincture 30ml Dr.Tili contain?\u003c\/h3\u003e\u003cp\u003eWaterfall. Glycerol. Propolis hydroalcoholic extract (45% vol. alc.). Sweetener: fructose. Flavoring: eucalyptus essential oil, mint essential oil\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Propoli Spray Forte propolis mother tincture 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003e2 sprays of Propolis Spray Forte propolis mother tincture 3 times a day. Any sediments are considered normal. Shake well before use.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Propoli Spray Forte propolis mother tincture 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003eDo not exceed the indicated intake quantities. Supplements are not intended as substitutes for a varied, balanced diet and a healthy lifestyle. The product is contraindicated in subjects predisposed to allergies, in particular to pollen and bee products, and in atopic or asthmatic subjects. Do not use during pregnancy. Keep out of reach of children under 3 years.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Propoli Spray Forte propolis mother tincture 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003e30ml\u003c\/p\u003e","brand":"Tilab","offers":[{"title":"Default Title","offer_id":40207819669619,"sku":"975044241","price":11.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/tilab-srl-propoli-spray-forte-tintura-madre-propoli-30ml-dr-tili-farmacia-dottor-tili-1213792869.jpg?v=1767123851"},{"product_id":"propoli-spray-hd-fragola-30ml-dr-tili","title":"Propolis Spray HD Strawberry 30ml Dr.Tili","description":"\u003cp data-mce-fragment=\"1\"\u003e\u003cimg height=\"125\" width=\"125\" alt=\"Supplement made in Italy\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\" style=\"float: none;\" data-mce-style=\"float: none;\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_glutine_480x480.png?v=1668012159\" alt=\"gluten-free supplement\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_glutine_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_lattosio_480x480.png?v=1668012159\" alt=\"lactose-free supplement\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_lattosio_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ingredienti_vegani_480x480.png?v=1668012159\" alt=\"vegan supplement\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ingredienti_vegani_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e  \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003ePropoli Spray HD Strawberry is a supplement based on highly titrated phytotherapeutic extract of propolis. Useful in case of \u003cstrong\u003esore throat\u003c\/strong\u003e, \u003cstrong\u003ecold\u003c\/strong\u003e, \u003cstrong\u003eseasonal flu symptoms\u003c\/strong\u003e e \u003cstrong\u003einflammation of the oral cavity\u003c\/strong\u003e. The particular formulation of Propolis Spray guarantees the stability of the active ingredient over time. His \u003cstrong\u003eparticular density\u003c\/strong\u003e improves the\u003cstrong\u003eadhesion of the substance to the mucous membranes\u003c\/strong\u003e for a prolonged action. Its excellent \u003cstrong\u003estrawberry flavour\u003c\/strong\u003e and the \u003cstrong\u003ealcohol-free formulation\u003c\/strong\u003e they make it \u003cstrong\u003esuitable for children\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003epropolis\u003c\/strong\u003e it is a natural substance produced by bees to insulate hive cells. It thus limits the entry of air, water, bacteria, viruses and pathogens. It appears as a gummy, sticky and water-insoluble resin. It can be made up of over 200 different compounds including \u003cstrong\u003eresins, wax, essential oils, pollen, flavonoids, organic compounds, mineral salts, vitamins\u003c\/strong\u003e and other elements. Its composition depends on the type of vegetation from which the bees obtain the starting material to synthesize it.\u003c\/p\u003e\n\u003cp\u003eProperties are attributed to propolis \u003cstrong\u003enatural antiviral and antibacterial\u003c\/strong\u003e, anti-inflammatory and immunostimulant, due in particular to the presence of \u003cstrong\u003eflavonoids\u003c\/strong\u003e (Galangina and Pinocembrina). Propolis is traditionally considered a \u003cstrong\u003enatural antibiotic\u003c\/strong\u003e which can inhibit the ability of bacteria to reproduce e \u003cstrong\u003enaturally disinfect the mucous membranes and oral cavity\u003c\/strong\u003e. It proves useful in case of \u003cstrong\u003eburning in the throat\u003c\/strong\u003e and inflammation of the upper respiratory tract such as pharyngitis, laryngitis. Propolis is also a \u003cstrong\u003enatural antiviral\u003c\/strong\u003e useful against viruses that cause the common seasonal flu.\u003cbr\u003eIndicated in case of: sore throat, flu, cold, pharyngitis, laryngitis, burning throat.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy should you use Propolis Spray HD Strawberry 30ml Dr.Tili? What is it for?\u003c\/h3\u003e\u003cp\u003eSupplement based on propolis extract, useful in case of sore throat, colds and seasonal flu disorders, with soothing action on the mucous membranes of the oral cavity; strawberry flavor and alcohol-free formulation, also suitable for children.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Propolis Spray HD Strawberry 30ml Dr.Tili contain?\u003c\/h3\u003e\u003cp\u003ePurified water. Poloxamer. Propolis d.e. 4:1. Preservative: potassium sorbate. Sweetener: sucralose, glycerinised ammonium, natural strawberry flavor (1.1%).\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eMEDIA ANALYSIS\u003c\/h2\u003e\n\u003ch3\u003eWhat does Dr.Tili Propolis Spray HD Strawberry 30ml contain?\u003c\/h3\u003e\u003cp\u003ePropolis d.e.: 100 mg.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Propolis Spray HD Strawberry 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003e2 sprays of Propolis Spray HD Strawberry 3 times a day. any sediments are considered normal, shake well before use\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Propolis Spray HD Strawberry 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003eDo not exceed the indicated intake quantities. Supplements are not intended as substitutes for a varied, balanced diet and a healthy lifestyle. The product is contraindicated in subjects predisposed to allergies, in particular to pollen and bee products, and in atopic or asthmatic subjects. Do not use during pregnancy. Keep out of reach of children under 3 years.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Propolis Spray HD Strawberry 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003e30ml\u003c\/p\u003e","brand":"Tilab","offers":[{"title":"Default Title","offer_id":40207819702387,"sku":"975044239","price":11.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/tilab-srl-propoli-spray-hd-fragola-30ml-dr-tili-farmacia-dottor-tili-1213792876.jpg?v=1767123910"},{"product_id":"propoli-spray-hd-limone-30ml-dr-tili","title":"Propolis Spray HD Lemon 30ml Dr.Tili","description":"\u003cp data-mce-fragment=\"1\"\u003e\u003cimg height=\"125\" width=\"125\" alt=\"Supplement made in Italy\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\" style=\"float: none;\" data-mce-style=\"float: none;\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_glutine_480x480.png?v=1668012159\" alt=\"gluten-free supplement\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_glutine_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_lattosio_480x480.png?v=1668012159\" alt=\"lactose-free supplement\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_lattosio_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ingredienti_vegani_480x480.png?v=1668012159\" alt=\"vegan supplement\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ingredienti_vegani_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e  \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003ePropoli Spray HD Lemon is a supplement based on a titrated phytotherapeutic extract of propolis. Useful in case of \u003cstrong\u003esore throat, cold, seasonal flu symptoms and inflammation of the oral cavity\u003c\/strong\u003e. The particular formulation of Propolis Spray guarantees the stability of the active ingredient over time. His \u003cstrong\u003eparticular density\u003c\/strong\u003e improves the\u003cstrong\u003eadhesion of the substance to the mucous membranes\u003c\/strong\u003e for a prolonged action. Its excellent \u003cstrong\u003elemon flavour\u003c\/strong\u003e and the \u003cstrong\u003ealcohol-free formulation\u003c\/strong\u003e they make it \u003cstrong\u003esuitable for children\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003ePropolis is a natural substance produced by bees to insulate hive cells. It thus limits the entry of air, water, bacteria, viruses and pathogens. It appears as a gummy, sticky and water-insoluble resin. It can be made up of over 200 different compounds including \u003cstrong\u003eresins, wax, essential oils, pollen, flavonoids, organic compounds, mineral salts, vitamins\u003c\/strong\u003e and other elements. Its composition depends on the type of vegetation from which the bees obtain the starting material to synthesize it.\u003c\/p\u003e\n\u003cp\u003eProperties are attributed to propolis \u003cstrong\u003enatural antiviral and antibacterial\u003c\/strong\u003e, anti-inflammatory and immunostimulant, due in particular to the presence of \u003cstrong\u003eflavonoids\u003c\/strong\u003e (Galangina and Pinocembrina). Propolis is traditionally considered a \u003cstrong\u003enatural antibiotic\u003c\/strong\u003e which can inhibit the ability of bacteria to reproduce e \u003cstrong\u003enaturally disinfect the mucous membranes and oral cavity\u003c\/strong\u003e. It proves useful in case of \u003cstrong\u003eburning in the throat\u003c\/strong\u003e and inflammation of the upper respiratory tract such as pharyngitis, laryngitis. Propolis is also a \u003cstrong\u003enatural antiviral\u003c\/strong\u003e useful against viruses that cause the common seasonal flu.\u003cbr\u003eIndicated in case of: sore throat, flu, cold, pharyngitis, laryngitis, burning throat.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy should you use Propolis Spray HD Lemon 30ml Dr.Tili? What is it for?\u003c\/h3\u003e\u003cp\u003eSupplement based on propolis extract, useful in case of sore throat, colds and seasonal flu disorders, with soothing action on the mucous membranes of the oral cavity; lemon flavor and alcohol-free formulation, also suitable for children.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Propolis Spray HD Lemon 30ml Dr.Tili contain?\u003c\/h3\u003e\u003cp\u003ePurified water. Poloxamer. Propolis d.e. 4:1. Preservative: potassium sorbate. Sweetener: sucralose, glycerinized ammonium, lemon natural flavor (1.1%).\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eMEDIA ANALYSIS\u003c\/h2\u003e\n\u003ch3\u003eWhat does Dr.Tili Propolis Spray HD Lemon 30ml contain?\u003c\/h3\u003e\u003cp\u003ePropolis d.e.: 100 mg.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Propolis Spray HD Lemon 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003e2 sprays of Propolis Spray HD Lemon 3 times a day, any sediments are considered normal, shake well before use\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Propolis Spray HD Lemon 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003eDo not exceed the indicated intake quantities. Supplements are not intended as substitutes for a varied, balanced diet and a healthy lifestyle. The product is contraindicated in subjects predisposed to allergies, in particular to pollen and bee products, and in atopic or asthmatic subjects. Do not use during pregnancy. Keep out of reach of children under 3 years.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Propolis Spray HD Lemon 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003e30ml\u003c\/p\u003e","brand":"Tilab","offers":[{"title":"Default Title","offer_id":40207819767923,"sku":"975044177","price":11.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/tilab-srl-propoli-spray-hd-limone-30ml-dr-tili-farmacia-dottor-tili-1213792863.jpg?v=1767124007"},{"product_id":"propoli-gocce-essenziali-dr-tili","title":"Propolis Essential Drops 50ml Dr.Tili","description":"\u003cp\u003e\u003cimg style=\"float: none;\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\" alt=\"Supplement made in Italy\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\" data-mce-style=\"float: none;\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg height=\"125\" width=\"125\" alt=\"gluten-free supplement\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_glutine_480x480.png?v=1668012159\" data-mce-fragment=\"1\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_glutine_480x480.png?v=1668012159\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg height=\"125\" width=\"125\" alt=\"lactose-free supplement\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_lattosio_480x480.png?v=1668012159\" data-mce-fragment=\"1\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_lattosio_480x480.png?v=1668012159\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg height=\"125\" width=\"125\" alt=\"vegan supplement\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ingredienti_vegani_480x480.png?v=1668012159\" data-mce-fragment=\"1\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ingredienti_vegani_480x480.png?v=1668012159\"\u003e\u003cspan\u003e  \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003ePropoli Gocce Essenziale is a supplement in drops based on phytotherapeutic propolis extract. Useful in case of seasonal ailments such as \u003cstrong\u003esore throat, cold and inflammation of the oral cavity\u003c\/strong\u003e. The high-titration phytotherapeutic extract of Propolis Essential Drops is rigorously stored in cobalt blue glass bottles. This preserves its quality and avoids degradation due to exposure to light. Its sweet flavor makes it pleasant and suitable for children too.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003epropolis\u003c\/strong\u003e it is a natural substance \u003cstrong\u003eantiseptic produced by bees\u003c\/strong\u003e to isolate the hive cells. It thus limits the entry of air, water, bacteria, viruses and pathogens. It appears as a gummy, sticky and water-insoluble resin. It can be made up of over 200 different compounds including resins, wax, essential oils, pollen, flavonoids, organic compounds, mineral salts, vitamins and other elements. Its composition depends on the type of vegetation from which the bees obtain the starting material to process it and for this reason it varies in color and flavour. \u003c\/p\u003e\n\u003cp\u003eThey are attributed to propolis \u003cstrong\u003enatural antiviral, antibacterial, anti-inflammatory and immunostimulant properties, \u003c\/strong\u003eall due in particular to the presence of flavonoids (Galangina and Pinocembrina). Thanks to its composition, \u003cstrong\u003epropolis is considered a natural antibiotic\u003c\/strong\u003e. It can inhibit the ability of bacteria to reproduce and naturally disinfects the mucous membranes and oral cavity. It is very useful in case of burning throat and inflammation of the upper respiratory tract such as pharyngitis, laryngitis. It is also used in case of canker sores, abscesses and gingivitis.\u003c\/p\u003e\n\u003cp\u003ePropolis is also \u003cstrong\u003ea natural antiviral useful in case of influenza and para influenza viruses\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy should you use Propolis Essential Drops 50ml Dr.Tili? What is it for?\u003c\/h3\u003e\u003cp\u003eIndicated in case of: sore throat, flu, canker sores, gingivitis, colds, pharyngitis, laryngitis, burning throat.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Propolis Essential Drops 50ml Dr.Tili contain?\u003c\/h3\u003e\u003cp\u003ePurified water. Propolis d.e. soluble hrd 4:1. Sweetener: sucralose. Preservative: potassium sorbate.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eMEDIA ANALYSIS\u003c\/h2\u003e\n\u003ch3\u003eWhat does Propolis Essential Drops 50ml Dr.Tili contain?\u003c\/h3\u003e\u003cp\u003ePropolis: 30 mg.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Propolis Essential Drops 50ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003eTake 25 gtt of Propolis Essential Drops 3 times a day.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Propolis Essential Drops 50ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003eDo not exceed the indicated intake quantities. However, the product should not be used in case of liver dysfunction or disease. Do not use during pregnancy, supplements should not be intended as substitutes for a varied, balanced diet and a healthy lifestyle. Keep out of reach of children under 3 years.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Propolis Essential Drops 50ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003e50ml\u003c\/p\u003e","brand":"Tilab","offers":[{"title":"Default Title","offer_id":40207820685427,"sku":"973603133","price":15.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/tilab-srl-propoli-gocce-essenziali-50ml-dr-tili-farmacia-dottor-tili-1213792812.jpg?v=1767124990"},{"product_id":"benagol-miele-e-limone-36-pastiglie-mal-di-gola","title":"Benagol Honey and Lemon 36 Tablets Sore Throat","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAntiseptic of the oral cavity.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBENAGOL Ginger and Spice flavored tablets Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), spice flavoring and ginger flavoring (containing cinnamale, citral, citronellol, eugenol, farinasol, geraniol, isoeugenol and linalool). BENAGOL Honey and Lemon flavored tablets Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid glucose (containing sulphites and wheat starch), liquid sucrose, mint essence and lemon essence (containing citral, d-limonene, geraniol and linalool), honey (invert sugar). BENAGOL Sugar-Free Lemon Flavor Lozenges Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid maltitol, isomalt, lemon flavoring (containing benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool). BENAGOL Strawberry flavor tablets without sugar Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid maltitol, isomalt, strawberry flavor (containing propylene glycol and benzyl alcohol). BENAGOL Cold Mint flavor tablets Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), mint flavor and eucalyptus essence (containing propylene glycol, benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool). BENAGOL Menthol-Eucalyptol flavor tablets Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg; menthol 8.0 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch) and eucalyptus essence (containing d-limonene). BENAGOL Tablets with Vitamin C Orange flavor Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg; sodium ascorbate 74.9 mg; ascorbic acid 33.5 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), orange flavor (containing citral, citronellol, d-limonene, geraniol, linalool), propylene glycol. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eBENAGOL Ginger and Spice flavored tablets\u003c\/u\u003e: One tablet contains: liquid sucrose, liquid glucose (containing sulphites and wheat starch), tartaric acid, anthocyanins (E163) (containing sodium), plum flavour, cream flavour, spice flavor and ginger flavor (containing cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool), medium-chain saturated triglycerides. \u003cu\u003eBENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e: One tablet contains: mint essence and lemon essence (containing citral, d-limonene, geraniol and linalool), tartaric acid, honey (invert sugar), liquid glucose (containing sulphites and wheat starch), liquid sucrose. \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets\u003c\/u\u003e: One tablet contains: indigo carmine (E 132) (containing sodium), eucalyptus essence (containing d-limonene), tartaric acid, liquid sucrose, liquid glucose (containing sulphites and wheat starch). \u003cu\u003eBENAGOL Orange flavored tablets with Vitamin C\u003c\/u\u003e: One tablet contains: liquid sucrose, liquid glucose (containing sulphites and wheat starch), tartaric acid, orange flavor (containing citral, citronellol, d-limonene, geraniol and linalool), levomenthol, propylene glycol. \u003cu\u003eBENAGOL Lemon flavored tablets without sugar\u003c\/u\u003e: One tablet contains: lemon flavoring (containing benzyl alcohol, citral, citronellol, dlimonene, geraniol and linalool), sodium saccharin, tartaric acid, liquid maltitol, isomalt. \u003cu\u003eBENAGOL Strawberry flavored tablets without sugar\u003c\/u\u003e: One tablet contains: strawberry flavor (containing propylene glycol and benzyl alcohol), anthocyanins (E163) (containing sodium), sodium saccharin, tartaric acid, liquid maltitol, isomalt. \u003cu\u003eBENAGOL Cold Mint flavor tablets\u003c\/u\u003e: One tablet contains: xylitol, levomenthol, mint flavor and eucalyptus essence (containing propylene glycol, benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool), liquid sucrose, liquid glucose (containing sulphites and wheat starch).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Do not administer to children under 6 years of age. BENAGOL Menthol-Eucalyptol flavor is contraindicated in children with a history of epilepsy or febrile convulsions. Do not administer BENAGOL Cold Mint flavor and BENAGOL Ginger and Spice flavor to children under 12 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e The lowest effective dose for the shortest duration necessary to relieve symptoms should be used. \u003cb\u003eAdults and children over 6 years of age:\u003c\/b\u003e One tablet every 2 or 3 hours. In children over 6 years of age, consult your doctor for an appropriate dosage. Do not exceed the recommended doses and in particular, for BENAGOL with Vitamin C Orange flavor and BENAGOL Cold Mint flavor, do not exceed the daily maximum of 8 tablets. For all other flavors of BENAGOL, do not exceed the maximum daily dose of 12 tablets. \u003cu\u003eAdminister BENAGOL Cold Mint flavor and BENAGOL Ginger and Spice flavor to adults and children over the age of 12\u003c\/u\u003e. The duration of treatment with BENAGOL Menthol-Eucalyptol flavor must not exceed 3 days. BENAGOL Lemon flavor Without Sugar and BENAGOL Strawberry flavor Without Sugar are suitable for those patients who need to control their sugar and calorie intake. \u003ci\u003eElderly population\u003c\/i\u003e No data available. \u003cu\u003eMethod of administration\u003c\/u\u003e Oromucosal administration. The tablet should be dissolved slowly in the mouth.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBe careful with pre-school children as if the tablets are swallowed whole they may cause choking. In the event of the appearance of sensitization or irritation phenomena, administration should be discontinued and suitable treatment instituted. BENAGOL Menthol-Eucalyptol flavor contains terpene derivatives which, in excessive doses, can cause neurological disorders such as convulsions in infants and children. Treatment with BENAGOL Menthol-Eucalyptol flavor must not be prolonged for more than 3 days due to the risks associated with the accumulation of terpene derivatives, such as \u003ci\u003eexample camphor, cineol, niaouli, wild thyme, terpineol, terpine, citral, menthol and essential oils of pine needles, eucalyptus and turpentine\u003c\/i\u003e (due to their lipophilic properties the rate of metabolism and disposal is not known) in tissues and the brain, in particular neuropsychological disorders. A higher than recommended dose should not be used to avoid an increased risk of adverse drug reactions and disorders associated with overdose (see section 4.9). BENAGOL Menthol-Eucalyptol flavor is flammable, it should not be brought near flames. \u003ci\u003eImportant information about some excipients\u003c\/i\u003e \u003cu\u003eBENAGOL Ginger and Spice flavored tablets, BENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e, \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets, BENAGOL Orange flavor tablets with Vitamin C, BENAGOL Cold Mint flavor tablets contain\u003c\/u\u003e Liquid glucose: - Patients suffering from rare hereditary problems of glucose-galactose malabsorption should not take this medicine. - To be taken into consideration in people suffering from diabetes mellitus: BENAGOL Ginger and Spice flavored tablets contains 1.10 g of glucose per tablet. BENAGOL Honey and Lemon flavored tablets contains 0.98 g of glucose per tablet. BENAGOL Menthol-Eucalyptol flavor tablets contains 1.01 g of glucose per tablet. BENAGOL Tablets with Vitamin C Orange flavor contains 0.97 g of glucose per tablet. BENAGOL Cold Mint flavor tablets contains 1.10 g of glucose per tablet. - Liquid glucose contains sulphites. These medicines can rarely cause serious hypersensitivity reactions and bronchospasm. - Liquid glucose contains wheat starch. These medicines contain only a very small amount of gluten (from wheat starch). These medicines are considered “gluten-free” and are very unlikely to cause problems if the patient has celiac disease. One tablet of BENAGOL Ginger and Spice flavored tablets contains no more than 22.04 micrograms of gluten. One tablet of BENAGOL Honey and Lemon flavored tablets contains no more than 19.52 micrograms of gluten. One tablet of BENAGOL Menthol-Eucalyptol flavor contains no more than 20.26 micrograms of gluten. One tablet of BENAGOL Tablets with Vitamin C Orange flavor contains no more than 19.38 micrograms of gluten. One tablet of BENAGOL Cold Mint flavor tablets contains no more than 22.04 micrograms of gluten. If the patient is allergic to wheat (a condition other than celiac disease) he should not take these medicines. Liquid sucrose: - Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. - To be taken into consideration in people suffering from diabetes mellitus: BENAGOL Ginger and Spice flavored tablets contains 1.38 g of sucrose per tablet. BENAGOL Honey and Lemon flavored tablets contains 1.44 g of sucrose per tablet. BENAGOL Menthol-Eucalyptol flavor tablets contains 1.50 g of sucrose per tablet. BENAGOL Tablets with Vitamin C Orange flavor contains 1.44 g of sucrose per tablet. BENAGOL Cold Mint flavor tablets contains 1.38 g of sucrose per tablet. \u003cu\u003eBENAGOL Ginger and Spice flavored tablets, BENAGOL Menthol-Eucalyptol flavored tablets\u003c\/u\u003e, \u003cu\u003eBENAGOL Tablets with Vitamin C Orange flavor, BENAGOL Tablets Lemon flavor Without Sugar, BENAGOL Tablets Strawberry flavor Without Sugar\u003c\/u\u003e These medicines contain less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'. \u003cu\u003eBENAGOL Lemon Flavor Tablets Without Sugar and BENAGOL Strawberry Flavor Tablets Without Sugar\u003c\/u\u003e These medicines contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. They may have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. \u003cu\u003eBENAGOL Ginger and Spice flavored tablets\u003c\/u\u003e This medicine contains a flavoring which contains cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool. Cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool can cause allergic reactions. This medicine contains excipients that can cause a warm sensation in the mouth and throat when you suck the lozenge. \u003cu\u003eBENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e This medicine contains a flavoring which contains citral, d-limonene, geraniol and linalool. Citral, d-limonene, geraniol and linalool can cause allergic reactions. This medicine contains honey (invert sugar). Patients suffering from rare hereditary problems of fructose intolerance, or glucose-galactose malabsorption, should not take this medicine. \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets\u003c\/u\u003e This medicine contains a flavoring which contains d-limonene. D-limonene can cause allergic reactions. \u003cu\u003eBENAGOL Orange flavored tablets with Vitamin C\u003c\/u\u003e This medicine contains a flavoring which contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. This medicine contains 3 mg of propylene glycol per tablet. \u003cu\u003eBENAGOL Lemon flavored tablets without sugar\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool. Benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. \u003cu\u003eBENAGOL Strawberry flavored tablets without sugar\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol. Benzyl alcohol can cause allergic reactions. This medicine contains 7.30 mg of propylene glycol in each tablet. \u003cu\u003eBENAGOL Cold Mint flavor tablets\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool. Benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool can cause allergic reactions. This medicine contains 1.89 mg of propylene glycol in each tablet.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBENAGOL Menthol-Eucalyptol flavor must not be used in conjunction with other products (medicines or cosmetics) containing terpene derivatives, regardless of the route of administration (oral, rectal, cutaneous, nasal or inhalation).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBENAGOL Menthol - Eucalyptol flavour: due to the presence of menthol and in case of non-compliance with the recommended doses there may be a risk of convulsions in children and infants. Adverse reactions associated with the use of 2,4 dichlorobenzyl alcohol, amylmetacresol, levomenthol and ascorbic acid are listed below, divided by frequency and organ class. Frequencies are defined as: Very common (≥1\/10); Common (≥1\/100 and \u003c1\/10); Uncommon (≥1\/1000 and \u003c1\/100); Rare (≥1\/10000 and \u003c1\/1000); Very rare (\u003c1\/10000); Not known (frequency cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Rare. Adverse reactions: Hypersensitivity\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Rare. Adverse reactions: Glossitis.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Adverse reactions: Abdominal pain, nausea, gastrointestinal discomfort.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Not known. Adverse reactions: Skin rash.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA possible overdose could only cause gastrointestinal disorders, for which appropriate symptomatic treatments must be adopted. BENAGOL Menthol-Eucalyptol flavour: in case of accidental oral intake or incorrect administration in infants and children there may be a risk of neurological disorders. If necessary, administer appropriate symptomatic treatment in specialized treatment centers.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn pregnant and breastfeeding women, the product should be administered only if clearly necessary. \u003cu\u003ePregnancy\u003c\/u\u003e There are no, or limited numbers, of data relating to the use of the active ingredients of BENAGOL in pregnant women. BENAGOL Menthol-Eucalyptol flavor is not recommended during pregnancy and in women of childbearing age who do not use contraceptive measures. \u003cu\u003eBreastfeeding\u003c\/u\u003e It is not known whether the active substances or their metabolites are excreted in breast milk. The risk to newborns and infants cannot be excluded. Ascorbic acid or its metabolites are excreted in breast milk. \u003cu\u003eFertility\u003c\/u\u003e No data are available regarding the effect on fertility. BENAGOL Menthol-Eucalyptol flavor is not recommended in women of childbearing age who are not using contraceptive measures.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo effects on the ability to drive or use machines are reported.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":40207822946419,"sku":"016242149","price":15.72,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-benagol-miele-e-limone-36-pastiglie-mal-di-gola-farmacia-dottor-tili-1258975935.jpg?v=1789562711"},{"product_id":"froben-gola-spray-mucosa-orale-15-ml-flurbiprofene-0-25","title":"Froben Throat Oral Mucosa Spray 15 ml Flurbiprofen 0.25%","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFroben Gola is indicated for the symptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• \u003cb\u003eFROBEN THROAT 250mg\/100ml Mouthwash\u003c\/b\u003e 100 ml of solution contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: Flurbiprofen 0.25 g \u003cu\u003eExcipients with known effect\u003c\/u\u003e: Ethanol, patent blue V(E131). • \u003cb\u003eFROBEN THROAT 250mg\/100ml Spray for oral mucosa\u003c\/b\u003e 100 ml of solution contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: Flurbiprofen 0.25 g \u003cu\u003eExcipients with known effect\u003c\/u\u003e: Ethanol, patent blue V(E131). For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePurified water, alcohol, patent blue VE 131, glycerol, mint essence, 40-polyoxyethylene hydrogenated castor oil, potassium bicarbonate, sodium saccharinate, sorbitol.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Froben Gola is also contraindicated in: • patients who have previously experienced hypersensitivity reactions (e.g. asthma, urticaria) after taking aspirin or other NSAIDs. • patients with a history of gastrointestinal bleeding or perforation related to previous treatment with NSAIDs. • patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal bleeding (defined as two or more distinct episodes of demonstrated ulceration or bleeding). • patients with severe cardiac, renal or hepatic insufficiency (see section 4.4). Froben Gola is contraindicated during the third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.4). It is recommended to use this medicine for a maximum of three days. \u003cb\u003eDosage:\u003c\/b\u003e • \u003cb\u003eMOUTHWASH\u003c\/b\u003e The recommended dose is two or three rinses or gargles per day with 10 ml of mouthwash. Can be diluted in water • \u003cb\u003eSPRAY FOR ORAL MUCOSA\u003c\/b\u003e The recommended dose is 2 sprays 3 times a day aimed directly at the affected part. \u003ci\u003ePediatric population\u003c\/i\u003e No adequate data are available on the pediatric population; therefore the use of the medicine is not recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMouthwash: this medicine must not be stored above 25 C. Oral mucosa spray: this medicine must not be stored above 25 C; Keep the bottle in the outer carton to protect the medicine from light.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eGeneral precautions \u003c\/b\u003e Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2 and the sections below on gastrointestinal and cardiovascular risks). \u003cb\u003eUse in elderly patients \u003c\/b\u003e Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal. \u003cb\u003e \u003ci\u003e \u003cu\u003eGastrointestinal effects \u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse events can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal events. The risk of gastrointestinal haemorrhage, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by haemorrhage and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low doses of aspirin or other drugs that may increase the risk of gastrointestinal events (see section below and section 4.5). Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. When gastrointestinal bleeding or ulceration occurs in patients taking Froben Gola, treatment should be suspended. \u003cb\u003e \u003ci\u003e \u003cu\u003eRespiratory Disorders\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma. \u003cb\u003e \u003ci\u003e \u003cu\u003eCardiac, renal and hepatic impairment \u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Particular caution must be taken when treating patients with severely compromised renal, cardiac or hepatic function, as the use of NSAIDs can lead to deterioration of renal function. In such patients the dosage should be kept as low as possible and renal function should be monitored. The administration of an NSAID can cause a dose-dependent reduction in the formation of prostaglandins, accelerating renal failure. Patients at highest risk of developing this reaction are those with impaired kidney function, heart failure and liver dysfunction, those taking diuretics and elderly people. Renal function should be monitored in these patients (see also section 4.3). Flurbiprofen should be administered with caution in patients with a history of heart failure or hypertension as cases of edema have been reported in association with the administration of flurbiprofen. \u003cb\u003e \u003ci\u003e \u003cu\u003eCardiovascular and cerebrovascular effects\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Adequate monitoring and appropriate instructions are necessary in patients with a history of hypertension and\/or mild to moderate congestive heart failure since, in association with the administration of flurbiprofen and treatment with NSAIDs, fluid retention and edema have been found. In these patients Froben Gola should be taken with caution. Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). \u003cb\u003e \u003cu\u003eSkin reactions\u003c\/u\u003e \u003c\/b\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs. In the early stages of therapy, patients appear to be at higher risk: the onset of the reaction occurs in most cases within the first month of treatment. Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003cb\u003e \u003ci\u003e \u003cu\u003eRenal effects\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Caution should be used when initiating treatment with NSAIDs such as flurbiprofen in patients with considerable dehydration. \u003cb\u003e \u003ci\u003e \u003cu\u003eHematological effects\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Flurbiprofen, like other NSAIDs, can inhibit platelet aggregation and prolong bleeding time. \u003cb\u003e \u003ci\u003e \u003cu\u003eSystemic lupus erythematosus (SLE) and connective system diseases\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e An increased risk of aseptic meningitis may occur in patients with Systemic Lupus Erythematosus (SLE) and connective system disorders (see section 4.8). The effects reported above have been reported in particular after the administration of formulations based on Flurbiprofen for systemic use. At the recommended doses, swallowing FROBEN GOLA does not cause any harm to the patient as these doses are significantly lower than those of the single dosage of the product systemically. The use of FROBEN GOLA, especially if prolonged, can give rise to local sensitization or irritation phenomena; in such cases it is necessary to interrupt the treatment and consult the doctor to institute, if necessary, a suitable therapy. Flurbiprofen should not be used for prolonged treatments. It is necessary to inform patients to seek medical advice if after short periods of treatment without appreciable results. \u003cb\u003eImpairment of fertility\u003c\/b\u003e The use of flurbiprofen may impair female fertility and is not recommended in women trying to become pregnant. In women who have difficulty conceiving or who are undergoing infertility investigations, discontinuation of treatment with flurbiprofen should be considered. \u003cb\u003e \u003ci\u003e \u003cu\u003eImportant information about some excipients\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e \u003cu\u003eFROBEN THROAT 250mg\/100ml Mouthwash\u003c\/u\u003e contains: • \u003ci\u003eSorbitol (E420)\u003c\/i\u003e. Patients with hereditary fructose intolerance should not be given this medicine. • \u003ci\u003eEthanol\u003c\/i\u003e. This medicine contains 12 vol% ethanol (alcohol), e.g. up to 1 g per dose, equivalent to 24 ml of beer, 10 ml of wine per dose. It can be harmful to alcoholics. To be taken into consideration in pregnant or breastfeeding women, children and high-risk groups such as people with liver disease or epilepsy. For those who carry out sporting activities, the use of medicines containing ethyl alcohol can lead to positive anti-doping tests in relation to the blood alcohol concentration limits indicated by some sports federations. • \u003ci\u003ePatent blue dye V(E131)\u003c\/i\u003e which can cause allergic reactions. \u003cu\u003eFROBEN THROAT 250mg\/100ml Spray for oral mucosa\u003c\/u\u003e contains: • \u003ci\u003eSorbitol\u003c\/i\u003e. The additive effect of co-administration of medicinal products containing sorbitol (or fructose) and daily dietary intake of sorbitol (or fructose) should be considered. The sorbitol content in oral medicinal products may modify the bioavailability of other co-administered oral medicinal products. • \u003ci\u003eEthanol\u003c\/i\u003e. This medicine contains 12 vol% ethanol (alcohol), e.g. up to 40 mg per dose, equivalent to 1 ml of beer, 0.4 ml of wine per dose. For those who carry out sporting activities, the use of medicines containing ethyl alcohol can lead to positive anti-doping tests in relation to the blood alcohol concentration limits indicated by some sports federations. • \u003ci\u003ePatent blue dye V(E131)\u003c\/i\u003e which can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. \u003cb\u003eDiuretics, ACE inhibitors and angiotensin II antagonists\u003c\/b\u003e: NSAIDs can reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of NSAID nephrotoxicity. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Flurbiprofen concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and on a periodic basis thereafter. \u003cb\u003eLithium salts:\u003c\/b\u003e decrease in lithium elimination. \u003cb\u003eMethotrexate: \u003c\/b\u003ecaution is advised in case of concomitant administration of flurbiprofen and methotrexate as NSAIDs can increase the levels of methotrexate and therefore its toxic effects). \u003cb\u003eAnticoagulants, such as warfarin: \u003c\/b\u003eincreased anticoagulant effect. \u003cb\u003eAnti-aggregating agents:\u003c\/b\u003e increased risk of gastrointestinal bleeding \u003cb\u003eSelective serotonin reuptake inhibitors (SSRIs):\u003c\/b\u003e increased risk of gastrointestinal bleeding. \u003cb\u003eAspirin:\u003c\/b\u003e As with other NSAID-containing medicines, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased side effects. \u003cb\u003eCardiac glycosides\u003c\/b\u003e: NSAIDs can exacerbate heart failure, reduce glomerular filtration rate and increase plasma levels of cardiac glycosides. \u003cb\u003eCyclosporins:\u003c\/b\u003e increased risk of nephrotoxicity with NSAIDs. \u003cb\u003eCorticosteroids:\u003c\/b\u003e increased risk of gastrointestinal ulcer or bleeding with NSAIDs. \u003cb\u003eCox-2 inhibitors and other NSAIDs:\u003c\/b\u003e Concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects. \u003cb\u003eMifepristone\u003c\/b\u003e: NSAIDs should not be taken for 8-12 days after administration of mifepristone as NSAIDs may reduce the effects of mifepristone. \u003cb\u003eQuinolone Antibiotics: \u003c\/b\u003eResults from animal studies suggest that NSAIDs may increase the risk of seizures associated with the use of quinolone antibiotics. Patients taking NSAIDs and Quinolones may have an increased risk of developing seizures. \u003cb\u003eTacrolimus\u003c\/b\u003e: possible increased risk of nephrotoxicity in case of co-administration with NSAIDs. \u003cb\u003eZidovudine\u003c\/b\u003e: increased risk of blood toxicity in case of co-administration with NSAIDs. There is evidence of an increased risk of haemarthrosis and haematoma in haemophilia patients affected by HIV in simultaneous treatment with Zidovudine and other NSAIDs. The interactions reported above have been reported in particular after the administration of Flurbiprofen-based formulations for systemic use. At the recommended doses of FROBEN GOLA, no interactions with other medicinal products or of any other nature have been reported. However, inform your doctor if you are taking other medicines.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following adverse reactions, reported in particular after the administration of formulations for systemic use, are reported according to the MedDRA classification. Frequency groupings are classified according to the following convention: very common (≥ 1\/10), Common (≥1\/100 to \u003c1\/10), Uncommon (≥1\/1000 to \u003c1\/100), Rare (≥ 1\/10,000 to \u003c1\/1000), Very rare (\u003c1\/10,000) and Not Known (frequency cannot be estimated).\u003c\/p\u003e\n\u003cp\u003eMedDRA system organ class: Frequency of Adverse Reactions.\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders: Uncommon Anemia.\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders: Very rare Leukopenia, agranulocytosis, aplastic anemia, neutropenia, thrombocytopenia, haemolytic anemia.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders: Uncommon Hypersensitivity\u003c\/p\u003e\n\u003cp\u003eImmune system disorders: Rare Anaphylactic reaction.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders: Rare Depression, Confusional state.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders: Very rare Hallucination.\u003c\/p\u003e\n\u003cp\u003eNervous System Disorders: Common Migraine, dizziness.\u003c\/p\u003e\n\u003cp\u003eNervous System Disorders: Uncommon Paraesthesia.\u003c\/p\u003e\n\u003cp\u003eNervous System Disorders: Rare Drowsiness, Insomnia.\u003c\/p\u003e\n\u003cp\u003eNervous System Disorders: Not known Optic neuritis, cerebrovascular accident, headache.\u003c\/p\u003e\n\u003cp\u003eEye disorders: Uncommon Visual disturbances.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders: Uncommon Tinnitus, vertigo.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders: Uncommon Asthma, dyspnoea.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders: Rare Bronchospasm.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Common Dyspepsia, diarrhoea, nausea, vomiting, abdominal pain, flatulence, constipation, melena, haematemesis, gastrointestinal haemorrhage.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Uncommon Gastritis, duodenal ulcer, gastric ulcer, mouth ulcer, gastrointestinal perforation.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Very rare Pancreatitis.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Not known Colitis and Crohn's disease.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders: Very rare Jaundice, cholestatic jaundice, abnormal liver function.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders: Not known Hepatitis.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders: Uncommon Rash, urticaria, pruritus, purpura, angioedema, photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders: Very rare Severe forms of bullous skin reactions (e.g. Erythema Multiforme, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis).\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders: Rare Nephrotoxicity in various forms i.e. interstitial nephritis, nephrotic syndrome, renal failure and acute renal failure. (see paragraph 4.4).\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders: Not known Glomerulonephritis.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and administration site conditions: Common Fatigue, malaise, edema.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders: Uncommon Heart failure.\u003c\/p\u003e\n\u003cp\u003eVascular disorders: Uncommon Hypertension.\u003c\/p\u003e\n\u003cp\u003eInvestigations: Common Liver function test abnormal, bleeding time prolonged.\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders: Common Fluid retention.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e Hypersensitivity reactions have been reported following treatment with NSAIDs. These consist of: a) non-specific allergic reactions and anaphylaxis; b) reactions affecting the respiratory tract including asthma, even severe, bronchospasm or dyspnoea, or c) various skin disorders, such as various types of skin rashes, itching, urticaria, purpura, angioedema and, very rarely, exfoliative and bullous dermatitis (including Toxic Epidermal Necrolysis and erythema multiforme). \u003cb\u003eCardiac and vascular pathologies\u003c\/b\u003e Cases of edema, hypertension and heart failure have been reported in association with treatment with NSAIDs. Clinical studies and epidemiological data suggest that the intake of some NSAIDs (especially if at high doses and in case of long-term treatment) may be associated with an increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4).\u003cb\u003eNervous System Pathologies \u003c\/b\u003e Aseptic meningitis (especially in patients with existing autoimmune disorders such as Systemic Lupus Erythematosus and connective tissue disorders) with symptoms such as stiff neck, headache, nausea, vomiting, fever or disorientation (see section 4.4). \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSymptoms\u003c\/b\u003e Symptoms of overdose may include nausea, vomiting, and gastrointestinal irritation. \u003cb\u003eTreatment\u003c\/b\u003e Treatment should include gastric lavage and, if necessary, correction of the serum electrolyte picture. There is no specific antidote for flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFertility\u003c\/i\u003e The use of FROBEN GOLA may negatively affect fertility and is not recommended in women who are trying to conceive. In women who have difficulty conceiving or who are undergoing fertility investigations, stopping taking FROBEN GOLA should be considered. \u003ci\u003ePregnancy \u003c\/i\u003e Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, flurbiprofen should not be administered unless strictly necessary. If flurbiprofen is used by a woman attempting to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: • Cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); • Renal dysfunction, which may progress to renal failure with oligohydramnios. The mother and the newborn, at the end of pregnancy, to: • Possible prolongation of bleeding time, an anti-aggregating effect which can occur even at very low doses; • Inhibition of uterine contractions resulting in delayed or prolonged labor. \u003cb\u003eConsequently, flurbiprofen is contraindicated during the third trimester of pregnancy (see section 4.3). \u003c\/b\u003e \u003ci\u003eBreastfeeding\u003c\/i\u003e In the few studies available so far, NSAIDs can appear in breast milk in very low concentrations. If possible, NSAIDs should be avoided during breastfeeding. See paragraph \u003ci\u003e4.4 Special warnings and precautions for use\u003c\/i\u003e, regarding fertility in women.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects such as dizziness, drowsiness, fatigue and visual disturbances are possible after taking NSAIDs. If these effects occur, patients should not drive or use machinery.\u003c\/p\u003e","brand":"Mylan","offers":[{"title":"Default Title","offer_id":40207824158835,"sku":"042822027","price":11.44,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/mylan-italia-srl-froben-gola-spray-mucosa-orale-15-ml-flurbiprofene-0-25-farmacia-dottor-tili-1213792740.jpg?v=1767126746"},{"product_id":"rinazina-spray-nasale-decongestionante-15ml-0-1","title":"Rinazina Decongestant Nasal Spray 15ml 0.1%","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNasal decongestant during acute catarrhal rhinitis and pharyngitis, allergic rhinitis, acute sinusitis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e1 ml of solution contains: Active ingredient: naphazoline nitrate 1 mg \u003cu\u003eExcipients with known effects\u003c\/u\u003e: benzalkonium chloride For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRINAZINA 1 mg\/ml nasal drops, solution: sodium chloride, disodium edetate, monobasic sodium phosphate dihydrate, concentrated phosphoric acid, \u003cb\u003ebenzalkonium chloride\u003c\/b\u003e, purified water. RINAZINA 1 mg\/ml nasal spray, solution: sodium chloride, disodium edetate, monobasic sodium phosphate dihydrate, concentrated phosphoric acid, \u003cb\u003ebenzalkonium chloride\u003c\/b\u003e, balsamic aroma, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Severe heart disease and arterial hypertension. Glaucoma. Hyperthyroidism. \u003cb\u003e \u003cu\u003eThe medicine is contraindicated in children under 12 years of age.\u003c\/u\u003e \u003c\/b\u003e Do not administer during and in the two weeks following therapy with antidepressant drugs.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eNasal drops:\u003c\/b\u003e Adults: 2-3 drops in each nostril, 2-3 times a day \u003cb\u003eNasal spray:\u003c\/b\u003e Adults: 1-2 sprays in each nostril, 2-3 times a day. \u003ci\u003ePediatric population\u003c\/i\u003e: The medicine is contraindicated in children under 12 years of age (see section 4.3). Carefully follow the recommended doses. A higher dosage of the product, even if taken topically and for a short period of time, can give rise to serious systemic effects. In the absence of a complete therapeutic response within a few days, consult your doctor; in any case, the treatment must not be continued for more than a week.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eRINAZINA 1 mg\/ml nasal spray, solution:\u003c\/i\u003e This medicinal product does not require any special storage conditions. \u003ci\u003eRINAZINA 1 mg\/ml nasal drops, solution\u003c\/i\u003e: Store below 25°C. Store upright.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUse with caution in the elderly and in those with prostatic hypertrophy due to the risk of urinary retention. In patients with cardiovascular diseases, especially in hypertensive patients, the use of nasal decongestants must in any case be subject to the doctor's judgment from time to time. The prolonged use of vasoconstrictors can alter the normal function of the mucosa of the nose and paranasal sinuses, also inducing addiction to the drug. Repeating applications over a long period of time can be harmful. RINAZINA nasal drops and nasal spray contain 0.1 mg\/ml of benzalkonium chloride. Benzalkonium chloride (BAC) contained as a preservative in RINAZINA nasal drops and nasal spray can cause irritation and swelling of the nasal mucosa, especially if used for long periods. If such a reaction (persistent nasal congestion) is suspected, a medicinal product for nasal use without BAC should be used, if possible. If such medicinal products for nasal use without BAC are not available, another pharmaceutical form should be considered. May cause bronchospasm. The use, especially if prolonged, of topical products can give rise to sensitization phenomena; in this case it is necessary to interrupt the treatment and, if necessary, institute suitable therapy. Rare cases of posterior reversible encephalopathy\/reversible cerebral vasoconstriction syndrome have been reported with the use of sympathomimetic drugs, to which naphazoline also belongs. Reported symptoms include sudden onset of severe headache, nausea, vomiting and vision disturbances. Most cases improve or resolve within a few days following appropriate treatment. The use of naphazoline should be discontinued immediately and a doctor should be consulted if signs and\/or symptoms of posterior reversible encephalopathy\/reversible cerebral vasoconstriction syndrome occur.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe drug may interact with antidepressant drugs.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product can locally cause rebound phenomena of sensitization and congestion of the mucous membranes. Due to rapid absorption of naphazoline through inflamed mucous membranes, systemic effects consisting of arterial hypertension, reflex bradycardia, headache, urination disorders may occur. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product, if accidentally ingested or if used for a long period in excessive doses, can cause toxic phenomena. It should be kept out of the reach of children as accidental ingestion can cause severe sedation. In case of overdose, arterial hypertension, tachycardia, photophobia, intense headache, chest tightness and, in children, hypothermia and severe depression of the Central Nervous System with marked sedation may appear, which require the adoption of adequate emergency measures.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDuring pregnancy and breastfeeding, RINAZINA must be used only after consulting your doctor and evaluating with him the risk\/benefit ratio in your case.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known side effects on the ability to drive or use machines.\u003c\/p\u003e","brand":"Gsk","offers":[{"title":"Default Title","offer_id":40207824191603,"sku":"000590051","price":11.59,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/glaxosmithkline-c-health-spa-rinazina-spray-nasale-decongestionante-15ml-0-1-farmacia-dottor-tili-1213792738.webp?v=1767126771"},{"product_id":"benactiv-gola-arancia-16-pastiglie","title":"Benactiv Throat Orange 16 Lozenges","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory conditions also associated with oropharyngeal pain (e.g. gingivitis, stomatitis, pharyngitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e 100 ml of mouthwash contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 250 mg Excipients with known effects: hydrogenated castor oil-40-polyoxyethylene, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene). \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e 100 ml of solution contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 250 mg Excipients with known effects: hydrogenated castor oil-40-polyoxyethylene, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene). \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e One tablet contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 8.75 mg Excipients with known effects: liquid glucose (containing sulphites and wheat starch), liquid sucrose, honey, lemon flavoring and levomenthol (containing butylated hydroxyanisole, citral, citronellol, d-limonene, farfalle, geraniol, linalool). \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e One tablet contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 8.75 mg Excipients with known effects: liquid maltitol (E965), isomalt (E953), orange flavoring and levomenthol (containing citral, citronellol, d-limonene, geraniol, linalool). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e Glycerol, ethanol (96 percent), sorbitol 70, hydrogenated castor oil-40-polyoxyethylene, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene), patent blue V (E131), purified water. \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e Glycerol, ethanol (96 percent), sorbitol 70, hydrogenated castor oil-40-polyoxyethylene, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene), patent blue V (E131), purified water. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e Liquid sucrose, liquid glucose (containing sulphites and wheat starch), macrogol 300, potassium hydroxide, lemon flavoring and levomenthol (containing butylated hydroxyanisole, citral, citronellol, d-limonene, farfalle, geraniol, linalool), honey. \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e Macrogol 300, potassium hydroxide, orange flavor and levomenthol (containing citral, citronellol, dlimonene, geraniol, linalool), acesulfame potassium (E950), liquid maltitol (E965), isomalt (E953).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not use the medicine in children under 12 years of age. Flurbiprofen is contraindicated in patients with known hypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Patients who have previously shown hypersensitivity reactions (e.g. asthma, urticaria, allergy, rhinitis, angioedema, bronchospasm) towards ibuprofen, acetylsalicylic acid (aspirin) or other non-steroidal anti-inflammatory drugs (NSAIDs). Flurbiprofen is also contraindicated in patients with a history of gastrointestinal bleeding or perforation related to previous NSAID treatment. Flurbiprofen should not be taken by patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal haemorrhage (defined as two or more distinct episodes of demonstrated ulceration or bleeding). Flurbiprofen is contraindicated in patients with severe heart failure, severe hepatic failure and renal failure (see section 4.4). Third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.4). \u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: 2-3 rinses or gargles per day with 10 ml (1 scoop) of mouthwash. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Rinse or keep in mouth while gargling for up to 1 minute. Do not ingest. The mouthwash can be used pure or diluted in half a glass of water. \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: apply one dose (2 sprays) 3 times a day, directed directly onto the affected part. Each spray delivers 0.2 ml of solution, equivalent to 0.5 mg of active ingredient. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Direct the nozzle towards the back of the throat and spray on the affected part. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: 1 tablet every 3-6 hours, as needed. Do not exceed the dose of 8 tablets in 24 hours. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Dissolve slowly in your mouth. As with all lozenges, in order to avoid local irritation, flurbiprofen lozenges should also be moved inside the mouth during administration. If mouth irritation occurs, treatment should be discontinued.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenactiv Gola Orange flavored sugar-free lozenges and Benactiv Gola Lemon and Honey flavored lozenges: store at temperatures below 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not cause any harm to the patient, as the dose of flurbiprofen is significantly lower than that commonly used in systemic treatments. Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal haemorrhage and perforation, which may be fatal. \u003ci\u003eRespiratory disorders \u003c\/i\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma or allergies. Flurbiprofen should be used with caution in these patients. \u003ci\u003eOther NSAIDs \u003c\/i\u003e It is advisable not to combine the medicine with other NSAIDs (see section 4.5). \u003ci\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease \u003c\/i\u003e Patients with systemic lupus erythematosus and mixed connective tissue disease may have an increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiac, hepatic and renal impairment \u003c\/i\u003e The medicine should be used with caution in patients with cardiac, renal or hepatic insufficiency. NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID can cause a dose-dependent reduction in the formation of prostaglandins and precipitate renal failure. Patients at highest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; however, this effect is not usually observed with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiovascular and cerebrovascular effects \u003c\/i\u003e Before starting treatment in patients with a positive history of hypertension and\/or heart failure, caution is required (discuss with your doctor or pharmacist), since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). \u003ci\u003eEffects on the central nervous system \u003c\/i\u003e Analgesic-induced headache. In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003ci\u003eGastrointestinal effects\u003c\/i\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. The risk of gastrointestinal haemorrhage, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by haemorrhage and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse reactions can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal reactions. Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2). Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003ci\u003eDermatological effects\u003c\/i\u003e The use of the medicine, especially if prolonged, can give rise to sensitization or local irritation phenomena. In such cases it is necessary to interrupt the treatment and consult a doctor to institute, if necessary, suitable therapy. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003ci\u003eInfections\u003c\/i\u003e Since isolated cases of exacerbation of inflammation related to infections (e.g. development of necrotizing fasciitis) have been described in temporal association with the systemic use of drugs belonging to the NSAID class, patients are recommended to immediately consult a doctor in case of appearance or worsening of signs of a bacterial infection during flurbiprofen-based therapy. A possible indication for starting antibiotic therapy must be taken into consideration. If mouth irritation develops, treatment should be discontinued. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain para-hydroxybenzoates which can cause allergic reactions (even delayed). BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain hydrogenated 40-polyoxyethylene castor oil which may cause localized skin reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain an aroma which in turn contains d-limonene. D-limonene can cause allergic reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain less than 1 mmol (23mg) sodium per 10 ml dose, i.e. essentially \"sodium-free\". BENACTIV GOLA Lemon and Honey flavored lozenges contain liquid glucose, liquid sucrose and honey (invert sugar). Patients suffering from rare problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. To be taken into consideration in people with diabetes mellitus: this medicine contains 1.07 g of glucose and 1.41 g of sucrose per tablet. BENACTIV GOLA Lemon and Honey flavored lozenges contain sulphites. Rarely it can cause serious hypersensitivity reactions and bronchospasm. BENACTIV GOLA Lemon and Honey flavored lozenges contain only a very small amount of gluten (from wheat starch). This medicine is considered “gluten-free” and is very unlikely to cause problems for a celiac patient. One tablet contains no more than 21.38 micrograms of gluten. If a patient is allergic to wheat (condition other than celiac disease) he or she should not take this medicine. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, farfalle, geraniol and linalool. Citral, citronellol, d-limonene, farfalle, geraniol and linalool can cause allergic reactions. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains butylated hydroxyanisole which can cause localized skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. BENACTIV GOLA Sugar-Free Lozenges Orange flavor is instead indicated for those patients who need to control their intake of sugars and calories. BENACTIV GOLA Orange flavored sugar-free lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. BENACTIV GOLA Orange flavored sugar-free lozenges contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. May have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. Do not use for prolonged treatments beyond 7 days. If you do not notice appreciable results after 3 days of treatment, the cause could be a different pathological condition. In these cases it is advisable to consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. However, inform your doctor if you are taking other medicines. Flurbiprofen should be avoided in association with: - Aspirin: unless the intake of low-dose aspirin (not exceeding 100 mg\/day or local prophylactic doses for cardiovascular protection) has been recommended by the doctor; As with other NSAID-containing medicinal products, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased side effects (see section 4.4). - Cox-2 inhibitors and other NSAIDs: concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects and an increased risk of adverse reactions (see section 4.4). Flurbiprofen should be used with caution in association with: - Anticoagulants: NSAIDs can potentiate the effects of anticoagulants such as warfarin (see section 4.4) - Antiaggregating agents: increased risk of gastrointestinal bleeding - Selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding - Antihypertensives (diuretics, ACE inhibitors and angiotensin II antagonists): i NSAIDs can reduce the effect of diuretics. Other antihypertensive drugs may potentiate nephrotoxicity caused by inhibition of cyclooxygenase, especially in patients with impaired renal function (these patients must be adequately hydrated) - Alcohol: may increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract - Cardiac glycosides: NSAIDs may exacerbate heart failure, reduce GFR (glomerular filtration rate) and increase plasma levels of glycosides - Cyclosporine: increased risk of nephrotoxicity - Corticosteroids: increased risk of gastrointestinal ulcer or haemorrhage with NSAIDs (see section 4.4) - Lithium: there is evidence for a possible increase in plasma lithium levels - Methotrexate: there may be an increase in plasma levels of methotrexate - Mifepristone: NSAIDs should not be used for 8-12 days after administration of mifepristone, as NSAIDs may reduce the effect of mifepristone - Quinolone antibiotics: data obtained in animals indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures - Tacrolimus: possible increased risk of nephrotoxicity when NSAIDs are administered together with tacrolimus - Zidovudine: increased risk of haematological toxicity when NSAIDs are administered with zidovudine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis (b) respiratory tract reactivity, e.g. asthma, aggravated asthma, bronchospasm, dyspnoea (c) various skin disorders, including for example skin rashes of different types, pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatosis (including necrolysis epidermal and erythema multiforme). The most commonly observed adverse reactions are gastrointestinal in nature. Local use of the medicine, especially if prolonged, can give rise to local sensitization or irritation phenomena. The dissolution of the medicine in tablet form in the oral cavity may be accompanied by sensations of heat or tingling in the oropharynx. In such cases it is necessary to interrupt treatment and institute, if necessary, suitable therapy. The following side effects have been reported, particularly after the administration of formulations for systemic use. They refer to those detected with the use of flurbiprofen used short term and at doses compatible with the classification of self-medication medicines. When treating chronic conditions and for long periods of time, additional side effects may occur. The side effects associated with the use of flurbiprofen are divided below based on system organ classification and frequency. Frequency is defined as: very common (≥ 1\/10), common (≥1\/100, \u003c1\/10), uncommon (≥1\/1,000, \u003c1\/100), rare (≥1\/10,000, \u003c1\/1,000), very rare (\u003c1\/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eDisorders of the blood and lymphatic system - Frequency: Not known. Adverse reactions: Anemia, thrombocytopenia, aplastic anemia and agranulocytosis.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Common. Adverse reactions: Dizziness, headache, paraesthesia.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Uncommon. Adverse reactions: Drowsiness.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Not known. Adverse reactions: Cerebrovascular accident, optic neuritis, migraine, confusional states, dizziness.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Rare. Adverse reactions: Anaphylactic reaction.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Not known. Adverse reactions: Angioedema, hypersensitivity\u003c\/p\u003e\n\u003cp\u003eEye disorders - Frequency: Not known. Adverse reactions: Vision impairment.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders - Frequency: Not known. Adverse reactions: Tinnitus.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Frequency: Not known. Adverse reactions: Heart failure, edema.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Frequency: Not known. Adverse reactions: Hypertension.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Common. Adverse reactions: Throat irritation.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Uncommon. Adverse reactions: Asthma, bronchospasm and dyspnea, oropharyngeal vesicular rash, oropharyngeal hypoesthesia.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Common. Adverse reactions: Diarrhoea, mouth ulceration, nausea, oral pain, oral paraesthesia, oropharyngeal pain, oral discomfort (hot or burning sensation, tingling in the mouth).\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Uncommon. Adverse reactions: Abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysesthesia, vomiting.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Adverse reactions: Melena, haematemesis, gastrointestinal haemorrhage, colitis, exacerbation of Crohn's disease, gastritis, peptic ulcer, gastric perforation, ulcer haemorrhage.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Uncommon. Adverse reactions: Skin rash, itching.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Not known. Adverse reactions: Urticaria, purpura, bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme).\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Frequency: Not known. Adverse reactions: Toxic nephropathy, tubulointerstitial nephritis and nephrotic syndrome, renal failure (as with other NSAIDs).\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and administration site conditions - Frequency: Uncommon. Adverse reactions: Pyrexia, pain.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and conditions relating to the administration site - Frequency: Not known. Adverse reactions: Discomfort, tiredness.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders - Frequency: Not known. Adverse reactions: Hepatitis.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Uncommon. Adverse reactions: Insomnia.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Not known. Adverse reactions: Depression, hallucination.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGiven the reduced content of the active ingredient and its local use, it is unlikely that overdose situations may occur. \u003cb\u003eSymptoms\u003c\/b\u003e The majority of patients who ingest clinically large quantities of NSAIDs develop nausea, vomiting, gastrointestinal irritation, epigastric pain, or more rarely diarrhea. Tinnitus, headache and gastrointestinal bleeding are also possible. In more severe cases of NSAID intoxication, central nervous system toxicity is observed, manifested by drowsiness, occasionally excitability, blurred vision and disorientation or coma. Occasionally patients develop seizures. In case of severe NSAID intoxication, metabolic acidosis may occur and the prothrombin time\/INR may be prolonged, probably due to interference with the action of coagulation factors present in circulation. Acute renal failure and liver damage may occur. An exacerbation of asthma is possible in asthmatic subjects. \u003cb\u003eTreatment\u003c\/b\u003e Treatment should be symptomatic and supportive and should include maintaining a patent airway and monitoring cardiac function and vital signs until stabilization. Oral administration of activated charcoal and, if necessary, correction of serum electrolytes should be considered if the patient presents within one hour of ingesting a potentially toxic amount. Seizures should be treated with intravenous diazepam or lorazepam if they are frequent or prolonged. Administer bronchodilators for asthma. There is no specific antidote for flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Flurbiprofen should not be administered during the first and second trimester of pregnancy unless strictly necessary. The use of flurbiprofen during the third trimester of pregnancy is contraindicated. \u003cu\u003eBreastfeeding\u003c\/u\u003e In a limited number of studies, flurbiprofen appears in breast milk in very low concentrations and is unlikely to have negative effects on the breastfed infant. However, administration of flurbiprofen is not recommended in breastfeeding mothers. \u003cu\u003eFertility\u003c\/u\u003e There is evidence to suggest that cyclooxygenase\/prostaglandin synthesis inhibitors may cause impairment of female fertility through an effect on ovulation. This is reversible upon discontinuation of treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt does not interfere with the ability to drive and use machinery.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":40207824552051,"sku":"033262078","price":12.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/reckitt-benckiser-h-it-spa-benactiv-gola-arancia-16-pastiglie-farmacia-dottor-tili-1213792732.webp?v=1767126886"},{"product_id":"argento-colloidale-puro-20-ppm-e-propoli-spray-30ml-dr-tili","title":"Pure Colloidal Silver 20 ppm and Propolis Spray 30ml Dr.Tili ","description":"\u003cp\u003e\u003cimg style=\"float: none;\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\" alt=\"Supplement made in Italy\" width=\"125\" height=\"125\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Made_in_Italy.png?v=1668012159\" data-mce-style=\"float: none;\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg height=\"125\" width=\"125\" alt=\"monitored heavy metals\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Privo_di_metalli_pesanti_480x480.png?v=1668012159\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/Privo_di_metalli_pesanti_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg height=\"125\" width=\"125\" alt=\"nickel tested\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/nichel_tested_480x480.png?v=1668012159\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/nichel_tested_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg height=\"125\" width=\"125\" alt=\"without added fragrance\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/fragrance_free_480x480.png?v=1668012159\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/fragrance_free_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg height=\"125\" width=\"125\" alt=\"without parabens\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_parabeni_480x480.png?v=1668012159\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/senza_parabeni_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003cspan\u003e \u003c\/span\u003e\u003cimg height=\"125\" width=\"125\" alt=\"silicone free\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/silicon_free_480x480.png?v=1668012159\" data-mce-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/silicon_free_480x480.png?v=1668012159\" data-mce-fragment=\"1\"\u003e\u003c\/p\u003e\nColloidal Silver 20 ppm and Propolis Spray 30ml is a unique and innovative product designed to synergistically combine the virtues of the highly titrated phytotherapeutic propolis extract with the properties of pure colloidal silver in ionic clusters. Colloidal Silver 20 ppm Propolis Spray 30ml is a product \u003cstrong\u003especific for oral use\u003c\/strong\u003e, whose particular density allows for long-lasting adhesion to the mucous membranes of the oral cavity for a long-lasting effect. Useful natural remedy in case of \u003cstrong\u003esore throat, seasonal flu, seasonal  and cold ailments.\u003c\/strong\u003e\n\u003cp\u003eObtained by dispersing very small particles of silver in water, the\u003cstrong\u003ecolloidal silver\u003c\/strong\u003e it was widely used in the treatment of the most varied infections before the advent of antibiotics. In fact, natural antibacterial, antiviral and antifungal properties are attributed to colloidal silver. This is why it is useful for \u003cstrong\u003edeeply disinfects the oral cavity \u003c\/strong\u003ein all its parts. Colloidal silver in ionic clusters, once absorbed by the body, manifests its properties \u003cstrong\u003esupporting natural immune defenses\u003c\/strong\u003e both in \u003cstrong\u003eprevention phase\u003c\/strong\u003e both during the communes \u003cstrong\u003eongoing infections\u003c\/strong\u003e.\u003cbr\u003eIt is indicated in cases of: inflammation of the oral cavity, sore throat, gingivitis, dental caries, seasonal and cold-related ailments.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003epropolis\u003c\/strong\u003e it is a natural substance produced by bees to insulate hive cells. It can be made up of over 200 different compounds including \u003cstrong\u003eresins, wax, essential oils, pollen, flavonoids, organic compounds, mineral salts, vitamins\u003c\/strong\u003e and other elements.\u003cbr\u003eProperties are attributed to propolis \u003cstrong\u003enatural antiviral and antibacterial\u003c\/strong\u003e, anti-inflammatory and immunostimulant, due in particular to the presence of \u003cstrong\u003eflavonoids\u003c\/strong\u003e (Galangina and Pinocembrina). Propolis is traditionally considered a \u003cstrong\u003enatural antibiotic\u003c\/strong\u003e which can inhibit the ability of bacteria to reproduce e \u003cstrong\u003enaturally disinfect the mucous membranes and oral cavity\u003c\/strong\u003e. It proves useful in case of \u003cstrong\u003eburning in the throat\u003c\/strong\u003e and inflammation of the upper respiratory tract such as pharyngitis, laryngitis. Propolis is also a \u003cstrong\u003enatural antiviral\u003c\/strong\u003e useful against viruses that cause the common seasonal flu.\u003cbr\u003eIndicated in case of: sore throat, flu, cold, pharyngitis, laryngitis, burning throat.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Pure Colloidal Silver 20 ppm and Propolis Spray 30ml Dr.Tili contain?\u003c\/h3\u003e\u003cp\u003eAqua. Propolisextract. Aloe barbadensis leaf juice. Citric acid. Maltodextrin. Xanthangum. Potassium sorbate. Rebaudiosi-de A. Colloidal silver.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Pure Colloidal Silver 20 ppm and Propolis Spray 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003eShake well before use. Two sprays of Pure Colloidal Silver ionic cluster 20 ppm Propolis Spray 30 ml several times a day on the affected areas. Helps give relief to the oral cavity.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Pure Colloidal Silver 20 ppm and Propolis Spray 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003eKeep out of reach of children.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow do you store Pure Colloidal Silver 20 ppm and Propolis Spray 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003eStore in a cool, dry place.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Pure Colloidal Silver 20 ppm and Propolis Spray 30ml Dr.Tili?\u003c\/h3\u003e\u003cp\u003e30ml\u003c\/p\u003e","brand":"Tilab","offers":[{"title":"Default Title","offer_id":40207841132659,"sku":"981377803","price":13.1,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/tilab-srl-argento-colloidale-puro-20-ppm-e-propoli-spray-30ml-dr-tili-farmacia-dottor-tili-1213792720.jpg?v=1767130270"},{"product_id":"benactiv-gola-miele-limone-16-pastiglie","title":"Benactiv Throat Honey Lemon 16 Lozenges","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory conditions also associated with oropharyngeal pain (e.g. gingivitis, stomatitis, pharyngitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e 100 ml of mouthwash contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 250 mg Excipients with known effects: hydrogenated castor oil-40-polyoxyethylene, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene). \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e 100 ml of solution contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 250 mg Excipients with known effects: hydrogenated castor oil-40-polyoxyethylene, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene). \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e One tablet contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 8.75 mg Excipients with known effects: liquid glucose (containing sulphites and wheat starch), liquid sucrose, honey, lemon flavoring and levomenthol (containing butylated hydroxyanisole, citral, citronellol, d-limonene, farfalle, geraniol, linalool). \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e One tablet contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 8.75 mg Excipients with known effects: liquid maltitol (E965), isomalt (E953), orange flavoring and levomenthol (containing citral, citronellol, d-limonene, geraniol, linalool). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e Glycerol, ethanol (96 percent), sorbitol 70, hydrogenated castor oil-40-polyoxyethylene, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene), patent blue V (E131), purified water. \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e Glycerol, ethanol (96 percent), sorbitol 70, hydrogenated castor oil-40-polyoxyethylene, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene), patent blue V (E131), purified water. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e Liquid sucrose, liquid glucose (containing sulphites and wheat starch), macrogol 300, potassium hydroxide, lemon flavoring and levomenthol (containing butylated hydroxyanisole, citral, citronellol, d-limonene, farfalle, geraniol, linalool), honey. \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e Macrogol 300, potassium hydroxide, orange flavor and levomenthol (containing citral, citronellol, dlimonene, geraniol, linalool), acesulfame potassium (E950), liquid maltitol (E965), isomalt (E953).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not use the medicine in children under 12 years of age. Flurbiprofen is contraindicated in patients with known hypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Patients who have previously shown hypersensitivity reactions (e.g. asthma, urticaria, allergy, rhinitis, angioedema, bronchospasm) towards ibuprofen, acetylsalicylic acid (aspirin) or other non-steroidal anti-inflammatory drugs (NSAIDs). Flurbiprofen is also contraindicated in patients with a history of gastrointestinal bleeding or perforation related to previous NSAID treatment. Flurbiprofen should not be taken by patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal haemorrhage (defined as two or more distinct episodes of demonstrated ulceration or bleeding). Flurbiprofen is contraindicated in patients with severe heart failure, severe hepatic failure and renal failure (see section 4.4). Third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.4). \u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: 2-3 rinses or gargles per day with 10 ml (1 scoop) of mouthwash. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Rinse or keep in mouth while gargling for up to 1 minute. Do not ingest. The mouthwash can be used pure or diluted in half a glass of water. \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: apply one dose (2 sprays) 3 times a day, directed directly onto the affected part. Each spray delivers 0.2 ml of solution, equivalent to 0.5 mg of active ingredient. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Direct the nozzle towards the back of the throat and spray on the affected part. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: 1 tablet every 3-6 hours, as needed. Do not exceed the dose of 8 tablets in 24 hours. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Dissolve slowly in your mouth. As with all lozenges, in order to avoid local irritation, flurbiprofen lozenges should also be moved inside the mouth during administration. If mouth irritation occurs, treatment should be discontinued.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenactiv Gola Orange flavored sugar-free lozenges and Benactiv Gola Lemon and Honey flavored lozenges: store at temperatures below 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not cause any harm to the patient, as the dose of flurbiprofen is significantly lower than that commonly used in systemic treatments. Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal haemorrhage and perforation, which may be fatal. \u003ci\u003eRespiratory disorders \u003c\/i\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma or allergies. Flurbiprofen should be used with caution in these patients. \u003ci\u003eOther NSAIDs \u003c\/i\u003e It is advisable not to combine the medicine with other NSAIDs (see section 4.5). \u003ci\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease \u003c\/i\u003e Patients with systemic lupus erythematosus and mixed connective tissue disease may have an increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiac, hepatic and renal impairment \u003c\/i\u003e The medicine should be used with caution in patients with cardiac, renal or hepatic insufficiency. NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID can cause a dose-dependent reduction in the formation of prostaglandins and precipitate renal failure. Patients at highest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; however, this effect is not usually observed with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiovascular and cerebrovascular effects \u003c\/i\u003e Before starting treatment in patients with a positive history of hypertension and\/or heart failure, caution is required (discuss with your doctor or pharmacist), since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). \u003ci\u003eEffects on the central nervous system \u003c\/i\u003e Analgesic-induced headache. In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003ci\u003eGastrointestinal effects\u003c\/i\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. The risk of gastrointestinal haemorrhage, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by haemorrhage and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse reactions can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal reactions. Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2). Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003ci\u003eDermatological effects\u003c\/i\u003e The use of the medicine, especially if prolonged, can give rise to sensitization or local irritation phenomena. In such cases it is necessary to interrupt the treatment and consult a doctor to institute, if necessary, suitable therapy. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003ci\u003eInfections\u003c\/i\u003e Since isolated cases of exacerbation of inflammation related to infections (e.g. development of necrotizing fasciitis) have been described in temporal association with the systemic use of drugs belonging to the NSAID class, patients are recommended to immediately consult a doctor in case of appearance or worsening of signs of a bacterial infection during flurbiprofen-based therapy. A possible indication for starting antibiotic therapy must be taken into consideration. If mouth irritation develops, treatment should be discontinued. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain para-hydroxybenzoates which can cause allergic reactions (even delayed). BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain hydrogenated 40-polyoxyethylene castor oil which may cause localized skin reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain an aroma which in turn contains d-limonene. D-limonene can cause allergic reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain less than 1 mmol (23mg) sodium per 10 ml dose, i.e. essentially \"sodium-free\". BENACTIV GOLA Lemon and Honey flavored lozenges contain liquid glucose, liquid sucrose and honey (invert sugar). Patients suffering from rare problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. To be taken into consideration in people with diabetes mellitus: this medicine contains 1.07 g of glucose and 1.41 g of sucrose per tablet. BENACTIV GOLA Lemon and Honey flavored lozenges contain sulphites. Rarely it can cause serious hypersensitivity reactions and bronchospasm. BENACTIV GOLA Lemon and Honey flavored lozenges contain only a very small amount of gluten (from wheat starch). This medicine is considered “gluten-free” and is very unlikely to cause problems for a celiac patient. One tablet contains no more than 21.38 micrograms of gluten. If a patient is allergic to wheat (condition other than celiac disease) he or she should not take this medicine. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, farfalle, geraniol and linalool. Citral, citronellol, d-limonene, farfalle, geraniol and linalool can cause allergic reactions. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains butylated hydroxyanisole which can cause localized skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. BENACTIV GOLA Sugar-Free Lozenges Orange flavor is instead indicated for those patients who need to control their intake of sugars and calories. BENACTIV GOLA Orange flavored sugar-free lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. BENACTIV GOLA Orange flavored sugar-free lozenges contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. May have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. Do not use for prolonged treatments beyond 7 days. If you do not notice appreciable results after 3 days of treatment, the cause could be a different pathological condition. In these cases it is advisable to consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. However, inform your doctor if you are taking other medicines. Flurbiprofen should be avoided in association with: - Aspirin: unless the intake of low-dose aspirin (not exceeding 100 mg\/day or local prophylactic doses for cardiovascular protection) has been recommended by the doctor; As with other NSAID-containing medicinal products, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased side effects (see section 4.4). - Cox-2 inhibitors and other NSAIDs: concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects and an increased risk of adverse reactions (see section 4.4). Flurbiprofen should be used with caution in association with: - Anticoagulants: NSAIDs can potentiate the effects of anticoagulants such as warfarin (see section 4.4) - Antiaggregating agents: increased risk of gastrointestinal bleeding - Selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding - Antihypertensives (diuretics, ACE inhibitors and angiotensin II antagonists): i NSAIDs can reduce the effect of diuretics. Other antihypertensive drugs may potentiate nephrotoxicity caused by inhibition of cyclooxygenase, especially in patients with impaired renal function (these patients must be adequately hydrated) - Alcohol: may increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract - Cardiac glycosides: NSAIDs may exacerbate heart failure, reduce GFR (glomerular filtration rate) and increase plasma levels of glycosides - Cyclosporine: increased risk of nephrotoxicity - Corticosteroids: increased risk of gastrointestinal ulcer or haemorrhage with NSAIDs (see section 4.4) - Lithium: there is evidence for a possible increase in plasma lithium levels - Methotrexate: there may be an increase in plasma levels of methotrexate - Mifepristone: NSAIDs should not be used for 8-12 days after administration of mifepristone, as NSAIDs may reduce the effect of mifepristone - Quinolone antibiotics: data obtained in animals indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures - Tacrolimus: possible increased risk of nephrotoxicity when NSAIDs are administered together with tacrolimus - Zidovudine: increased risk of haematological toxicity when NSAIDs are administered with zidovudine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis (b) respiratory tract reactivity, e.g. asthma, aggravated asthma, bronchospasm, dyspnoea (c) various skin disorders, including for example skin rashes of different types, pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatosis (including necrolysis epidermal and erythema multiforme). The most commonly observed adverse reactions are gastrointestinal in nature. Local use of the medicine, especially if prolonged, can give rise to local sensitization or irritation phenomena. The dissolution of the medicine in tablet form in the oral cavity may be accompanied by sensations of heat or tingling in the oropharynx. In such cases it is necessary to interrupt treatment and institute, if necessary, suitable therapy. The following side effects have been reported, particularly after the administration of formulations for systemic use. They refer to those detected with the use of flurbiprofen used short term and at doses compatible with the classification of self-medication medicines. When treating chronic conditions and for long periods of time, additional side effects may occur. The side effects associated with the use of flurbiprofen are divided below based on system organ classification and frequency. Frequency is defined as: very common (≥ 1\/10), common (≥1\/100, \u003c1\/10), uncommon (≥1\/1,000, \u003c1\/100), rare (≥1\/10,000, \u003c1\/1,000), very rare (\u003c1\/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eDisorders of the blood and lymphatic system - Frequency: Not known. Adverse reactions: Anemia, thrombocytopenia, aplastic anemia and agranulocytosis.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Common. Adverse reactions: Dizziness, headache, paraesthesia.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Uncommon. Adverse reactions: Drowsiness.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Not known. Adverse reactions: Cerebrovascular accident, optic neuritis, migraine, confusional states, dizziness.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Rare. Adverse reactions: Anaphylactic reaction.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Not known. Adverse reactions: Angioedema, hypersensitivity\u003c\/p\u003e\n\u003cp\u003eEye disorders - Frequency: Not known. Adverse reactions: Vision impairment.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders - Frequency: Not known. Adverse reactions: Tinnitus.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Frequency: Not known. Adverse reactions: Heart failure, edema.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Frequency: Not known. Adverse reactions: Hypertension.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Common. Adverse reactions: Throat irritation.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Uncommon. Adverse reactions: Asthma, bronchospasm and dyspnea, oropharyngeal vesicular rash, oropharyngeal hypoesthesia.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Common. Adverse reactions: Diarrhoea, mouth ulceration, nausea, oral pain, oral paraesthesia, oropharyngeal pain, oral discomfort (hot or burning sensation, tingling in the mouth).\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Uncommon. Adverse reactions: Abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysesthesia, vomiting.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Adverse reactions: Melena, haematemesis, gastrointestinal haemorrhage, colitis, exacerbation of Crohn's disease, gastritis, peptic ulcer, gastric perforation, ulcer haemorrhage.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Uncommon. Adverse reactions: Skin rash, itching.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Not known. Adverse reactions: Urticaria, purpura, bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme).\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Frequency: Not known. Adverse reactions: Toxic nephropathy, tubulointerstitial nephritis and nephrotic syndrome, renal failure (as with other NSAIDs).\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and administration site conditions - Frequency: Uncommon. Adverse reactions: Pyrexia, pain.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and conditions relating to the administration site - Frequency: Not known. Adverse reactions: Discomfort, tiredness.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders - Frequency: Not known. Adverse reactions: Hepatitis.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Uncommon. Adverse reactions: Insomnia.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Not known. Adverse reactions: Depression, hallucination.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGiven the reduced content of the active ingredient and its local use, it is unlikely that overdose situations may occur. \u003cb\u003eSymptoms\u003c\/b\u003e The majority of patients who ingest clinically large quantities of NSAIDs develop nausea, vomiting, gastrointestinal irritation, epigastric pain, or more rarely diarrhea. Tinnitus, headache and gastrointestinal bleeding are also possible. In more severe cases of NSAID intoxication, central nervous system toxicity is observed, manifested by drowsiness, occasionally excitability, blurred vision and disorientation or coma. Occasionally patients develop seizures. In case of severe NSAID intoxication, metabolic acidosis may occur and the prothrombin time\/INR may be prolonged, probably due to interference with the action of coagulation factors present in circulation. Acute renal failure and liver damage may occur. An exacerbation of asthma is possible in asthmatic subjects. \u003cb\u003eTreatment\u003c\/b\u003e Treatment should be symptomatic and supportive and should include maintaining a patent airway and monitoring cardiac function and vital signs until stabilization. Oral administration of activated charcoal and, if necessary, correction of serum electrolytes should be considered if the patient presents within one hour of ingesting a potentially toxic amount. Seizures should be treated with intravenous diazepam or lorazepam if they are frequent or prolonged. Administer bronchodilators for asthma. There is no specific antidote for flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Flurbiprofen should not be administered during the first and second trimester of pregnancy unless strictly necessary. The use of flurbiprofen during the third trimester of pregnancy is contraindicated. \u003cu\u003eBreastfeeding\u003c\/u\u003e In a limited number of studies, flurbiprofen appears in breast milk in very low concentrations and is unlikely to have negative effects on the breastfed infant. However, administration of flurbiprofen is not recommended in breastfeeding mothers. \u003cu\u003eFertility\u003c\/u\u003e There is evidence to suggest that cyclooxygenase\/prostaglandin synthesis inhibitors may cause impairment of female fertility through an effect on ovulation. This is reversible upon discontinuation of treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt does not interfere with the ability to drive and use machinery.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":40720891445363,"sku":"033262027","price":12.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/reckitt-benckiser-h-it-spa-benactiv-gola-miele-limone-16-pastiglie-farmacia-dottor-tili-1213792527.webp?v=1767131032"},{"product_id":"oki-infiammazione-e-dolore-gola-spray-15ml","title":"Oki Inflammation and Pain Throat Spray 15ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 ml of spray for oral mucosa contains as active ingredient: Ketoprofen lysine salt 0.16 grams corresponding to 0.10 grams of Ketoprofen Excipient with known effects: Methyl parahydroxybenzoate, mint flavor (containing d-Limonene, eugenol, linalool), ever cool flavor (containing linalool). For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGlycerol 85%, xylitol, \u003cb\u003emethyl parahydroxybenzoate\u003c\/b\u003e, monobasic sodium phosphate, poloxamer 407, \u003cb\u003emint flavor (containing d-Limonene, eugenol, linalool)\u003c\/b\u003e, \u003cb\u003eever cool aroma (containing linalool)\u003c\/b\u003e, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOKi throat 0.16% spray for oral mucosa must not be administered in case of hypersensitivity to the active ingredient, to other non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients, to patients in whom substances with a similar mechanism of action (for example acetylsalicylic acid or other NSAIDs) cause asthma attacks, bronchospasm, acute rhinitis, or cause nasal polyps, urticaria or angioneurotic edema, in case of previous bronchial asthma, during pregnancy and breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e1-2 sprays up to 3 times a day, aimed directly at the affected part. Each spray delivers approximately 0.2 ml of solution, equivalent to 0.32 mg of active ingredient.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo special instructions\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially if prolonged, of topical drugs could give rise to sensitization phenomena, in which case it is necessary to suspend the treatment and adopt suitable therapeutic measures. This medicine contains methyl parahydroxybenzoate, known to cause allergic reactions (including delayed reactions). This medicine contains mint flavouring, which in turn contains d-limonene, eugenol and linalool which may cause allergic reactions. This medicine contains the ever cool flavour, which itself contains linalool which may cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt present there are no known interactions with other drugs: interactions which can also be excluded by considering the route of administration and the dosage of drug administered.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal side effects following topical administration on the oral mucosa of ketoprofen lysine salt solution are extremely rare and consist of irritative or allergic phenomena (angioneurotic edema), especially in subjects with hypersensitivity to NSAIDs. However, no systemic side effects emerged considering the route of administration and the dosage of drug administered. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTo date, there are no known cases of overdose even considering the quantity of active ingredient which would not make accidental overdose possible.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e There are no clinical data associated with the use of topical formulations of ketoprofen during pregnancy. Despite the lower systemic exposure compared to oral administration, it is not known whether the systemic exposure of ketoprofen achieved following topical administration could be harmful to an embryo\/fetus. During the third trimester of pregnancy, the systemic use of prostaglandin synthesis inhibitors, including ketoprofen, can induce cardiopulmonary and renal toxicity in the fetus. At the end of pregnancy there may be a prolongation of the bleeding time of the mother and the newborn and labor may be delayed. Consequently, Oki throat is contraindicated during pregnancy (see section 4.3). \u003cu\u003eBreastfeeding\u003c\/u\u003e Oki throat 0.16% spray for oral mucosa should not be used during breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known effects on the ability to drive and use machinery: effects which can be excluded considering the route of administration and the dosage of the drug administered.\u003c\/p\u003e","brand":"Dompé","offers":[{"title":"Default Title","offer_id":40740171087987,"sku":"041797022","price":11.16,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/dompe-farmaceutici-spa-oki-infiammazione-e-dolore-gola-spray-15ml-farmacia-dottor-tili-1213792514.webp?v=1767131207"},{"product_id":"aspi-mal-di-gola-spray-antidolorifico-15-ml-0-25","title":"Aspi Sore Throat Painkiller Spray 15 ml 0.25%","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eASPI THROAT Mouthwash\u003c\/b\u003e \u003cb\u003eASPI THROAT Spray for oral mucosa\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eASPI GOLA 0.25% Mouthwash 100 ml of solution contains: Active ingredient: Flurbiprofen 0.25 g ASPI GOLA 0.25% Spray for oral mucosa 100 ml of solution contains: Active ingredient: Flurbiprofen 0.25 g \u003ci\u003e \u003cu\u003eExcipients with known effects\u003c\/u\u003e \u003c\/i\u003e: ethanol 8.64 g methyl p-hydroxybenzoate 0.10 g propyl p-hydroxybenzoate 0.02 g hydrogenated castor oil-40 polyoxyethylene 2.00 g blue patent V dye (E131) 0.0006 g For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eASPI GOLA Mouthwash and ASPI GOLA Spray for oral mucosa Glycerol (98%), ethanol, non-crystallizable liquid sorbitol, hydrogenated castor oil-40 polyoxyethylene, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint flavour, patent blue V (E131), anhydrous citric acid, sodium hydroxide, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFlurbiprofen is contraindicated in patients with known hypersensitivity (asthma, bronchospasm, urticaria or allergic type) towards flurbiprofen or to any of the excipients listed in paragraph 6.1, and towards acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Flurbiprofen is also contraindicated in patients with a history of gastrointestinal bleeding or perforation related to previous NSAID treatment. Flurbiprofen should not be taken by patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal bleeding (defined as two or more distinct episodes of demonstrated ulceration or bleeding). Flurbiprofen is contraindicated in patients with severe heart failure. Third trimester of pregnancy\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.4). \u003cb\u003eASPI THROAT Mouthwash\u003c\/b\u003e 2-3 rinses or gargles per day with 10 ml (1 measuring spoon) of mouthwash diluted in half a glass of water or pure. \u003cb\u003eASPI THROAT Spray for oral mucosa\u003c\/b\u003e 2 sprays 3 times a day aimed directly at the affected part. Each spray delivers 0.2 ml of solution, equivalent to 0.5 mg of active ingredient.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special precautions for storage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, when using the product in its various pharmaceutical forms, any swallowing does not cause any harm to the patient, as the dose of flurbiprofen is widely lower than that commonly used in systemic treatments. Use of the product, especially if prolonged, can give rise to sensitization or local irritation phenomena; in such cases it is necessary to interrupt the treatment and consult the doctor to institute, if necessary, a suitable therapy. In patients with renal, cardiac or hepatic insufficiency the product should be used with caution. It is advisable not to combine the product with other NSAIDs. Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma. \u003ci\u003e \u003cu\u003eGastrointestinal effects\u003c\/u\u003e \u003c\/i\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. The risk of gastrointestinal haemorrhage, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by haemorrhage and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse events can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal events. Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2). \u003cb\u003eImportant information about some excipients\u003c\/b\u003e ASPI GOLA mouthwash and ASPI GOLA Spray contain para-hydroxybenzoates which can cause delayed allergic reactions, such as contact dermatitis; more rarely they can cause immediate reactions, with urticaria and bronchospasm. The dye patent blue V (E131) may cause allergic reactions. Polyoxyethylene Hydrogenated Castor Oil-40 may cause localized skin reactions. Both the mouthwash and the spray contain a small amount of ethyl alcohol, less than 100 mg per dose. Do not use for prolonged treatments. After short periods of treatment without appreciable results, consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. However, inform your doctor if you are taking other medicines. \u003cb\u003eAspirin\u003c\/b\u003e: As with other NSAID-containing medicines, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased side effects. \u003cb\u003eAnti-aggregating agents\u003c\/b\u003e: increased risk of gastrointestinal bleeding. \u003cb\u003eSelective serotonin reuptake inhibitors (SSRIs)\u003c\/b\u003e: increased risk of gastrointestinal bleeding. \u003cb\u003eCorticosteroids\u003c\/b\u003e: increased risk of gastrointestinal ulcer or bleeding with NSAIDs. \u003cb\u003eCox-2 inhibitors and other NSAIDs\u003c\/b\u003e: Concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following side effects have been reported, particularly after the administration of formulations for systemic use:\u003cb\u003ePathologies of the blood and lymphatic system\u003c\/b\u003e Thrombocytopenia, aplastic anemia and agranulocytosis \u003cb\u003eImmune system disorders\u003c\/b\u003e Anaphylaxis, angioedema, allergic reaction. \u003cb\u003eNervous system disorders\u003c\/b\u003e Dizziness, cerebrovascular accident, visual disturbances, optic neuritis, migraine, paraesthesia, depression, confusion, hallucination, vertigo, discomfort, fatigue and drowsiness. \u003cb\u003eEar and labyrinth disorders\u003c\/b\u003e Tinnitus \u003cb\u003eRespiratory, thoracic and mediastinal disorders\u003c\/b\u003e Respiratory tract reactivity (asthma, bronchospasm and dyspnea) \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e The most commonly observed adverse events are gastrointestinal in nature. The following have been reported after administration of flurbiprofen: nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melena, haematemesis, ulcerative stomatitis, gastrointestinal haemorrhage and exacerbation of colitis and Crohn's disease. Less frequently, gastritis, peptic ulcer, perforation and ulcer bleeding have been observed. \u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e Skin disorders including rash, pruritus, urticaria, purpura and very rarely bullous dermatoses (including Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis and Erythema multiforme). \u003cb\u003eRenal and urinary disorders\u003c\/b\u003e Nephrotoxicity in various forms, including interstitial nephritis and nephrotic syndrome. As with other NSAIDs, rare cases of renal failure have been reported. Topical use of the product, especially if prolonged, can give rise to sensitization or local irritation phenomena. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGiven the reduced content of the active ingredient and its local use, it is unlikely that overdose situations may occur. \u003cb\u003eSymptoms\u003c\/b\u003e Symptoms of overdose may include nausea, vomiting, and gastrointestinal irritation. \u003cb\u003eTreatment\u003c\/b\u003e Treatment should include gastric lavage and, if necessary, correction of the serum electrolyte picture. There is no specific antidote for flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDuring the first and second trimester of pregnancy, flurbiprofen should not be administered unless strictly necessary. The administration of flurbiprofen is not recommended in breastfeeding mothers.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt does not interfere with the ability to drive vehicles and use machines.\u003c\/p\u003e","brand":"Bayer","offers":[{"title":"Default Title","offer_id":46368895500615,"sku":"041513021","price":10.74,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/bayer-spa-aspi-mal-di-gola-spray-antidolorifico-15-ml-0-25-farmacia-dottor-tili-1213792509.webp?v=1767131327"},{"product_id":"aspi-gola-dolact-8-75mg-dose-spray-per-mucosa-orale-15ml","title":"Aspi Gola Dolact 8.75mg\/dose oral mucosa spray 15ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAspigoladolact is indicated for the short-term symptomatic treatment of acute pain in sore throat in adults.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne spray contains 2.91 mg of flurbiprofen. 3 sprays are equivalent to one dose, which contains 8.75 mg of flurbiprofen, corresponding to 17.16 mg\/ml of flurbiprofen. \u003cu\u003eExcipients with known effect: \u003c\/u\u003e ethanol: 0.22 mg\/dose. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBetadex (E459), Hydroxypropylbetadex, Dibasic sodium phosphate dodecahydrate, Citric acid monohydrate, Sodium hydroxide, Cherry flavouring, Sodium saccharin (E954), Purified water. \u003ci\u003eQualitative composition of the Cherry aroma\u003c\/i\u003e: Flavoring substances, Flavoring preparation, Ethyl alcohol, Glyceryl triacetate (E1518), Propylene glycol (E1520), Ascorbic acid (E300), Di-alpha tocopherol (E307), Water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. - Patients who have previously shown hypersensitivity reactions (e.g., asthma, bronchospasm, rhinitis, angioedema or urticaria) in response to acetylsalicylic acid or other NSAIDs. - Patients with current or previous recurrent peptic ulcers\/haemorrhages (two or more distinct episodes of demonstrated ulceration) and intestinal ulcer. - Patients with a history of gastrointestinal bleeding or perforation, severe colitis, bleeding or haematopoietic disorders related to previous therapy with NSAIDs. - Severe heart failure, renal failure or hepatic failure (see section 4.4). - Last trimester of pregnancy (see section 4.6). - Children and adolescents under 18 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage \u003c\/u\u003e \u003ci\u003eAdults aged 18 years and over:\u003c\/i\u003e One dose (3 sprays) directed to the affected part of the throat every 3-6 hours as needed, up to a maximum of 5 doses in a 24-hour period. \u003ci\u003eDo not reduce the number of sprays per dose\u003c\/i\u003e. This medicine should not be used for more than 3 days. \u003ci\u003ePediatric population\u003c\/i\u003e The safety and effectiveness of Aspigoladolact have not been established in children or adolescents under 18 years of age. \u003ci\u003eElderly patients\u003c\/i\u003e A general dosing recommendation cannot be given, as clinical experience to date is limited. Elderly people are at increased risk of serious consequences in case of adverse reactions. The lowest effective dose should be administered for the shortest possible duration of treatment needed to control symptoms (see section 4.4). \u003cu\u003eMethod of administration\u003c\/u\u003e Do not inhale while dispensing. For administration on the oral mucosa and only for short-term treatments. Before first use, it is necessary to activate the pump 4 times, pointing the nozzle away from your body, until the release of a uniform and constant mist is obtained. The pump is then ready for use. Between one use and another, dispense a minimum quantity of product, away from your body, in order to ensure that the nebulization is uniform and constant. Before using the product, always make sure that the nebulization is uniform and constant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not refrigerate or freeze.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by using the lowest effective dose for the shortest duration of treatment needed to control symptoms. \u003cu\u003eInfections\u003c\/u\u003e Since isolated cases of exacerbation of inflammation related to infections (e.g. development of necrotizing fasciitis) have been described in temporal association with the systemic use of drugs belonging to the NSAID class, patients are recommended to immediately consult a doctor in case of appearance or worsening of signs of a bacterial infection during therapy based on flurbiprofen spray. A possible indication for starting antibiotic therapy must be taken into consideration. In case of purulent bacterial pharyngitis\/tonsillitis, the patient should consult the doctor for a re-evaluation of the treatment. Treatment should not be administered for more than 3 days. \u003cu\u003eRespiratory disorders\u003c\/u\u003e Bronchospasm may be precipitated in patients with or with a history of bronchial asthma or allergic disease. Flurbiprofen spray should be used with caution in these patients. \u003cu\u003eOther NSAIDs\u003c\/u\u003e The use of flurbiprofen spray should be avoided concomitantly with other NSAIDs, including selective cyclooxygenase-2 inhibitors (see section 4.5). \u003cu\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease\u003c\/u\u003e Patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease may be at increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for short-term use such as flurbiprofen spray. \u003cu\u003eCardiovascular, renal and hepatic impairment\u003c\/u\u003e NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID can cause a dose-dependent reduction in prostaglandin formation and precipitate renal failure. Patients at highest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; this effect is not usually observed with products intended for short-term use such as flurbiprofen spray. \u003cu\u003eHepatic effects\u003c\/u\u003e Mild to moderate hepatic dysfunction (see sections 4.3 and 4.8). \u003cu\u003eCardiovascular and cerebrovascular effects\u003c\/u\u003e Before starting treatment in patients with a positive history of hypertension and\/or heart failure, caution is required (discuss with your doctor or pharmacist) since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Data from clinical and epidemiological studies suggest that the use of some NSAIDs (particularly at high doses and in long-term treatments) may be associated with a slight increase in the risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude this risk with flurbiprofen when administered at a daily dosage of less than 5 doses (3 actuations for each dose). \u003cu\u003eEffects on the central nervous system\u003c\/u\u003e Headache induced by analgesics - In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e NSAIDs should be administered with caution in patients with a history of gastrointestinal diseases (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Gastrointestinal bleeding, ulceration or perforation, which may be fatal, have been reported with all NSAIDs at any time during treatment, in the presence or absence of warning symptoms or a history of serious gastrointestinal events. The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing doses of NSAIDs, in patients with a history of ulcer, especially if complicated with the presence of haemorrhage or perforation (see section 4.3) and in the elderly; this effect is not usually observed with products intended for short-term use such as flurbiprofen spray. Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) to their healthcare provider. Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003cu\u003eHematological effects\u003c\/u\u003e Flurbiprofen, like other NSAIDs, can inhibit platelet aggregation and prolong bleeding time. Flurbiprofen spray should be used with caution in patients with potential bleeding abnormalities. \u003cu\u003eDermatological effects\u003c\/u\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen spray should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. This medicinal product contains less than 1 mmol (23 mg) sodium per dose (3 sprays), i.e. essentially 'sodium-free'. This medicine contains 0.22mg ethanol per dose (3 sprays), which is equivalent to 0.044% (w\/v). The amount in the dose of this medicine is equivalent to less than 0.9 ml of beer or 0.4 ml of wine. Treatment should be reevaluated if symptoms worsen or new symptoms occur. If mouth irritation develops, treatment with flurbiprofen should be discontinued. \u003cu\u003eElderly population\u003c\/u\u003e Elderly people experience an increased frequency of adverse reactions to NSAIDs, especially bleeding and gastrointestinal perforation, which can be fatal.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFlurbiprofen should be avoided in association with:\u003c\/p\u003e\n\u003cp\u003eOther NSAIDs including selective cyclooxygenase-2 inhibitors: Avoid concomitant use of two or more NSAIDs, as this may increase the risk of adverse effects (especially gastrointestinal adverse events such as ulcers and bleeding) (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eAcetylsalicylic acid (low doses): Unless taking low doses of aspirin (not exceeding 75 mg\/day) has been recommended by your doctor, as the potential risk of adverse events may increase (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eFlurbiprofen should be used with caution in association with:\u003c\/p\u003e\n\u003cp\u003eAnticoagulants: NSAIDs may potentiate the effects of anticoagulants such as warfarin (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eAntiplatelet agents: There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eAntihypertensive drugs (Diuretics, ACE inhibitors, Angiotensin II antagonists): NSAIDs can reduce the effect of diuretics. Other antihypertensive drugs may potentiate nephrotoxicity caused by cyclooxygenase inhibition, especially in patients with impaired renal function.\u003c\/p\u003e\n\u003cp\u003eCardiac glycosides: NSAIDs can exacerbate heart failure, reduce VGR (glomerular filtration rate) and increase plasma levels of glycosides, therefore adequate control and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003eCyclosporine: There is an increased risk of nephrotoxicity.\u003c\/p\u003e\n\u003cp\u003eCorticosteroids: There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eLithium: There may be an increase in serum lithium levels - adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003eMethotrexate: The administration of NSAIDs within 24 hours before or after the administration of methotrexate can lead to high concentrations of methotrexate and an increase in its toxic effects.\u003c\/p\u003e\n\u003cp\u003eMifepristone: NSAIDs should not be used for 8 - 12 days following administration of mifepristone, as they may reduce the effect of mifepristone.\u003c\/p\u003e\n\u003cp\u003eOral antidiabetics: Alterations in blood glucose levels have been reported (increasing the frequency of checks is recommended).\u003c\/p\u003e\n\u003cp\u003ePhenytoin: Serum levels of phenytoin may increase, therefore adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003ePotassium-sparing diuretics: Concomitant use may cause hyperkalemia.\u003c\/p\u003e\n\u003cp\u003eProbenecid and Sulfinpyrazone: Medicines containing probenecid and sulfinpyrazone may delay the excretion of flurbiprofen.\u003c\/p\u003e\n\u003cp\u003eQuinolone antibiotics: Animal data indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may be at increased risk of developing seizures.\u003c\/p\u003e\n\u003cp\u003eSelective serotonin reuptake inhibitors (SSRIs): There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eTacrolimus: An increased risk of nephrotoxicity is possible when NSAIDs are administered concomitantly with tacrolimus.\u003c\/p\u003e\n\u003cp\u003eZidovudine: There is an increased risk of hematological toxicity when NSAIDs are administered with zidovudine.\u003c\/p\u003e\n\u003cp\u003eAlcohol: May increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract.\u003c\/p\u003e\n\u003cp\u003eNo studies have yet found any interaction between flurbiprofen and tolbutamide or antacids. \u003cu\u003ePediatric population\u003c\/u\u003e No additional information is available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis; (b) respiratory tract reactivity, e.g. asthma, aggravated asthma, bronchospasm, dyspnoea; (c) various skin reactions, e.g. pruritus, urticaria, angioedema and, more rarely, exfoliative and bullous dermatosis (including epidermal necrolysis and erythema multiforme). Edema, hypertension and heart failure have been reported in association with treatment with NSAIDs. Data are insufficient to exclude this risk following the use of flurbiprofen oral mucosal spray, solution. The list of adverse effects reported below refers to what was experienced with flurbiprofen, used short term and at doses compatible with those reported in point 4.2. Very common (≥ 1\/10); Common (≥ 1\/100 to \u003c1\/10); Uncommon (≥1\/1,000 to \u003c1\/100); Rare (≥ 1\/10,000 to \u003c1\/1,000); Very rare (\u003c1\/10,000); Not known (frequency cannot be estimated from the available data). \u003ci\u003ePathologies of the blood and lymphatic system.\u003c\/i\u003e Not known: anemia, thrombocytopenia. \u003ci\u003eCardiovascular and cerebrovascular diseases.\u003c\/i\u003e Not known: edema, hypertension, heart failure. \u003ci\u003eNervous system disorders.\u003c\/i\u003e Common: dizziness, headache, paraesthesia. Uncommon: drowsiness. \u003ci\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/i\u003e Common: throat irritation; Uncommon: exacerbation of asthma and bronchospasm, dyspnoea, wheezing, oropharyngeal blistering, pharyngeal hypoesthesia. \u003ci\u003eGastrointestinal disorders.\u003c\/i\u003e Common: diarrhoea, mouth ulceration, nausea, oral pain, oral paraesthesia, oropharyngeal pain, oral discomfort (hot or burning sensation, tingling in the mouth); Uncommon: abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysesthesia, vomiting. \u003ci\u003ePathologies of the skin and subcutaneous tissue.\u003c\/i\u003e Uncommon: various types of skin rashes, itching; Not known: severe skin reactions such as bullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. \u003ci\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/i\u003e Uncommon: pyrexia, pain. \u003ci\u003eImmune system disorders.\u003c\/i\u003e Rare: anaphylactic reaction. \u003ci\u003ePsychiatric disorders.\u003c\/i\u003e Uncommon: insomnia. \u003ci\u003eHepatobiliary disorders.\u003c\/i\u003e Not known: hepatitis \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSymptoms\u003c\/u\u003e The majority of patients who have ingested clinically large quantities of NSAIDs will develop nausea, vomiting, epigastric pain, or more rarely diarrhea. Tinnitus, headache and gastrointestinal bleeding are also possible. In more severe cases of NSAID intoxication, central nervous system toxicity is observed, manifested by drowsiness, occasionally excitability, blurred vision and disorientation or coma. Occasionally patients develop seizures. In case of severe NSAID intoxication, metabolic acidosis may occur and the prothrombin time\/INR may be prolonged, probably due to interference with the action of coagulation factors present in circulation. Acute renal failure and liver damage may occur. An exacerbation of asthma is possible in asthmatic subjects. \u003cu\u003eTreatment\u003c\/u\u003e Treatment should be symptomatic and supportive and should include maintaining a patent airway and monitoring cardiac function and vital signs until stabilization. Oral administration of activated charcoal or gastric lavage and, if necessary, correction of serum electrolytes should be considered if the patient presents within one hour of ingesting a potentially toxic amount. Seizures should be treated with intravenous diazepam or lorazepam if they are frequent or prolonged. Administer bronchodilators for asthma. There is no specific antidote for flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis can negatively influence pregnancy and\/or embryonic\/fetal development. Data obtained from epidemiological studies suggest an increased risk of miscarriage, cardiac malformations and gastroschisis following the use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiovascular malformations was increased from less than 1% to approximately 1.5%. The risk is thought to increase with the dose and duration of therapy. In animals, the administration of a prostaglandin synthesis inhibitor has been shown to cause an increase in pre- and post-implantation losses and embryo-foetal lethality. In addition, an increased incidence of several malformations, including cardiovascular ones, has been reported in animals administered a prostaglandin synthesis inhibitor during the organogenetic period. Flurbiprofen should not be administered during the first and second trimester of pregnancy. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose: • the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction which may progress to renal failure with oligohydramnios. • the mother and newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, an anti-aggregating effect which can occur even at very low doses. - inhibition of uterine contractions resulting in a delay or prolongation of labor. Consequently, flurbiprofen is contraindicated during the third trimester of pregnancy (see section 4.3). \u003cu\u003eBreastfeeding\u003c\/u\u003e In a limited number of studies, flurbiprofen appears in breast milk at very low concentrations and is unlikely to have negative effects on the breastfed infant. However, due to the possible adverse effects of NSAIDs on breast-fed infants, the use of flurbiprofen spray by breastfeeding mothers is not recommended. \u003cu\u003eFertility\u003c\/u\u003e There is evidence to suggest that cyclooxygenase\/prostaglandin synthesis inhibitors may cause impairment of female fertility through an effect on ovulation. This is reversible upon discontinuation of treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo studies on the effects on the ability to drive and use machines have been performed. Dizziness, drowsiness and visual disturbances are side effects that can arise following the intake of NSAIDs. If these effects occur, patients should not drive or use machinery.\u003c\/p\u003e","brand":"Bayer","offers":[{"title":"Default Title","offer_id":51131202339143,"sku":"046444016","price":12.37,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/bayer-spa-aspi-gola-dolact-8-75mg-dose-spray-per-mucosa-orale-15ml-farmacia-dottor-tili-1213792392.jpg?v=1767132804"},{"product_id":"benagol-24-pastiglie-con-vitamina-c-gusto-arancia","title":"Benagol 24 tablets with vitamin C orange flavour","description":"\u003cp\u003e\u003cstrong\u003eBenagol with Vitamin C\u003c\/strong\u003e it's a \u003cstrong\u003eantiseptic for the throat\u003c\/strong\u003e formulated to relieve the \u003cstrong\u003esore throat\u003c\/strong\u003e and protect the oropharyngeal mucosa. Thanks to the combination of \u003cstrong\u003e2,4-dichlorobenzyl alcohol\u003c\/strong\u003e e \u003cstrong\u003eamylmetacresol\u003c\/strong\u003e, performs an action \u003cstrong\u003eantibacterial and disinfectant\u003c\/strong\u003e, helping to combat the microorganisms responsible for irritation.\u003c\/p\u003e\n\u003cp\u003eEnriched with \u003cstrong\u003eVitamin C\u003c\/strong\u003e, these tablets contribute to the normal functioning of the immune system, offering a \u003cstrong\u003edouble benefit\u003c\/strong\u003e against flu symptoms. The \u003cstrong\u003eorange flavour\u003c\/strong\u003e makes them pleasant to take, while the orosoluble formulation guarantees a gradual release for prolonged relief. The packaging from \u003cstrong\u003e16 tablets\u003c\/strong\u003e it is ideal for a practical and effective treatment.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy do you use Benagol 24 tablets with orange flavor vitamin C? What is it for?\u003c\/h3\u003e\u003cp\u003eAntiseptic of the oral cavity.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Benagol 24 orange flavored tablets with vitamin C?\u003c\/h3\u003e\u003cp\u003eBENAGOL Ginger and Spice flavored tablets Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), spice flavoring and ginger flavoring (containing cinnamale, citral, citronellol, eugenol, farinasol, geraniol, isoeugenol and linalool). BENAGOL Honey and Lemon flavored tablets Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid glucose (containing sulphites and wheat starch), liquid sucrose, mint essence and lemon essence (containing citral, d-limonene, geraniol and linalool), honey (invert sugar). BENAGOL Sugar-Free Lemon Flavor Lozenges Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid maltitol, isomalt, lemon flavoring (containing benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool). BENAGOL Strawberry flavor tablets without sugar Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid maltitol, isomalt, strawberry flavor (containing propylene glycol and benzyl alcohol). BENAGOL Cold Mint flavor tablets Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), mint flavor and eucalyptus essence (containing propylene glycol, benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool). BENAGOL Menthol-Eucalyptol flavor tablets Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg; menthol 8.0 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch) and eucalyptus essence (containing d-limonene). BENAGOL Tablets with Vitamin C Orange flavor Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg; sodium ascorbate 74.9 mg; ascorbic acid 33.5 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), orange flavor (containing citral, citronellol, d-limonene, geraniol, linalool), propylene glycol. For the full list of excipients, see section 6.1.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e\u003cu\u003eBENAGOL Ginger and Spice flavored tablets\u003c\/u\u003e: One tablet contains: liquid sucrose, liquid glucose (containing sulphites and wheat starch), tartaric acid, anthocyanins (E163) (containing sodium), plum flavour, cream flavour, spice flavor and ginger flavor (containing cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool), medium-chain saturated triglycerides. \u003cu\u003eBENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e: One tablet contains: mint essence and lemon essence (containing citral, d-limonene, geraniol and linalool), tartaric acid, honey (invert sugar), liquid glucose (containing sulphites and wheat starch), liquid sucrose. \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets\u003c\/u\u003e: One tablet contains: indigo carmine (E 132) (containing sodium), eucalyptus essence (containing d-limonene), tartaric acid, liquid sucrose, liquid glucose (containing sulphites and wheat starch). \u003cu\u003eBENAGOL Orange flavored tablets with Vitamin C\u003c\/u\u003e: One tablet contains: liquid sucrose, liquid glucose (containing sulphites and wheat starch), tartaric acid, orange flavor (containing citral, citronellol, d-limonene, geraniol and linalool), levomenthol, propylene glycol. \u003cu\u003eBENAGOL Lemon flavored tablets without sugar\u003c\/u\u003e: One tablet contains: lemon flavoring (containing benzyl alcohol, citral, citronellol, dlimonene, geraniol and linalool), sodium saccharin, tartaric acid, liquid maltitol, isomalt. \u003cu\u003eBENAGOL Strawberry flavored tablets without sugar\u003c\/u\u003e: One tablet contains: strawberry flavor (containing propylene glycol and benzyl alcohol), anthocyanins (E163) (containing sodium), sodium saccharin, tartaric acid, liquid maltitol, isomalt. \u003cu\u003eBENAGOL Cold Mint flavor tablets\u003c\/u\u003e: One tablet contains: xylitol, levomenthol, mint flavor and eucalyptus essence (containing propylene glycol, benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool), liquid sucrose, liquid glucose (containing sulphites and wheat starch).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow to take Benagol 24 tablets with orange flavor vitamin C?\u003c\/h3\u003e\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e The lowest effective dose for the shortest duration necessary to relieve symptoms should be used. \u003cb\u003eAdults and children over 6 years of age:\u003c\/b\u003e One tablet every 2 or 3 hours. In children over 6 years of age, consult your doctor for an appropriate dosage. Do not exceed the recommended doses and in particular, for BENAGOL with Vitamin C Orange flavor and BENAGOL Cold Mint flavor, do not exceed the daily maximum of 8 tablets. For all other flavors of BENAGOL, do not exceed the maximum daily dose of 12 tablets. \u003cu\u003eAdminister BENAGOL Cold Mint flavor and BENAGOL Ginger and Spice flavor to adults and children over the age of 12\u003c\/u\u003e. The duration of treatment with BENAGOL Menthol-Eucalyptol flavor must not exceed 3 days. BENAGOL Lemon flavor Without Sugar and BENAGOL Strawberry flavor Without Sugar are suitable for those patients who need to control their sugar and calorie intake. \u003ci\u003eElderly population\u003c\/i\u003e No data available. \u003cu\u003eMethod of administration\u003c\/u\u003e Oromucosal administration. The tablet should be dissolved slowly in the mouth.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Benagol 24 tablets with vitamin C orange flavor not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Do not administer to children under 6 years of age. BENAGOL Menthol-Eucalyptol flavor is contraindicated in children with a history of epilepsy or febrile convulsions. Do not administer BENAGOL Cold Mint flavor and BENAGOL Ginger and Spice flavor to children under 12 years of age.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eBENAGOL Menthol - Eucalyptol flavour: due to the presence of menthol and in case of non-compliance with the recommended doses there may be a risk of convulsions in children and infants. Adverse reactions associated with the use of 2,4 dichlorobenzyl alcohol, amylmetacresol, levomenthol and ascorbic acid are listed below, divided by frequency and organ class. Frequencies are defined as: Very common (≥1\/10); Common (≥1\/100 and \u003c1\/10); Uncommon (≥1\/1000 and \u003c1\/100); Rare (≥1\/10000 and \u003c1\/1000); Very rare (\u003c1\/10000); Not known (frequency cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eClassification by systems and organs\u003c\/b\u003e \u003cb\u003eFrequency\u003c\/b\u003e \u003cb\u003eAdverse reactions\u003c\/b\u003e\u003cbr\u003eImmune system disorders Rare Hypersensitivity\u003cbr\u003eGastrointestinal disorders Rare Glossitis\u003cbr\u003eNot known Abdominal pain, nausea, gastrointestinal discomfort\u003cbr\u003eSkin and subcutaneous tissue disorders Not known Rash\u003c\/p\u003e\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003eWhich medicines or foods can modify the effect of Benagol 24 orange flavored tablets with vitamin C?\u003c\/h3\u003e\u003cp\u003eBENAGOL Menthol-Eucalyptol flavor must not be used in conjunction with other products (medicines or cosmetics) containing terpene derivatives, regardless of the route of administration (oral, rectal, cutaneous, nasal or inhalation).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003eCan Benagol 24 tablets with vitamin C orange flavor be used during pregnancy and breastfeeding?\u003c\/h3\u003e\u003cp\u003eIn pregnant and breastfeeding women, the product should be administered only if clearly necessary. \u003cu\u003ePregnancy\u003c\/u\u003e There are no, or limited numbers, of data relating to the use of the active ingredients of BENAGOL in pregnant women. BENAGOL Menthol-Eucalyptol flavor is not recommended during pregnancy and in women of childbearing age who do not use contraceptive measures. \u003cu\u003eBreastfeeding\u003c\/u\u003e It is not known whether the active substances or their metabolites are excreted in breast milk. The risk to newborns and infants cannot be excluded. Ascorbic acid or its metabolites are excreted in breast milk. \u003cu\u003eFertility\u003c\/u\u003e No data are available regarding the effect on fertility. BENAGOL Menthol-Eucalyptol flavor is not recommended in women of childbearing age who are not using contraceptive measures.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Benagol 24 orange flavored tablets with vitamin C?\u003c\/h3\u003e\u003cp\u003eBe careful with pre-school children as if the tablets are swallowed whole they may cause choking. In the event of the appearance of sensitization or irritation phenomena, administration should be discontinued and suitable treatment instituted. BENAGOL Menthol-Eucalyptol flavor contains terpene derivatives which, in excessive doses, can cause neurological disorders such as convulsions in infants and children. Treatment with BENAGOL Menthol-Eucalyptol flavor must not be prolonged for more than 3 days due to the risks associated with the accumulation of terpene derivatives, such as \u003ci\u003eexample camphor, cineol, niaouli, wild thyme, terpineol, terpine, citral, menthol and essential oils of pine needles, eucalyptus and turpentine\u003c\/i\u003e (due to their lipophilic properties the rate of metabolism and disposal is not known) in tissues and the brain, in particular neuropsychological disorders. A higher than recommended dose should not be used to avoid an increased risk of adverse drug reactions and disorders associated with overdose (see section 4.9). BENAGOL Menthol-Eucalyptol flavor is flammable, it should not be brought near flames. \u003ci\u003eImportant information about some excipients\u003c\/i\u003e \u003cu\u003eBENAGOL Ginger and Spice flavored tablets, BENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e, \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets, BENAGOL Orange flavor tablets with Vitamin C, BENAGOL Cold Mint flavor tablets contain\u003c\/u\u003e Liquid glucose: - Patients suffering from rare hereditary problems of glucose-galactose malabsorption should not take this medicine. - To be taken into consideration in people suffering from diabetes mellitus: BENAGOL Ginger and Spice flavored tablets contains 1.10 g of glucose per tablet. BENAGOL Honey and Lemon flavored tablets contains 0.98 g of glucose per tablet. BENAGOL Menthol-Eucalyptol flavor tablets contains 1.01 g of glucose per tablet. BENAGOL Tablets with Vitamin C Orange flavor contains 0.97 g of glucose per tablet. BENAGOL Cold Mint flavor tablets contains 1.10 g of glucose per tablet. - Liquid glucose contains sulphites. These medicines can rarely cause serious hypersensitivity reactions and bronchospasm. - Liquid glucose contains wheat starch. These medicines contain only a very small amount of gluten (from wheat starch). These medicines are considered “gluten-free” and are very unlikely to cause problems if the patient has celiac disease. One tablet of BENAGOL Ginger and Spice flavored tablets contains no more than 22.04 micrograms of gluten. One tablet of BENAGOL Honey and Lemon flavored tablets contains no more than 19.52 micrograms of gluten. One tablet of BENAGOL Menthol-Eucalyptol flavor contains no more than 20.26 micrograms of gluten. One tablet of BENAGOL Tablets with Vitamin C Orange flavor contains no more than 19.38 micrograms of gluten. One tablet of BENAGOL Cold Mint flavor tablets contains no more than 22.04 micrograms of gluten. If the patient is allergic to wheat (a condition other than celiac disease) he should not take these medicines. Liquid sucrose: - Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. - To be taken into consideration in people suffering from diabetes mellitus: BENAGOL Ginger and Spice flavored tablets contains 1.38 g of sucrose per tablet. BENAGOL Honey and Lemon flavored tablets contains 1.44 g of sucrose per tablet. BENAGOL Menthol-Eucalyptol flavor tablets contains 1.50 g of sucrose per tablet. BENAGOL Tablets with Vitamin C Orange flavor contains 1.44 g of sucrose per tablet. BENAGOL Cold Mint flavor tablets contains 1.38 g of sucrose per tablet. \u003cu\u003eBENAGOL Ginger and Spice flavored tablets, BENAGOL Menthol-Eucalyptol flavored tablets\u003c\/u\u003e, \u003cu\u003eBENAGOL Tablets with Vitamin C Orange flavor, BENAGOL Tablets Lemon flavor Without Sugar, BENAGOL Tablets Strawberry flavor Without Sugar\u003c\/u\u003e These medicines contain less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'. \u003cu\u003eBENAGOL Lemon Flavor Tablets Without Sugar and BENAGOL Strawberry Flavor Tablets Without Sugar\u003c\/u\u003e These medicines contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. They may have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. \u003cu\u003eBENAGOL Ginger and Spice flavored tablets\u003c\/u\u003e This medicine contains a flavoring which contains cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool. Cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool can cause allergic reactions. This medicine contains excipients that can cause a warm sensation in the mouth and throat when you suck the lozenge. \u003cu\u003eBENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e This medicine contains a flavoring which contains citral, d-limonene, geraniol and linalool. Citral, d-limonene, geraniol and linalool can cause allergic reactions. This medicine contains honey (invert sugar). Patients suffering from rare hereditary problems of fructose intolerance, or glucose-galactose malabsorption, should not take this medicine. \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets\u003c\/u\u003e This medicine contains a flavoring which contains d-limonene. D-limonene can cause allergic reactions. \u003cu\u003eBENAGOL Orange flavored tablets with Vitamin C\u003c\/u\u003e This medicine contains a flavoring which contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. This medicine contains 3 mg of propylene glycol per tablet. \u003cu\u003eBENAGOL Lemon flavored tablets without sugar\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool. Benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. \u003cu\u003eBENAGOL Strawberry flavored tablets without sugar\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol. Benzyl alcohol can cause allergic reactions. This medicine contains 7.30 mg of propylene glycol in each tablet. \u003cu\u003eBENAGOL Cold Mint flavor tablets\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool. Benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool can cause allergic reactions. This medicine contains 1.89 mg of propylene glycol in each tablet.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eA possible overdose could only cause gastrointestinal disorders, for which appropriate symptomatic treatments must be adopted. BENAGOL Menthol-Eucalyptol flavour: in case of accidental oral intake or incorrect administration in infants and children there may be a risk of neurological disorders. If necessary, administer appropriate symptomatic treatment in specialized treatment centers.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eNo effects on the ability to drive or use machines are reported.\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow do you store Benagol 24 orange flavored tablets with vitamin C?\u003c\/h3\u003e\u003cp\u003eDo not store above 25°C.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Benagol 24 tablets with orange flavor vitamin C?\u003c\/h3\u003e\u003cp\u003e24 tablets\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51131202470215,"sku":"016242075","price":12.28,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-benagol-24-pastiglie-con-vitamina-c-gusto-arancia-farmacia-dottor-tili-1213792390.webp?v=1767132831"},{"product_id":"benagol-24-pastiglie-gusto-miele-e-limone","title":"Benagol 24 tablets honey and lemon flavour","description":"\u003cp\u003e\u003cstrong\u003eBenagol Honey and Lemon\u003c\/strong\u003e it's a \u003cstrong\u003eantiseptic for the throat\u003c\/strong\u003e in tablets, indicated for the treatment of \u003cstrong\u003eoropharyngeal irritation\u003c\/strong\u003e and of \u003cstrong\u003esore throat\u003c\/strong\u003e mild or moderate. Thanks to the combination of \u003cstrong\u003e2,4-dichlorobenzyl alcohol\u003c\/strong\u003e e \u003cstrong\u003eamylmetacresol\u003c\/strong\u003e, performs an action \u003cstrong\u003eantibacterial and disinfectant\u003c\/strong\u003e, helping to combat the microorganisms responsible for infections.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003ehoney and lemon flavour\u003c\/strong\u003e makes the intake more pleasant, while the formulation in \u003cstrong\u003eorosoluble tablets\u003c\/strong\u003e guarantees immediate and prolonged relief. Ideal for \u003cstrong\u003erelieve burning, pain and discomfort in the throat\u003c\/strong\u003e, Benagol is a practical and effective remedy to always keep on hand. The package contains \u003cstrong\u003e16 tablets\u003c\/strong\u003e, perfect for prolonged treatment.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy do you use Benagol 24 honey and lemon flavored tablets? What is it for?\u003c\/h3\u003e\u003cp\u003eAntiseptic of the oral cavity.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Benagol 24 honey and lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003eBENAGOL Ginger and Spice flavored tablets Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), spice flavoring and ginger flavoring (containing cinnamale, citral, citronellol, eugenol, farinasol, geraniol, isoeugenol and linalool). BENAGOL Honey and Lemon flavored tablets Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid glucose (containing sulphites and wheat starch), liquid sucrose, mint essence and lemon essence (containing citral, d-limonene, geraniol and linalool), honey (invert sugar). BENAGOL Sugar-Free Lemon Flavor Lozenges Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid maltitol, isomalt, lemon flavoring (containing benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool). BENAGOL Strawberry flavor tablets without sugar Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid maltitol, isomalt, strawberry flavor (containing propylene glycol and benzyl alcohol). BENAGOL Cold Mint flavor tablets Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), mint flavor and eucalyptus essence (containing propylene glycol, benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool). BENAGOL Menthol-Eucalyptol flavor tablets Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg; menthol 8.0 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch) and eucalyptus essence (containing d-limonene). BENAGOL Tablets with Vitamin C Orange flavor Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg; sodium ascorbate 74.9 mg; ascorbic acid 33.5 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), orange flavor (containing citral, citronellol, d-limonene, geraniol, linalool), propylene glycol. For the full list of excipients, see section 6.1.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e\u003cu\u003eBENAGOL Ginger and Spice flavored tablets\u003c\/u\u003e: One tablet contains: liquid sucrose, liquid glucose (containing sulphites and wheat starch), tartaric acid, anthocyanins (E163) (containing sodium), plum flavour, cream flavour, spice flavor and ginger flavor (containing cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool), medium-chain saturated triglycerides. \u003cu\u003eBENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e: One tablet contains: mint essence and lemon essence (containing citral, d-limonene, geraniol and linalool), tartaric acid, honey (invert sugar), liquid glucose (containing sulphites and wheat starch), liquid sucrose. \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets\u003c\/u\u003e: One tablet contains: indigo carmine (E 132) (containing sodium), eucalyptus essence (containing d-limonene), tartaric acid, liquid sucrose, liquid glucose (containing sulphites and wheat starch). \u003cu\u003eBENAGOL Orange flavored tablets with Vitamin C\u003c\/u\u003e: One tablet contains: liquid sucrose, liquid glucose (containing sulphites and wheat starch), tartaric acid, orange flavor (containing citral, citronellol, d-limonene, geraniol and linalool), levomenthol, propylene glycol. \u003cu\u003eBENAGOL Lemon flavored tablets without sugar\u003c\/u\u003e: One tablet contains: lemon flavoring (containing benzyl alcohol, citral, citronellol, dlimonene, geraniol and linalool), sodium saccharin, tartaric acid, liquid maltitol, isomalt. \u003cu\u003eBENAGOL Strawberry flavored tablets without sugar\u003c\/u\u003e: One tablet contains: strawberry flavor (containing propylene glycol and benzyl alcohol), anthocyanins (E163) (containing sodium), sodium saccharin, tartaric acid, liquid maltitol, isomalt. \u003cu\u003eBENAGOL Cold Mint flavor tablets\u003c\/u\u003e: One tablet contains: xylitol, levomenthol, mint flavor and eucalyptus essence (containing propylene glycol, benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool), liquid sucrose, liquid glucose (containing sulphites and wheat starch).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow to take Benagol 24 honey and lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e The lowest effective dose for the shortest duration necessary to relieve symptoms should be used. \u003cb\u003eAdults and children over 6 years of age:\u003c\/b\u003e One tablet every 2 or 3 hours. In children over 6 years of age, consult your doctor for an appropriate dosage. Do not exceed the recommended doses and in particular, for BENAGOL with Vitamin C Orange flavor and BENAGOL Cold Mint flavor, do not exceed the daily maximum of 8 tablets. For all other flavors of BENAGOL, do not exceed the maximum daily dose of 12 tablets. \u003cu\u003eAdminister BENAGOL Cold Mint flavor and BENAGOL Ginger and Spice flavor to adults and children over the age of 12\u003c\/u\u003e. The duration of treatment with BENAGOL Menthol-Eucalyptol flavor must not exceed 3 days. BENAGOL Lemon flavor Without Sugar and BENAGOL Strawberry flavor Without Sugar are suitable for those patients who need to control their sugar and calorie intake. \u003ci\u003eElderly population\u003c\/i\u003e No data available. \u003cu\u003eMethod of administration\u003c\/u\u003e Oromucosal administration. The tablet should be dissolved slowly in the mouth.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Benagol 24 honey and lemon flavored tablets not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Do not administer to children under 6 years of age. BENAGOL Menthol-Eucalyptol flavor is contraindicated in children with a history of epilepsy or febrile convulsions. Do not administer BENAGOL Cold Mint flavor and BENAGOL Ginger and Spice flavor to children under 12 years of age.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eBENAGOL Menthol - Eucalyptol flavour: due to the presence of menthol and in case of non-compliance with the recommended doses there may be a risk of convulsions in children and infants. Adverse reactions associated with the use of 2,4 dichlorobenzyl alcohol, amylmetacresol, levomenthol and ascorbic acid are listed below, divided by frequency and organ class. Frequencies are defined as: Very common (≥1\/10); Common (≥1\/100 and \u003c1\/10); Uncommon (≥1\/1000 and \u003c1\/100); Rare (≥1\/10000 and \u003c1\/1000); Very rare (\u003c1\/10000); Not known (frequency cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.\u003c\/p\u003e\u003cb\u003eClassification by systems and organs\u003c\/b\u003e \u003cb\u003eFrequency\u003c\/b\u003e \u003cb\u003eAdverse reactions\u003c\/b\u003e\u003cbr\u003eImmune system disorders Rare Hypersensitivity\u003cbr\u003eGastrointestinal disorders Rare Glossitis\u003cbr\u003eNot known Abdominal pain, nausea, gastrointestinal discomfort\u003cbr\u003eSkin and subcutaneous tissue disorders Not known Rash\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003eWhich medicines or foods can modify the effect of Benagol 24 honey and lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003eBENAGOL Menthol-Eucalyptol flavor must not be used in conjunction with other products (medicines or cosmetics) containing terpene derivatives, regardless of the route of administration (oral, rectal, cutaneous, nasal or inhalation).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003eCan Benagol 24 honey and lemon flavored tablets be used during pregnancy and breastfeeding?\u003c\/h3\u003e\u003cp\u003eIn pregnant and breastfeeding women, the product should be administered only if clearly necessary. \u003cu\u003ePregnancy\u003c\/u\u003e There are no, or limited numbers, of data relating to the use of the active ingredients of BENAGOL in pregnant women. BENAGOL Menthol-Eucalyptol flavor is not recommended during pregnancy and in women of childbearing age who do not use contraceptive measures. \u003cu\u003eBreastfeeding\u003c\/u\u003e It is not known whether the active substances or their metabolites are excreted in breast milk. The risk to newborns and infants cannot be excluded. Ascorbic acid or its metabolites are excreted in breast milk. \u003cu\u003eFertility\u003c\/u\u003e No data are available regarding the effect on fertility. BENAGOL Menthol-Eucalyptol flavor is not recommended in women of childbearing age who are not using contraceptive measures.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Benagol 24 honey and lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003eBe careful with pre-school children as if the tablets are swallowed whole they may cause choking. In the event of the appearance of sensitization or irritation phenomena, administration should be discontinued and suitable treatment instituted. BENAGOL Menthol-Eucalyptol flavor contains terpene derivatives which, in excessive doses, can cause neurological disorders such as convulsions in infants and children. Treatment with BENAGOL Menthol-Eucalyptol flavor must not be prolonged for more than 3 days due to the risks associated with the accumulation of terpene derivatives, such as \u003ci\u003eexample camphor, cineol, niaouli, wild thyme, terpineol, terpine, citral, menthol and essential oils of pine needles, eucalyptus and turpentine\u003c\/i\u003e (due to their lipophilic properties the rate of metabolism and disposal is not known) in tissues and the brain, in particular neuropsychological disorders. A higher than recommended dose should not be used to avoid an increased risk of adverse drug reactions and disorders associated with overdose (see section 4.9). BENAGOL Menthol-Eucalyptol flavor is flammable, it should not be brought near flames. \u003ci\u003eImportant information about some excipients\u003c\/i\u003e \u003cu\u003eBENAGOL Ginger and Spice flavored tablets, BENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e, \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets, BENAGOL Orange flavor tablets with Vitamin C, BENAGOL Cold Mint flavor tablets contain\u003c\/u\u003e Liquid glucose: - Patients suffering from rare hereditary problems of glucose-galactose malabsorption should not take this medicine. - To be taken into consideration in people suffering from diabetes mellitus: BENAGOL Ginger and Spice flavored tablets contains 1.10 g of glucose per tablet. BENAGOL Honey and Lemon flavored tablets contains 0.98 g of glucose per tablet. BENAGOL Menthol-Eucalyptol flavor tablets contains 1.01 g of glucose per tablet. BENAGOL Tablets with Vitamin C Orange flavor contains 0.97 g of glucose per tablet. BENAGOL Cold Mint flavor tablets contains 1.10 g of glucose per tablet. - Liquid glucose contains sulphites. These medicines can rarely cause serious hypersensitivity reactions and bronchospasm. - Liquid glucose contains wheat starch. These medicines contain only a very small amount of gluten (from wheat starch). These medicines are considered “gluten-free” and are very unlikely to cause problems if the patient has celiac disease. One tablet of BENAGOL Ginger and Spice flavored tablets contains no more than 22.04 micrograms of gluten. One tablet of BENAGOL Honey and Lemon flavored tablets contains no more than 19.52 micrograms of gluten. One tablet of BENAGOL Menthol-Eucalyptol flavor contains no more than 20.26 micrograms of gluten. One tablet of BENAGOL Tablets with Vitamin C Orange flavor contains no more than 19.38 micrograms of gluten. One tablet of BENAGOL Cold Mint flavor tablets contains no more than 22.04 micrograms of gluten. If the patient is allergic to wheat (a condition other than celiac disease) he should not take these medicines. Liquid sucrose: - Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. - To be taken into consideration in people suffering from diabetes mellitus: BENAGOL Ginger and Spice flavored tablets contains 1.38 g of sucrose per tablet. BENAGOL Honey and Lemon flavored tablets contains 1.44 g of sucrose per tablet. BENAGOL Menthol-Eucalyptol flavor tablets contains 1.50 g of sucrose per tablet. BENAGOL Tablets with Vitamin C Orange flavor contains 1.44 g of sucrose per tablet. BENAGOL Cold Mint flavor tablets contains 1.38 g of sucrose per tablet. \u003cu\u003eBENAGOL Ginger and Spice flavored tablets, BENAGOL Menthol-Eucalyptol flavored tablets\u003c\/u\u003e, \u003cu\u003eBENAGOL Tablets with Vitamin C Orange flavor, BENAGOL Tablets Lemon flavor Without Sugar, BENAGOL Tablets Strawberry flavor Without Sugar\u003c\/u\u003e These medicines contain less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'. \u003cu\u003eBENAGOL Lemon Flavor Tablets Without Sugar and BENAGOL Strawberry Flavor Tablets Without Sugar\u003c\/u\u003e These medicines contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. They may have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. \u003cu\u003eBENAGOL Ginger and Spice flavored tablets\u003c\/u\u003e This medicine contains a flavoring which contains cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool. Cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool can cause allergic reactions. This medicine contains excipients that can cause a warm sensation in the mouth and throat when you suck the lozenge. \u003cu\u003eBENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e This medicine contains a flavoring which contains citral, d-limonene, geraniol and linalool. Citral, d-limonene, geraniol and linalool can cause allergic reactions. This medicine contains honey (invert sugar). Patients suffering from rare hereditary problems of fructose intolerance, or glucose-galactose malabsorption, should not take this medicine. \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets\u003c\/u\u003e This medicine contains a flavoring which contains d-limonene. D-limonene can cause allergic reactions. \u003cu\u003eBENAGOL Orange flavored tablets with Vitamin C\u003c\/u\u003e This medicine contains a flavoring which contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. This medicine contains 3 mg of propylene glycol per tablet. \u003cu\u003eBENAGOL Lemon flavored tablets without sugar\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool. Benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. \u003cu\u003eBENAGOL Strawberry flavored tablets without sugar\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol. Benzyl alcohol can cause allergic reactions. This medicine contains 7.30 mg of propylene glycol in each tablet. \u003cu\u003eBENAGOL Cold Mint flavor tablets\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool. Benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool can cause allergic reactions. This medicine contains 1.89 mg of propylene glycol in each tablet.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eA possible overdose could only cause gastrointestinal disorders, for which appropriate symptomatic treatments must be adopted. BENAGOL Menthol-Eucalyptol flavour: in case of accidental oral intake or incorrect administration in infants and children there may be a risk of neurological disorders. If necessary, administer appropriate symptomatic treatment in specialized treatment centers.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eNo effects on the ability to drive or use machines are reported.\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow do you store Benagol 24 honey and lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003eDo not store above 25°C.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Benagol 24 honey and lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003e24 tablets\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51131220459847,"sku":"016242063","price":12.28,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-benagol-24-pastiglie-gusto-miele-e-limone-farmacia-dottor-tili-1213792353.jpg?v=1767142726"},{"product_id":"benagol-24-pastiglie-gusto-limone-senza-zucchero","title":"Benagol 24 lemon flavoured tablets without sugar","description":"\u003cp\u003eBenagol 24 sugar-free lemon flavored tablets is a product formulated to offer an action \u003cstrong\u003eantiseptic of the oral cavity\u003c\/strong\u003e. Each tablet contains the active ingredients \u003cstrong\u003e2,4-dichlorobenzyl alcohol\u003c\/strong\u003e e \u003cstrong\u003eamylmetacresol\u003c\/strong\u003e, known for their antibacterial properties. This product is ideal for those looking for a sugar-free option, thanks to the use of \u003cstrong\u003eliquid maltitol\u003c\/strong\u003e e \u003cstrong\u003eisomalt\u003c\/strong\u003e as sweeteners. The lemon aroma, enriched with components such as \u003cstrong\u003ebenzyl alcohol\u003c\/strong\u003e, \u003cstrong\u003ecitral\u003c\/strong\u003e, \u003cstrong\u003ecitronellol\u003c\/strong\u003e, \u003cstrong\u003ed-limonene\u003c\/strong\u003e, \u003cstrong\u003egeraniol\u003c\/strong\u003e e \u003cstrong\u003elinalool\u003c\/strong\u003e, gives a fresh and pleasant taste. The tablets are designed to dissolve slowly in the mouth, ensuring a gradual release of the active ingredients. Benagol is an effective choice for maintaining oral health by reducing the growth of bacteria in the throat and mouth.\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy do I use Benagol 24 sugar-free lemon flavored tablets? What is it for?\u003c\/h3\u003e\u003cp\u003eAntiseptic of the oral cavity.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Benagol 24 sugar-free lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003eBENAGOL Ginger and Spice flavored tablets Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), spice flavoring and ginger flavoring (containing cinnamale, citral, citronellol, eugenol, farinasol, geraniol, isoeugenol and linalool). BENAGOL Honey and Lemon flavored tablets Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid glucose (containing sulphites and wheat starch), liquid sucrose, mint essence and lemon essence (containing citral, d-limonene, geraniol and linalool), honey (invert sugar). BENAGOL Sugar-Free Lemon Flavor Lozenges Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid maltitol, isomalt, lemon flavoring (containing benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool). BENAGOL Strawberry flavor tablets without sugar Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid maltitol, isomalt, strawberry flavor (containing propylene glycol and benzyl alcohol). BENAGOL Cold Mint flavor tablets Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), mint flavor and eucalyptus essence (containing propylene glycol, benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool). BENAGOL Menthol-Eucalyptol flavor tablets Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg; menthol 8.0 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch) and eucalyptus essence (containing d-limonene). BENAGOL Tablets with Vitamin C Orange flavor Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg; sodium ascorbate 74.9 mg; ascorbic acid 33.5 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), orange flavor (containing citral, citronellol, d-limonene, geraniol, linalool), propylene glycol. For the full list of excipients, see section 6.1.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp\u003e\u003cu\u003eBENAGOL Ginger and Spice flavored tablets\u003c\/u\u003e: One tablet contains: liquid sucrose, liquid glucose (containing sulphites and wheat starch), tartaric acid, anthocyanins (E163) (containing sodium), plum flavour, cream flavour, spice flavor and ginger flavor (containing cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool), medium-chain saturated triglycerides. \u003cu\u003eBENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e: One tablet contains: mint essence and lemon essence (containing citral, d-limonene, geraniol and linalool), tartaric acid, honey (invert sugar), liquid glucose (containing sulphites and wheat starch), liquid sucrose. \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets\u003c\/u\u003e: One tablet contains: indigo carmine (E 132) (containing sodium), eucalyptus essence (containing d-limonene), tartaric acid, liquid sucrose, liquid glucose (containing sulphites and wheat starch). \u003cu\u003eBENAGOL Orange flavored tablets with Vitamin C\u003c\/u\u003e: One tablet contains: liquid sucrose, liquid glucose (containing sulphites and wheat starch), tartaric acid, orange flavor (containing citral, citronellol, d-limonene, geraniol and linalool), levomenthol, propylene glycol. \u003cu\u003eBENAGOL Lemon flavored tablets without sugar\u003c\/u\u003e: One tablet contains: lemon flavoring (containing benzyl alcohol, citral, citronellol, dlimonene, geraniol and linalool), sodium saccharin, tartaric acid, liquid maltitol, isomalt. \u003cu\u003eBENAGOL Strawberry flavored tablets without sugar\u003c\/u\u003e: One tablet contains: strawberry flavor (containing propylene glycol and benzyl alcohol), anthocyanins (E163) (containing sodium), sodium saccharin, tartaric acid, liquid maltitol, isomalt. \u003cu\u003eBENAGOL Cold Mint flavor tablets\u003c\/u\u003e: One tablet contains: xylitol, levomenthol, mint flavor and eucalyptus essence (containing propylene glycol, benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool), liquid sucrose, liquid glucose (containing sulphites and wheat starch).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow to take Benagol 24 sugar-free lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e The lowest effective dose for the shortest duration necessary to relieve symptoms should be used. \u003cb\u003eAdults and children over 6 years of age:\u003c\/b\u003e One tablet every 2 or 3 hours. In children over 6 years of age, consult your doctor for an appropriate dosage. Do not exceed the recommended doses and in particular, for BENAGOL with Vitamin C Orange flavor and BENAGOL Cold Mint flavor, do not exceed the daily maximum of 8 tablets. For all other flavors of BENAGOL, do not exceed the maximum daily dose of 12 tablets. \u003cu\u003eAdminister BENAGOL Cold Mint flavor and BENAGOL Ginger and Spice flavor to adults and children over the age of 12\u003c\/u\u003e. The duration of treatment with BENAGOL Menthol-Eucalyptol flavor must not exceed 3 days. BENAGOL Lemon flavor Without Sugar and BENAGOL Strawberry flavor Without Sugar are suitable for those patients who need to control their sugar and calorie intake. \u003ci\u003eElderly population\u003c\/i\u003e No data available. \u003cu\u003eMethod of administration\u003c\/u\u003e Oromucosal administration. The tablet should be dissolved slowly in the mouth.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Benagol 24 sugar-free lemon flavored tablets not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Do not administer to children under 6 years of age. BENAGOL Menthol-Eucalyptol flavor is contraindicated in children with a history of epilepsy or febrile convulsions. Do not administer BENAGOL Cold Mint flavor and BENAGOL Ginger and Spice flavor to children under 12 years of age.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp\u003eBENAGOL Menthol - Eucalyptol flavour: due to the presence of menthol and in case of non-compliance with the recommended doses there may be a risk of convulsions in children and infants. Adverse reactions associated with the use of 2,4 dichlorobenzyl alcohol, amylmetacresol, levomenthol and ascorbic acid are listed below, divided by frequency and organ class. Frequencies are defined as: Very common (≥1\/10); Common (≥1\/100 and \u003c1\/10); Uncommon (≥1\/1000 and \u003c1\/100); Rare (≥1\/10000 and \u003c1\/1000); Very rare (\u003c1\/10000); Not known (frequency cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.\u003c\/p\u003eSystem organ classification Frequency Adverse reactions\u003cbr\u003eImmune system disorders Rare Hypersensitivity\u003cbr\u003eGastrointestinal disorders Rare Glossitis\u003cbr\u003eNot known Abdominal pain, nausea, gastrointestinal discomfort\u003cbr\u003eSkin and subcutaneous tissue disorders Not known Rash\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003eWhich medicines or foods can change the effect of Benagol 24 sugar-free lemon flavored lozenges?\u003c\/h3\u003e\u003cp\u003eBENAGOL Menthol-Eucalyptol flavor must not be used in conjunction with other products (medicines or cosmetics) containing terpene derivatives, regardless of the route of administration (oral, rectal, cutaneous, nasal or inhalation).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003eCan Benagol 24 sugar-free lemon flavored tablets be used during pregnancy and breastfeeding?\u003c\/h3\u003e\u003cp\u003eIn pregnant and breastfeeding women, the product should be administered only if clearly necessary. \u003cu\u003ePregnancy\u003c\/u\u003e There are no, or limited numbers, of data relating to the use of the active ingredients of BENAGOL in pregnant women. BENAGOL Menthol-Eucalyptol flavor is not recommended during pregnancy and in women of childbearing age who do not use contraceptive measures. \u003cu\u003eBreastfeeding\u003c\/u\u003e It is not known whether the active substances or their metabolites are excreted in breast milk. The risk to newborns and infants cannot be excluded. Ascorbic acid or its metabolites are excreted in breast milk. \u003cu\u003eFertility\u003c\/u\u003e No data are available regarding the effect on fertility. BENAGOL Menthol-Eucalyptol flavor is not recommended in women of childbearing age who are not using contraceptive measures.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Benagol 24 sugar-free lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003eBe careful with pre-school children as if the tablets are swallowed whole they may cause choking. In the event of the appearance of sensitization or irritation phenomena, administration should be discontinued and suitable treatment instituted. BENAGOL Menthol-Eucalyptol flavor contains terpene derivatives which, in excessive doses, can cause neurological disorders such as convulsions in infants and children. Treatment with BENAGOL Menthol-Eucalyptol flavor must not be prolonged for more than 3 days due to the risks associated with the accumulation of terpene derivatives, such as \u003ci\u003eexample camphor, cineol, niaouli, wild thyme, terpineol, terpine, citral, menthol and essential oils of pine needles, eucalyptus and turpentine\u003c\/i\u003e (due to their lipophilic properties the rate of metabolism and disposal is not known) in tissues and the brain, in particular neuropsychological disorders. A higher than recommended dose should not be used to avoid an increased risk of adverse drug reactions and disorders associated with overdose (see section 4.9). BENAGOL Menthol-Eucalyptol flavor is flammable, it should not be brought near flames. \u003ci\u003eImportant information about some excipients\u003c\/i\u003e \u003cu\u003eBENAGOL Ginger and Spice flavored tablets, BENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e, \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets, BENAGOL Orange flavor tablets with Vitamin C, BENAGOL Cold Mint flavor tablets contain\u003c\/u\u003e Liquid glucose: - Patients suffering from rare hereditary problems of glucose-galactose malabsorption should not take this medicine. - To be taken into consideration in people suffering from diabetes mellitus: BENAGOL Ginger and Spice flavored tablets contains 1.10 g of glucose per tablet. BENAGOL Honey and Lemon flavored tablets contains 0.98 g of glucose per tablet. BENAGOL Menthol-Eucalyptol flavor tablets contains 1.01 g of glucose per tablet. BENAGOL Tablets with Vitamin C Orange flavor contains 0.97 g of glucose per tablet. BENAGOL Cold Mint flavor tablets contains 1.10 g of glucose per tablet. - Liquid glucose contains sulphites. These medicines can rarely cause serious hypersensitivity reactions and bronchospasm. - Liquid glucose contains wheat starch. These medicines contain only a very small amount of gluten (from wheat starch). These medicines are considered “gluten-free” and are very unlikely to cause problems if the patient has celiac disease. One tablet of BENAGOL Ginger and Spice flavored tablets contains no more than 22.04 micrograms of gluten. One tablet of BENAGOL Honey and Lemon flavored tablets contains no more than 19.52 micrograms of gluten. One tablet of BENAGOL Menthol-Eucalyptol flavor contains no more than 20.26 micrograms of gluten. One tablet of BENAGOL Tablets with Vitamin C Orange flavor contains no more than 19.38 micrograms of gluten. One tablet of BENAGOL Cold Mint flavor tablets contains no more than 22.04 micrograms of gluten. If the patient is allergic to wheat (a condition other than celiac disease) he should not take these medicines. Liquid sucrose: - Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. - To be taken into consideration in people suffering from diabetes mellitus: BENAGOL Ginger and Spice flavored tablets contains 1.38 g of sucrose per tablet. BENAGOL Honey and Lemon flavored tablets contains 1.44 g of sucrose per tablet. BENAGOL Menthol-Eucalyptol flavor tablets contains 1.50 g of sucrose per tablet. BENAGOL Tablets with Vitamin C Orange flavor contains 1.44 g of sucrose per tablet. BENAGOL Cold Mint flavor tablets contains 1.38 g of sucrose per tablet. \u003cu\u003eBENAGOL Ginger and Spice flavored tablets, BENAGOL Menthol-Eucalyptol flavored tablets\u003c\/u\u003e, \u003cu\u003eBENAGOL Tablets with Vitamin C Orange flavor, BENAGOL Tablets Lemon flavor Without Sugar, BENAGOL Tablets Strawberry flavor Without Sugar\u003c\/u\u003e These medicines contain less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'. \u003cu\u003eBENAGOL Lemon Flavor Tablets Without Sugar and BENAGOL Strawberry Flavor Tablets Without Sugar\u003c\/u\u003e These medicines contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. They may have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. \u003cu\u003eBENAGOL Ginger and Spice flavored tablets\u003c\/u\u003e This medicine contains a flavoring which contains cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool. Cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool can cause allergic reactions. This medicine contains excipients that can cause a warm sensation in the mouth and throat when you suck the lozenge. \u003cu\u003eBENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e This medicine contains a flavoring which contains citral, d-limonene, geraniol and linalool. Citral, d-limonene, geraniol and linalool can cause allergic reactions. This medicine contains honey (invert sugar). Patients suffering from rare hereditary problems of fructose intolerance, or glucose-galactose malabsorption, should not take this medicine. \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets\u003c\/u\u003e This medicine contains a flavoring which contains d-limonene. D-limonene can cause allergic reactions. \u003cu\u003eBENAGOL Orange flavored tablets with Vitamin C\u003c\/u\u003e This medicine contains a flavoring which contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. This medicine contains 3 mg of propylene glycol per tablet. \u003cu\u003eBENAGOL Lemon flavored tablets without sugar\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool. Benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. \u003cu\u003eBENAGOL Strawberry flavored tablets without sugar\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol. Benzyl alcohol can cause allergic reactions. This medicine contains 7.30 mg of propylene glycol in each tablet. \u003cu\u003eBENAGOL Cold Mint flavor tablets\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool. Benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool can cause allergic reactions. This medicine contains 1.89 mg of propylene glycol in each tablet.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp\u003eA possible overdose could only cause gastrointestinal disorders, for which appropriate symptomatic treatments must be adopted. BENAGOL Menthol-Eucalyptol flavour: in case of accidental oral intake or incorrect administration in infants and children there may be a risk of neurological disorders. If necessary, administer appropriate symptomatic treatment in specialized treatment centers.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp\u003eNo effects on the ability to drive or use machines are reported.\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow do you store Benagol 24 sugar-free lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003eDo not store above 25°C.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Benagol 24 sugar-free lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003e24 tablets\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51131224326471,"sku":"016242087","price":12.28,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-benagol-24-pastiglie-gusto-limone-senza-zucchero-farmacia-dottor-tili-1213792345.jpg?v=1767142809"},{"product_id":"nurofen-influenza-e-raffreddore-200mg-30mg-12-compresse-rivestite","title":"Nurofen Cold and Flu 200mg + 30mg 12 coated tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNUROFEN FLU AND COLDS 200 mg + 30 mg Coated Tablets, is indicated in adults and adolescents over 12 years of age. Treatment of cold and flu symptoms such as nasal and sinus congestion, pain, fever, sore throat, headache.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne tablet contains: Ibuprofen 200 mg, Pseudoephedrine hydrochloride 30 mg Excipients with known effects: sodium, sunset yellow FCF (E 110). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTricalcium phosphate, sodium carboxymethylcellulose, microcrystalline cellulose, povidone, methylhydroxypropylcellulose, magnesium stearate, talc, colourants: E 104, E 110, E 171.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Patients suffering from peptic ulcer. History of gastrointestinal hemorrhage or perforation related to previous active treatments or history of recurrent hemorrhage\/peptic ulcer (two or more distinct episodes of demonstrated ulceration or bleeding). Subjects who have previously shown hypersensitivity reactions (such as nasal polyposis, asthma, rhinitis, angioedema or urticaria) following the use of ibuprofen, acetylsalicylic acid or other analgesics, antipyretics, other non-steroidal anti-inflammatory drugs (NSAIDs). Severe kidney or liver failure. Severe heart failure (NYHA class IV) Patients with serious cardiovascular diseases, tachycardia, hypertension, angina pectoris, hyperthyroidism, diabetes, pheochromocytoma, glaucoma, prostatic syndrome. Pregnancy. Breastfeeding (see section 4.6). Children under 12 years old. Patients taking or have taken monoamine oxidase inhibitors (MAOIs) in the previous 14 days (see section 4.5).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e Only for a short period of treatment. • maximum 5 days of therapy for the adult population; • 3 days maximum therapy for the pediatric population (12-18 years). Undesirable effects can be minimized by using the lowest effective dose for the shortest possible treatment duration needed to control symptoms (see section 4.4). If the use of the medicine is necessary for more than 5 days in adults and for more than 3 days in adolescents, or in the case of worsening of symptoms, the doctor should be consulted. \u003cu\u003ePediatric population\u003c\/u\u003e: Do not administer to children under 12 years of age \u003cu\u003eAdults and adolescents over 12 years old\u003c\/u\u003e: The initial dose is 1-2 tablets per day, then, if necessary, 1-2 tablets every 4 hours. Do not exceed the dose of 6 tablets in 24 hours. \u003cu\u003eElderly\u003c\/u\u003e: No changes to the recommended dosage are required in the elderly except in patients with renal or hepatic alterations for whom it is necessary to individually adapt the dosage. \u003cu\u003eMethod of administration\u003c\/u\u003e: Oral use.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2 and the sections below on Gastrointestinal and Cardiovascular Risks). Other NSAIDs: the use of NUROFEN COLD AND FLU should be avoided in conjunction with NSAIDs, including selective COX-2 inhibitors. Avoid the simultaneous use of two or more analgesics, antipyretics, non-steroidal anti-inflammatory drugs, as this leads to an increased risk of side effects. The use of NSAIDs must be carefully evaluated in patients suffering from coagulation disorders as a reduction in coagulability is possible. The same applies to patients being treated with oral anticoagulants, due to the possibility of an enhancement of the anticoagulant effect (see also section 4.5). Gastrointestinal safety: as with all anti-inflammatories, the drug should not be taken if the patient suffers from ulcers or gastric disorders. Gastrointestinal haemorrhage, ulceration and perforation: Gastrointestinal haemorrhage, ulceration and perforation, which may be fatal, have been reported at any time during treatment with all NSAIDs, with or without warning symptoms or previous history of serious gastrointestinal events. In the elderly and in patients with a history of ulcer, especially if complicated by haemorrhage or perforation (see section 4.3), the risk of gastrointestinal haemorrhage, ulceration or perforation is higher with increased doses of NSAIDs. These patients should start treatment with the lowest available dose. The concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low doses of acetylsalicylic acid or other drugs that may increase the risk of gastrointestinal events (see section 4.5 below). Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal bleeding) particularly in the initial stages of treatment. Caution should be exercised in patients taking concomitant medications that may increase the risk of ulceration or haemorrhage, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking NUROFEN FLU AND COLDS, treatment should be discontinued. NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Cardiovascular and cerebrovascular effects: caution is required (discuss with your doctor or pharmacist) before starting treatment in patients with a positive history of hypertension and\/or heart failure since fluid retention, hypertension and edema have been found in association with treatment with NSAIDs. Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg\/day), may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke). In general, epidemiological studies do not suggest that low doses of ibuprofen (e.g. ≤ 1200 mg\/day) are associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA class II-III), established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with ibuprofen only after careful consideration and high doses (2400 mg\/day) should be avoided. Be careful consideration must also be exercised before starting long-term treatment for patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidemia, diabetes mellitus, cigarette smoking habit), especially if high doses (2400 mg\/day) of ibuprofen are necessary. Skin reactions: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). In the early stages of therapy, patients appear to be at higher risk: the onset of the reaction occurs in most cases in the early stages of treatment. NUROFEN FLU AND COLDS should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. Severe skin reactions: Severe skin reactions, such as acute generalized exanthematous pustulosis (PEAG), may occur with medicines containing ibuprofen and pseudoephedrine. This acute pustular eruption may occur within the first 2 days of treatment, with fever and numerous, small, mostly non-follicular pustules resulting from a widespread edematous erythema and localized mainly on the skin folds, trunk and upper limbs. Patients should be carefully monitored. If signs and symptoms such as pyrexia, erythema or numerous small pustules are observed, the administration of Nurofen Flu and Cold should be stopped and appropriate measures taken if necessary. Respiratory disorders: bronchospasm may occur in patients with bronchial asthma or current or previous allergic diseases. Do not take the product in cases of asthma and allergy to acetylsalicylic acid unless after consulting your doctor (see paragraph 4.3). SLE and mixed connective tissue disease: in case of systemic lupus erythematosus and mixed connective tissue disease it may lead to an increased risk of aseptic meningitis (see section 4.8). Renal function: renal failure, as renal function may be impaired (see sections 4.3 and 4.8). Liver function: liver dysfunction (see sections 4.3 and 4.8). Impaired female fertility: see paragraph 4.6 regarding female fertility. To be used with caution in combination with antihypertensives including neuronal adrenergic blockers and beta blockers (see section 4.5). To be used with caution with other sympathomimetic agents such as decongestants, appetite suppressants and amphetamine psycho-stimulants (see section 4.5). To be used with caution in case of hyperexcitation. If hallucinations, restlessness or sleep disturbances occur during administration of the medicine, use of the medicine should be discontinued. Elderly: Elderly patients present a higher frequency of adverse reactions to NSAIDs, in particular gastrointestinal haemorrhage and perforation which can be fatal (see section 4.2). Pediatric population: In dehydrated adolescents there is a risk of impaired renal function. Ischemic colitis: Some cases of ischemic colitis have been reported with pseudoephedrine. If sudden abdominal pain, rectal bleeding, or other symptoms of ischemic colitis develop, pseudoephedrine should be discontinued and a physician should be consulted. \u003cu\u003eIschemic optic neuropathy\u003c\/u\u003e Cases of ischemic optic neuropathy have been reported with pseudoephedrine. Pseudoephedrine should be discontinued if sudden loss of vision or reduction in visual acuity occurs, for example in the case of a scotoma. \u003cu\u003eMasking of symptoms of underlying infections\u003c\/u\u003e Nurofen Flu and Cold can mask the symptoms of infection, which could delay starting appropriate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and bacterial complications of chickenpox. When Nurofen Flu and Cold is administered for the relief of fever or pain related to infection, monitoring of the infection is recommended. In non-hospital settings, the patient should seek medical attention if symptoms persist or worsen. This medicinal product contains: • less than 1 mmol (23 mg) of \u003cb\u003esodium\u003c\/b\u003e per tablet, i.e. essentially “sodium-free”; • \u003cb\u003esunset yellow dye FCF (E 110)\u003c\/b\u003e, which can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAnticoagulants: NSAIDs may increase the effects of anticoagulants, such as warfarin (see section 4.4). Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal haemorrhage (see section 4.4). Corticosteroids: increased risk of gastrointestinal ulceration or haemorrhage (see section 4.4). The product must not be taken by patients being treated with monoamine oxidase inhibitors and for 14 days following the cessation of such treatment. The product may enhance the effect of other sympathomimetic agents, such as decongestants. The effect of pseudoephedrine could be reduced by guanethidine, reserpine and methyldopa and could be influenced by tricyclic antidepressants. In turn, pseudoephedrine may reduce the effect of guanethidine and may increase the possibility of arrhythmias in digitized patients, or in patients taking anticholinergics (including tricyclic antidepressants) or quinidine. Diuretics, ACE inhibitors and Angiotensin II antagonists: NSAIDs can reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking NUROFEN FLU AND COLDS concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy. Acetylsalicylic acid: concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased side effects (see section 4.4). Experimental data suggest that ibuprofen may competitively inhibit the effect of low-dose acetylsalicylic acid on platelet aggregation when the drugs are administered simultaneously. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility cannot be excluded that regular, long-term use of ibuprofen may reduce the cardioprotective effect of acetylsalicylic acid at low doses. No relevant clinical effects are considered likely following occasional use of ibuprofen (see section 5.1). Other NSAIDs including selective cyclooxygenase-2 inhibitors: concomitant use of two or more NSAIDs should be avoided as it may increase the risk of adverse events (see section 4.4). Cardiac glucosides: NSAIDs can worsen heart failure, reduce GFR (glomerular filtration rate) and plasma levels of glucosides. Lithium. There is evidence of the possibility of a potential increase in lithium levels in the blood. Methotrexate. There is evidence of the possibility of an increase in plasma levels of methotrexate. Cyclosporins: increase the risk of nephrotoxicity. Mifepristone: NSAIDs cannot be administered for 8-12 days following administration of mifepristone as NSAIDs may reduce the effect of mifepristone. Tacrolimus: Possible increased risk of nephrotoxicity when NSAIDs are administered with tacrolimus. Zidovudine: Increased risk of hematological toxicity when NSAIDs are used concomitantly with Zidovudine. There is evidence of increased risk of hemarthrosis and hematoma in HIV-positive haemophilia patients if treated simultaneously with zidovudine and ibuprofen. Quinolone antibiotics: Data from animal studies indicate that NSAIDs may increase the risk of seizures associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures. Ergot alkaloids (ergotamine and methysergide): increased risk of ergotism. Appetite suppressants (anorectics) and amphetamine-like psychostimulants: risk of hypertension. Oxytocin: risk of hypertension\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe list of the following side effects includes those that have been observed during treatment with ibuprofen at self-medication doses (up to a maximum of 1200mg per day) and with sympathomimetics including pseudoephedrine for short periods of administration. Side effects associated with the administration of ibuprofen and sympathomimetics such as pseudoephedrine are listed below according to system organ class and frequency. \u003ci\u003eFor the frequency of occurrence of side effects, the following expressions are used:\u003c\/i\u003e \u003ci\u003eVery common (\u003c\/i\u003e≥ \u003ci\u003e1\/10)\u003c\/i\u003e \u003ci\u003eMunicipality (\u003c\/i\u003e \u003csub\u003e≥ \u003c\/sub\u003e \u003ci\u003e1\/100, \u0026lt;1\/10)\u003c\/i\u003e \u003ci\u003eUncommon (\u003c\/i\u003e \u003csub\u003e≥ \u003c\/sub\u003e \u003ci\u003e1\/1000, \u0026lt;1\/100)\u003c\/i\u003e \u003ci\u003eRare (\u003c\/i\u003e \u003csub\u003e≥ \u003c\/sub\u003e \u003ci\u003e1\/10.000, \u0026lt;1\/1000)\u003c\/i\u003e \u003ci\u003eVery rare (\u003c1\/10,000)\u003c\/i\u003e \u003ci\u003eNot known (frequency cannot be estimated from the available data)\u003c\/i\u003e \u003ci\u003eWithin each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/i\u003e \u003cb\u003eTable of side effects\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders - Frequency: Uncommon. Adverse Reaction: Hypersensitivity reactions characterized by urticaria and pruritus²\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders - Frequency: Very rare. Adverse Reaction: Hematopoietic disorders¹. Severe hypersensitivity reactions. Symptoms may be: swelling of the face, tongue and larynx, dyspnoea, tachycardia, hypotension (anaphylaxis, angioedema or severe shock).²\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Not known. Adverse Reaction: Insomnia, anxiety, restlessness, agitation, hallucinations.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Uncommon. Adverse Reaction: Headache, tremors.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Very rare. Adverse Reaction: Aseptic meningitis³\u003c\/p\u003e\n\u003cp\u003eEye disorders - Frequency: Not known. Adverse Reaction: Ischemic optic neuropathy.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Frequency: Not known. Adverse Reaction: Heart failure and edema4, tachycardia, chest pain, arrhythmia, palpitations.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Frequency: Not known. Adverse Reaction: Hypertension4.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Not known. Adverse Reaction: Reactivity of the respiratory system including asthma, bronchospasm or dyspnoea²\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Uncommon. Adverse Reaction: Abdominal pain, nausea and dyspepsia5.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Rare. Adverse Reaction: Diarrhoea, flatulence, constipation and vomiting.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Very rare. Adverse Reaction: Peptic ulcer, gastrointestinal perforation or haemorrhage, melena, haematemesis, sometimes fatal, particularly in the elderly (see section 4.4). Ulcerative stomatitis, mouth ulcerations, gastritis.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Adverse Reaction: Dry mouth. Exacerbation of colitis and Crohn's disease (see section 4.4). Ischemic colitis.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders - Frequency: Very rare. Adverse Reaction: Liver disorders.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Uncommon. Adverse Reaction: Skin rashes ²\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Very rare. Adverse Reaction: Bullous reactions including Stevens-Johnson syndrome, erythema multiforme and Toxic Epidermal Necrolysis may occur.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Not known. Adverse Reaction: Hyperhidrosis. Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome). Severe skin reactions, including acute generalized exanthematous pustulosis (PEAG). Photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003eMusculoskeletal system and connective tissue disorders - Frequency: Not known. Adverse Reaction: Muscle weakness.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Frequency: Very rare. Adverse Reaction: Severe renal failure 6.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Frequency: Not known. Adverse Reaction: Urinary retention.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and conditions relating to the administration site - Frequency: Not known. Adverse Reaction: Irritability, thirst.\u003c\/p\u003e\n\u003cp\u003eDiagnostic tests - Frequency: Very rare. Adverse Reaction: Decreased hemoglobin level in the blood.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eDescription of some side effects\u003c\/b\u003e 1) Examples of hematopoietic disorders include anemia, leukopenia, thrombocytopenia, pancytopenia, and agranulocytosis. The first symptoms are fever, sore throat, superficial mouth ulcers, flu-like symptoms, severe feeling of tiredness, unexplained bleeding and bruising. 2) Hypersensitivity reactions: these reactions include a) non-specific allergic reactions and anaphylaxis, b) respiratory tract reactivity including asthma, worsening of asthma, bronchospasm or dyspnoea or c) various skin conditions such as various skin rashes, pruritus, urticaria, purpura, angioedema and very rarely bullous and exfoliative dermatitis including toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme, d) cross-reactivity reactions with pseudoephedrine 3) The pathogenesis of drug-induced aseptic meningitis is not completely known. However, the data available on aseptic meningitis related to the administration of NSAIDs leads us to think of an immune hypersensitivity reaction (due to a temporary relationship with the intake of the medicine and the disappearance of symptoms after discontinuation of treatment). Of note, individual cases of aseptic meningitis symptoms (such as stiff neck, headache, nausea, vomiting, fever and disorientation) have been observed during treatment with ibuprofen in patients with autoimmune disorders (such as systemic lupus erythematosus, mixed connective tissue disease). 4) Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg\/day) may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke) (see section 4.4) 5) Gastrointestinal: the most commonly observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or gastrointestinal haemorrhage, sometimes fatal, may occur, particularly in the elderly (see section 4.4). 6) Especially during long treatments, associated with an increase in serum urea and edema. Also includes papillary necrosis. Gastrointestinal intolerance, bleeding, sweating, dizziness, precordial pain, difficulty urinating and insomnia may occur. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioniavverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSymptoms\u003c\/u\u003e Nausea, vomiting, abdominal pain and more rarely diarrhea may occur. Tinnitus, headaches and gastrointestinal bleeding may also occur. In more severe cases of poisoning, central nervous system toxicity is observed, manifested by dizziness, drowsiness, occasionally excitation and disorientation or coma. Occasionally patients develop seizures. In cases of severe poisoning, metabolic acidosis and a prolongation of the prothrombin time\/INR may occur, probably caused by interference with the action of coagulation factors present in the circulation. Acute renal failure, liver damage and respiratory depression may also occur. In asthmatic subjects, asthma exacerbation may occur. As with other sympathomimetics, an excessive dose of pseudoephedrine can cause symptoms related to central nervous system disorders and cardiovascular stimulation, including\u003cb\u003e:\u003c\/b\u003e irritability, restlessness, tremors, thirst, blurred vision, anxiety anxiety, insomnia, fever, sweating, exophthalmos, hallucinations, muscle weakness\u003cb\u003e,\u003c\/b\u003e palpitations, convulsions, urinary retention, hypertension, difficulty urinating, nausea, vomiting, tachycardia and cardiac arrhythmias. \u003cu\u003eTreatment\u003c\/u\u003e Treatment must be symptomatic and supportive, particularly of the cardiovascular and respiratory systems, and must include maintaining a patent airway and monitoring cardiac function and vital signs until the patient is stabilized. Oral administration of activated charcoal should be considered if the patient presents within 1 hour of ingesting a potentially toxic quantity. If necessary, corrective intervention of serum electrolytes should be used. Seizures should be treated with intravenous benzodiazepines if they are frequent or prolonged. Administer bronchodilators in case of asthma. The elimination of pseudoephedrine can be accelerated by acid diuresis or dialysis. Hypertensive phenomena can be treated with IV alpha receptor blocking drugs. Cardiac arrhythmias may require the use of beta-adrenergic blocking agents after administration of alpha-adrenergic blockers. Hyperexcitability and hallucinations can be treated with chlorpromazine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product should not be used during pregnancy and breastfeeding. \u003cb\u003ePregnancy:\u003c\/b\u003e Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction which may progress to renal failure with oligo-hydramnios; The mother and newborn, at the end of pregnancy, are exposed to: - possible prolongation of bleeding time, an anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. There is the possibility of an association between the onset of fetal anomalies and taking pseudoephedrine in the first trimester of pregnancy. \u003cb\u003eBreastfeeding:\u003c\/b\u003e Although ibuprofen is present in breast milk in very low concentrations, pseudoephedrine is secreted into milk in significant quantities; for this reason the product must not be used during breastfeeding. \u003cb\u003eFertility:\u003c\/b\u003e As with other NSAIDs, the use of NUROFEN FLU AND COLDS can alter female fertility due to its effect on ovulation. It is therefore not recommended in women wishing to conceive.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot applicable\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51131232026951,"sku":"034246013","price":11.53,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-nurofen-influenza-e-raffreddore-200mg-30mg-12-compresse-rivestite-farmacia-dottor-tili-1213792327.jpg?v=1767143169"},{"product_id":"nurofen-influenza-e-raffreddore-200mg-30mg-24-compresse-rivestite","title":"Nurofen Cold and Flu 200mg + 30mg 24 coated tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNUROFEN FLU AND COLDS 200 mg + 30 mg Coated Tablets, is indicated in adults and adolescents over 12 years of age. Treatment of cold and flu symptoms such as nasal and sinus congestion, pain, fever, sore throat, headache.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne tablet contains: Ibuprofen 200 mg, Pseudoephedrine hydrochloride 30 mg Excipients with known effects: sodium, sunset yellow FCF (E 110). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTricalcium phosphate, sodium carboxymethylcellulose, microcrystalline cellulose, povidone, methylhydroxypropylcellulose, magnesium stearate, talc, colourants: E 104, E 110, E 171.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Patients suffering from peptic ulcer. History of gastrointestinal hemorrhage or perforation related to previous active treatments or history of recurrent hemorrhage\/peptic ulcer (two or more distinct episodes of demonstrated ulceration or bleeding). Subjects who have previously shown hypersensitivity reactions (such as nasal polyposis, asthma, rhinitis, angioedema or urticaria) following the use of ibuprofen, acetylsalicylic acid or other analgesics, antipyretics, other non-steroidal anti-inflammatory drugs (NSAIDs). Severe kidney or liver failure. Severe heart failure (NYHA class IV) Patients with serious cardiovascular diseases, tachycardia, hypertension, angina pectoris, hyperthyroidism, diabetes, pheochromocytoma, glaucoma, prostatic syndrome. Pregnancy. Breastfeeding (see section 4.6). Children under 12 years old. Patients taking or have taken monoamine oxidase inhibitors (MAOIs) in the previous 14 days (see section 4.5).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e Only for a short period of treatment. • maximum 5 days of therapy for the adult population; • 3 days maximum therapy for the pediatric population (12-18 years). Undesirable effects can be minimized by using the lowest effective dose for the shortest possible treatment duration needed to control symptoms (see section 4.4). If the use of the medicine is necessary for more than 5 days in adults and for more than 3 days in adolescents, or in the case of worsening of symptoms, the doctor should be consulted. \u003cu\u003ePediatric population\u003c\/u\u003e: Do not administer to children under 12 years of age \u003cu\u003eAdults and adolescents over 12 years old\u003c\/u\u003e: The initial dose is 1-2 tablets per day, then, if necessary, 1-2 tablets every 4 hours. Do not exceed the dose of 6 tablets in 24 hours. \u003cu\u003eElderly\u003c\/u\u003e: No changes to the recommended dosage are required in the elderly except in patients with renal or hepatic alterations for whom it is necessary to individually adapt the dosage. \u003cu\u003eMethod of administration\u003c\/u\u003e: Oral use.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2 and the sections below on Gastrointestinal and Cardiovascular Risks). Other NSAIDs: the use of NUROFEN COLD AND FLU should be avoided in conjunction with NSAIDs, including selective COX-2 inhibitors. Avoid the simultaneous use of two or more analgesics, antipyretics, non-steroidal anti-inflammatory drugs, as this leads to an increased risk of side effects. The use of NSAIDs must be carefully evaluated in patients suffering from coagulation disorders as a reduction in coagulability is possible. The same applies to patients being treated with oral anticoagulants, due to the possibility of an enhancement of the anticoagulant effect (see also section 4.5). Gastrointestinal safety: as with all anti-inflammatories, the drug should not be taken if the patient suffers from ulcers or gastric disorders. Gastrointestinal haemorrhage, ulceration and perforation: Gastrointestinal haemorrhage, ulceration and perforation, which may be fatal, have been reported at any time during treatment with all NSAIDs, with or without warning symptoms or previous history of serious gastrointestinal events. In the elderly and in patients with a history of ulcer, especially if complicated by haemorrhage or perforation (see section 4.3), the risk of gastrointestinal haemorrhage, ulceration or perforation is higher with increased doses of NSAIDs. These patients should start treatment with the lowest available dose. The concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low doses of acetylsalicylic acid or other drugs that may increase the risk of gastrointestinal events (see section 4.5 below). Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal bleeding) particularly in the initial stages of treatment. Caution should be exercised in patients taking concomitant medications that may increase the risk of ulceration or haemorrhage, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking NUROFEN FLU AND COLDS, treatment should be discontinued. NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Cardiovascular and cerebrovascular effects: caution is required (discuss with your doctor or pharmacist) before starting treatment in patients with a positive history of hypertension and\/or heart failure since fluid retention, hypertension and edema have been found in association with treatment with NSAIDs. Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg\/day), may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke). In general, epidemiological studies do not suggest that low doses of ibuprofen (e.g. ≤ 1200 mg\/day) are associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (NYHA class II-III), established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with ibuprofen only after careful consideration and high doses (2400 mg\/day) should be avoided. Be careful consideration must also be exercised before starting long-term treatment for patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidemia, diabetes mellitus, cigarette smoking habit), especially if high doses (2400 mg\/day) of ibuprofen are necessary. Skin reactions: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). In the early stages of therapy, patients appear to be at higher risk: the onset of the reaction occurs in most cases in the early stages of treatment. NUROFEN FLU AND COLDS should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. Severe skin reactions: Severe skin reactions, such as acute generalized exanthematous pustulosis (PEAG), may occur with medicines containing ibuprofen and pseudoephedrine. This acute pustular eruption may occur within the first 2 days of treatment, with fever and numerous, small, mostly non-follicular pustules resulting from a widespread edematous erythema and localized mainly on the skin folds, trunk and upper limbs. Patients should be carefully monitored. If signs and symptoms such as pyrexia, erythema or numerous small pustules are observed, the administration of Nurofen Flu and Cold should be stopped and appropriate measures taken if necessary. Respiratory disorders: bronchospasm may occur in patients with bronchial asthma or current or previous allergic diseases. Do not take the product in cases of asthma and allergy to acetylsalicylic acid unless after consulting your doctor (see paragraph 4.3). SLE and mixed connective tissue disease: in case of systemic lupus erythematosus and mixed connective tissue disease it may lead to an increased risk of aseptic meningitis (see section 4.8). Renal function: renal failure, as renal function may be impaired (see sections 4.3 and 4.8). Liver function: liver dysfunction (see sections 4.3 and 4.8). Impaired female fertility: see paragraph 4.6 regarding female fertility. To be used with caution in combination with antihypertensives including neuronal adrenergic blockers and beta blockers (see section 4.5). To be used with caution with other sympathomimetic agents such as decongestants, appetite suppressants and amphetamine psycho-stimulants (see section 4.5). To be used with caution in case of hyperexcitation. If hallucinations, restlessness or sleep disturbances occur during administration of the medicine, use of the medicine should be discontinued. Elderly: Elderly patients present a higher frequency of adverse reactions to NSAIDs, in particular gastrointestinal haemorrhage and perforation which can be fatal (see section 4.2). Pediatric population: In dehydrated adolescents there is a risk of impaired renal function. Ischemic colitis: Some cases of ischemic colitis have been reported with pseudoephedrine. If sudden abdominal pain, rectal bleeding, or other symptoms of ischemic colitis develop, pseudoephedrine should be discontinued and a physician should be consulted. \u003cu\u003eIschemic optic neuropathy\u003c\/u\u003e Cases of ischemic optic neuropathy have been reported with pseudoephedrine. Pseudoephedrine should be discontinued if sudden loss of vision or reduction in visual acuity occurs, for example in the case of a scotoma. \u003cu\u003eMasking of symptoms of underlying infections\u003c\/u\u003e Nurofen Flu and Cold can mask the symptoms of infection, which could delay starting appropriate treatment and therefore worsen the outcome of the infection. This has been observed in community-acquired bacterial pneumonia and bacterial complications of chickenpox. When Nurofen Flu and Cold is administered for the relief of fever or pain related to infection, monitoring of the infection is recommended. In non-hospital settings, the patient should seek medical attention if symptoms persist or worsen. This medicinal product contains: • less than 1 mmol (23 mg) of \u003cb\u003esodium\u003c\/b\u003e per tablet, i.e. essentially “sodium-free”; • \u003cb\u003esunset yellow dye FCF (E 110)\u003c\/b\u003e, which can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAnticoagulants: NSAIDs may increase the effects of anticoagulants, such as warfarin (see section 4.4). Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal haemorrhage (see section 4.4). Corticosteroids: increased risk of gastrointestinal ulceration or haemorrhage (see section 4.4). The product must not be taken by patients being treated with monoamine oxidase inhibitors and for 14 days following the cessation of such treatment. The product may enhance the effect of other sympathomimetic agents, such as decongestants. The effect of pseudoephedrine could be reduced by guanethidine, reserpine and methyldopa and could be influenced by tricyclic antidepressants. In turn, pseudoephedrine may reduce the effect of guanethidine and may increase the possibility of arrhythmias in digitized patients, or in patients taking anticholinergics (including tricyclic antidepressants) or quinidine. Diuretics, ACE inhibitors and Angiotensin II antagonists: NSAIDs can reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking NUROFEN FLU AND COLDS concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy. Acetylsalicylic acid: concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential for increased side effects (see section 4.4). Experimental data suggest that ibuprofen may competitively inhibit the effect of low-dose acetylsalicylic acid on platelet aggregation when the drugs are administered simultaneously. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility cannot be excluded that regular, long-term use of ibuprofen may reduce the cardioprotective effect of acetylsalicylic acid at low doses. No relevant clinical effects are considered likely following occasional use of ibuprofen (see section 5.1). Other NSAIDs including selective cyclooxygenase-2 inhibitors: concomitant use of two or more NSAIDs should be avoided as it may increase the risk of adverse events (see section 4.4). Cardiac glucosides: NSAIDs can worsen heart failure, reduce GFR (glomerular filtration rate) and plasma levels of glucosides. Lithium. There is evidence of the possibility of a potential increase in lithium levels in the blood. Methotrexate. There is evidence of the possibility of an increase in plasma levels of methotrexate. Cyclosporins: increase the risk of nephrotoxicity. Mifepristone: NSAIDs cannot be administered for 8-12 days following administration of mifepristone as NSAIDs may reduce the effect of mifepristone. Tacrolimus: Possible increased risk of nephrotoxicity when NSAIDs are administered with tacrolimus. Zidovudine: Increased risk of hematological toxicity when NSAIDs are used concomitantly with Zidovudine. There is evidence of increased risk of hemarthrosis and hematoma in HIV-positive haemophilia patients if treated simultaneously with zidovudine and ibuprofen. Quinolone antibiotics: Data from animal studies indicate that NSAIDs may increase the risk of seizures associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures. Ergot alkaloids (ergotamine and methysergide): increased risk of ergotism. Appetite suppressants (anorectics) and amphetamine-like psychostimulants: risk of hypertension. Oxytocin: risk of hypertension\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe list of the following side effects includes those that have been observed during treatment with ibuprofen at self-medication doses (up to a maximum of 1200mg per day) and with sympathomimetics including pseudoephedrine for short periods of administration. Side effects associated with the administration of ibuprofen and sympathomimetics such as pseudoephedrine are listed below according to system organ class and frequency. \u003ci\u003eFor the frequency of occurrence of side effects, the following expressions are used:\u003c\/i\u003e \u003ci\u003eVery common (\u003c\/i\u003e≥ \u003ci\u003e1\/10)\u003c\/i\u003e \u003ci\u003eMunicipality (\u003c\/i\u003e \u003csub\u003e≥ \u003c\/sub\u003e \u003ci\u003e1\/100, \u0026lt;1\/10)\u003c\/i\u003e \u003ci\u003eUncommon (\u003c\/i\u003e \u003csub\u003e≥ \u003c\/sub\u003e \u003ci\u003e1\/1000, \u0026lt;1\/100)\u003c\/i\u003e \u003ci\u003eRare (\u003c\/i\u003e \u003csub\u003e≥ \u003c\/sub\u003e \u003ci\u003e1\/10.000, \u0026lt;1\/1000)\u003c\/i\u003e \u003ci\u003eVery rare (\u003c1\/10,000)\u003c\/i\u003e \u003ci\u003eNot known (frequency cannot be estimated from the available data)\u003c\/i\u003e \u003ci\u003eWithin each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/i\u003e \u003cb\u003eTable of side effects\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders - Frequency: Uncommon. Adverse Reaction: Hypersensitivity reactions characterized by urticaria and pruritus²\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders - Frequency: Very rare. Adverse Reaction: Hematopoietic disorders¹. Severe hypersensitivity reactions. Symptoms may be: swelling of the face, tongue and larynx, dyspnoea, tachycardia, hypotension (anaphylaxis, angioedema or severe shock).²\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Not known. Adverse Reaction: Insomnia, anxiety, restlessness, agitation, hallucinations.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Uncommon. Adverse Reaction: Headache, tremors.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Very rare. Adverse Reaction: Aseptic meningitis³\u003c\/p\u003e\n\u003cp\u003eEye disorders - Frequency: Not known. Adverse Reaction: Ischemic optic neuropathy.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Frequency: Not known. Adverse Reaction: Heart failure and edema4, tachycardia, chest pain, arrhythmia, palpitations.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Frequency: Not known. Adverse Reaction: Hypertension4.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Not known. Adverse Reaction: Reactivity of the respiratory system including asthma, bronchospasm or dyspnoea²\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Uncommon. Adverse Reaction: Abdominal pain, nausea and dyspepsia5.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Rare. Adverse Reaction: Diarrhoea, flatulence, constipation and vomiting.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Very rare. Adverse Reaction: Peptic ulcer, gastrointestinal perforation or haemorrhage, melena, haematemesis, sometimes fatal, particularly in the elderly (see section 4.4). Ulcerative stomatitis, mouth ulcerations, gastritis.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Adverse Reaction: Dry mouth. Exacerbation of colitis and Crohn's disease (see section 4.4). Ischemic colitis.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders - Frequency: Very rare. Adverse Reaction: Liver disorders.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Uncommon. Adverse Reaction: Skin rashes ²\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Very rare. Adverse Reaction: Bullous reactions including Stevens-Johnson syndrome, erythema multiforme and Toxic Epidermal Necrolysis may occur.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Not known. Adverse Reaction: Hyperhidrosis. Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome). Severe skin reactions, including acute generalized exanthematous pustulosis (PEAG). Photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003eMusculoskeletal system and connective tissue disorders - Frequency: Not known. Adverse Reaction: Muscle weakness.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Frequency: Very rare. Adverse Reaction: Severe renal failure 6.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Frequency: Not known. Adverse Reaction: Urinary retention.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and conditions relating to the administration site - Frequency: Not known. Adverse Reaction: Irritability, thirst.\u003c\/p\u003e\n\u003cp\u003eDiagnostic tests - Frequency: Very rare. Adverse Reaction: Decreased hemoglobin level in the blood.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eDescription of some side effects\u003c\/b\u003e 1) Examples of hematopoietic disorders include anemia, leukopenia, thrombocytopenia, pancytopenia, and agranulocytosis. The first symptoms are fever, sore throat, superficial mouth ulcers, flu-like symptoms, severe feeling of tiredness, unexplained bleeding and bruising. 2) Hypersensitivity reactions: these reactions include a) non-specific allergic reactions and anaphylaxis, b) respiratory tract reactivity including asthma, worsening of asthma, bronchospasm or dyspnoea or c) various skin conditions such as various skin rashes, pruritus, urticaria, purpura, angioedema and very rarely bullous and exfoliative dermatitis including toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme, d) cross-reactivity reactions with pseudoephedrine 3) The pathogenesis of drug-induced aseptic meningitis is not completely known. However, the data available on aseptic meningitis related to the administration of NSAIDs leads us to think of an immune hypersensitivity reaction (due to a temporary relationship with the intake of the medicine and the disappearance of symptoms after discontinuation of treatment). Of note, individual cases of aseptic meningitis symptoms (such as stiff neck, headache, nausea, vomiting, fever and disorientation) have been observed during treatment with ibuprofen in patients with autoimmune disorders (such as systemic lupus erythematosus, mixed connective tissue disease). 4) Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg\/day) may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke) (see section 4.4) 5) Gastrointestinal: the most commonly observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or gastrointestinal haemorrhage, sometimes fatal, may occur, particularly in the elderly (see section 4.4). 6) Especially during long treatments, associated with an increase in serum urea and edema. Also includes papillary necrosis. Gastrointestinal intolerance, bleeding, sweating, dizziness, precordial pain, difficulty urinating and insomnia may occur. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioniavverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSymptoms\u003c\/u\u003e Nausea, vomiting, abdominal pain and more rarely diarrhea may occur. Tinnitus, headaches and gastrointestinal bleeding may also occur. In more severe cases of poisoning, central nervous system toxicity is observed, manifested by dizziness, drowsiness, occasionally excitation and disorientation or coma. Occasionally patients develop seizures. In cases of severe poisoning, metabolic acidosis and a prolongation of the prothrombin time\/INR may occur, probably caused by interference with the action of coagulation factors present in the circulation. Acute renal failure, liver damage and respiratory depression may also occur. In asthmatic subjects, asthma exacerbation may occur. As with other sympathomimetics, an excessive dose of pseudoephedrine can cause symptoms related to central nervous system disorders and cardiovascular stimulation, including\u003cb\u003e:\u003c\/b\u003e irritability, restlessness, tremors, thirst, blurred vision, anxiety anxiety, insomnia, fever, sweating, exophthalmos, hallucinations, muscle weakness\u003cb\u003e,\u003c\/b\u003e palpitations, convulsions, urinary retention, hypertension, difficulty urinating, nausea, vomiting, tachycardia and cardiac arrhythmias. \u003cu\u003eTreatment\u003c\/u\u003e Treatment must be symptomatic and supportive, particularly of the cardiovascular and respiratory systems, and must include maintaining a patent airway and monitoring cardiac function and vital signs until the patient is stabilized. Oral administration of activated charcoal should be considered if the patient presents within 1 hour of ingesting a potentially toxic quantity. If necessary, corrective intervention of serum electrolytes should be used. Seizures should be treated with intravenous benzodiazepines if they are frequent or prolonged. Administer bronchodilators in case of asthma. The elimination of pseudoephedrine can be accelerated by acid diuresis or dialysis. Hypertensive phenomena can be treated with IV alpha receptor blocking drugs. Cardiac arrhythmias may require the use of beta-adrenergic blocking agents after administration of alpha-adrenergic blockers. Hyperexcitability and hallucinations can be treated with chlorpromazine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product should not be used during pregnancy and breastfeeding. \u003cb\u003ePregnancy:\u003c\/b\u003e Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction which may progress to renal failure with oligo-hydramnios; The mother and newborn, at the end of pregnancy, are exposed to: - possible prolongation of bleeding time, an anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. There is the possibility of an association between the onset of fetal anomalies and taking pseudoephedrine in the first trimester of pregnancy. \u003cb\u003eBreastfeeding:\u003c\/b\u003e Although ibuprofen is present in breast milk in very low concentrations, pseudoephedrine is secreted into milk in significant quantities; for this reason the product must not be used during breastfeeding. \u003cb\u003eFertility:\u003c\/b\u003e As with other NSAIDs, the use of NUROFEN FLU AND COLDS can alter female fertility due to its effect on ovulation. It is therefore not recommended in women wishing to conceive.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot applicable\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51131252539719,"sku":"034246025","price":18.51,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-nurofen-influenza-e-raffreddore-200mg-30mg-24-compresse-rivestite-farmacia-dottor-tili-1213792309.jpg?v=1767143529"},{"product_id":"aspi-gola-8-75mg-16-pastiglie-gusto-miele-limone","title":"Aspi Gola 8.75mg 16 Honey Lemon Flavored Lozenges","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic treatment of irritative-inflammatory conditions also associated with oropharyngeal pain (e.g. gingivitis, stomatitis, pharyngitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: flurbiprofen 8.75 mg \u003cu\u003eExcipients with known effects: \u003c\/u\u003eglucose, sucrose For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSucrose, glucose, macrogol, potassium hydroxide, lemon flavouring, levomenthol, honey.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not use the medicine in children under 12 years of age. Flurbiprofen is contraindicated in patients with known hypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Patients who have previously shown hypersensitivity reactions (e.g. asthma, urticaria, allergy, rhinitis, angioedema, bronchospasm) towards ibuprofen, acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Flurbiprofen is also contraindicated in patients with a history of gastrointestinal bleeding or perforation related to previous NSAID treatment. Flurbiprofen should not be taken by patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal haemorrhage (defined as two or more distinct episodes of demonstrated ulceration or bleeding). Flurbiprofen is contraindicated in patients with severe heart failure, severe hepatic failure and renal failure (see section 4.4). Third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.4). \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: 1 tablet every 3-6 hours, as needed. Do not exceed the dose of 8 tablets in 24 hours. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe renal impairment (see section 4.3). \u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Dissolve slowly in your mouth. As with all lozenges, in order to avoid local irritation, flurbiprofen lozenges should also be moved inside the mouth during administration. If mouth irritation occurs, treatment should be discontinued.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special precautions for storage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not cause any harm to the patient, as the dose of flurbiprofen is significantly lower than that commonly used in systemic treatments. \u003ci\u003eElderly\u003c\/i\u003e: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal. \u003ci\u003eRespiratory disorders\u003c\/i\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma or allergies. Flurbiprofen should be used with caution in these patients. \u003ci\u003eOther NSAIDs\u003c\/i\u003e It is advisable not to combine the medicine with other NSAIDs (see section 4.5). \u003ci\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease\u003c\/i\u003e Patients with systemic lupus erythematosus and mixed connective tissue disease may have an increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiac, hepatic and renal impairment\u003c\/i\u003e The medicine should be used with caution in patients with cardiac, renal or hepatic insufficiency. NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID can cause a dose-dependent reduction in the formation of prostaglandins and precipitate renal failure. Patients at highest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; however, this effect is not usually observed with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiovascular and cerebrovascular effects\u003c\/i\u003e Before starting treatment in patients with a positive history of hypertension and\/or heart failure, caution is required (discuss with your doctor or pharmacist), since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). \u003ci\u003eEffects on the central nervous system\u003c\/i\u003e Analgesic-induced headache. In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003ci\u003e \u003cu\u003eGastrointestinal effects\u003c\/u\u003e \u003c\/i\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. The risk of gastrointestinal bleeding, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by bleeding and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse reactions can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal reactions. Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2). Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003ci\u003eDermatological effects\u003c\/i\u003e The use of the medicine, especially if prolonged, can give rise to sensitization or local irritation phenomena. In such cases it is necessary to interrupt the treatment and consult a doctor to institute, if necessary, suitable therapy. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003ci\u003eInfections\u003c\/i\u003e Since isolated cases of exacerbation of inflammation related to infections (e.g. development of necrotizing fasciitis) have been described in temporal association with the systemic use of drugs belonging to the NSAID class, patients are recommended to immediately consult a doctor in case of appearance or worsening of signs of a bacterial infection during flurbiprofen-based therapy. A possible indication for starting antibiotic therapy must be taken into consideration. If mouth irritation develops, treatment should be discontinued. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e ASPI GOLA Lemon and Honey flavored lozenges contain glucose. Patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine. ASPI GOLA Lemon and Honey flavored lozenges contain sucrose. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. Do not use for prolonged treatments beyond 7 days. If you do not notice appreciable results after 3 days of treatment, the cause could be a different pathological condition. In these cases it is advisable to consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. However, inform your doctor if you are taking other medicines. Flurbiprofen should be avoided in association with: - \u003ci\u003eAcetylsalicylic acid\u003c\/i\u003e: unless the intake of acetylsalicylic acid in low doses (not exceeding 100 mg\/day or local prophylactic doses for cardiovascular protection) has been recommended by the doctor; As with other medicinal products containing NSAIDs, concomitant administration of flurbiprofen and acetylsalicylic acid is generally not recommended due to the potential for increased side effects (see section 4.4). - \u003ci\u003eCox-2 inhibitors and other NSAIDs\u003c\/i\u003e: Concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects and an increased risk of adverse reactions (see section 4.4)\u003ci\u003e.\u003c\/i\u003e Flurbiprofen should be used with caution in association with: - \u003ci\u003eAnticoagulants:\u003c\/i\u003e NSAIDs may potentiate the effects of anticoagulants such as warfarin (see section 4.4). - \u003ci\u003eAntiplatelet agents\u003c\/i\u003e: increased risk of gastrointestinal bleeding. - \u003ci\u003eSelective serotonin reuptake inhibitors (SSRIs)\u003c\/i\u003e: increased risk of gastrointestinal bleeding. - \u003ci\u003eAntihypertensives (diuretics, ACE inhibitors and angiotensin II antagonists)\u003c\/i\u003e: NSAIDs can reduce the effect of diuretics. Other antihypertensive drugs may potentiate nephrotoxicity caused by cyclooxygenase inhibition, especially in patients with impaired renal function (these patients must be adequately hydrated). - \u003ci\u003eAlcohol\u003c\/i\u003e: may increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract. - \u003ci\u003eCardiac glycosides\u003c\/i\u003e: NSAIDs can exacerbate heart failure, reduce VGR (glomerular filtration rate) and increase plasma levels of glycosides. - \u003ci\u003eCyclosporine\u003c\/i\u003e: increased risk of nephrotoxicity. - \u003ci\u003eCorticosteroids\u003c\/i\u003e: increased risk of gastrointestinal ulcer or haemorrhage with NSAIDs (see section 4.4). - \u003ci\u003eLithium:\u003c\/i\u003e there is evidence for a possible increase in plasma lithium levels. - \u003ci\u003eMethotrexate\u003c\/i\u003e: There may be an increase in plasma levels of methotrexate. - \u003ci\u003eMifepristone\u003c\/i\u003e: NSAIDs should not be used for 8-12 days after administration of mifepristone, as NSAIDs may reduce the effect of mifepristone. - \u003ci\u003eQuinolone antibiotics\u003c\/i\u003e: Animal data indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures. - \u003ci\u003eTacrolimus\u003c\/i\u003e: possible increased risk of nephrotoxicity when NSAIDs are administered together with tacrolimus. - \u003ci\u003eZidovudine\u003c\/i\u003e: Increased risk of haematological toxicity when NSAIDs are administered with zidovudine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis (b) respiratory tract reactivity, e.g. asthma, aggravated asthma, bronchospasm, dyspnoea (c) various skin disorders, including for example skin rashes of different types, pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatosis (including necrolysis epidermal and erythema multiforme). The most commonly observed adverse reactions are gastrointestinal in nature. Local use of the medicine, especially if prolonged, can give rise to local sensitization or irritation phenomena. The dissolution of the medicine in tablet form in the oral cavity may be accompanied by sensations of heat or tingling in the oropharynx. In such cases it is necessary to interrupt treatment and institute, if necessary, suitable therapy. The following side effects have been reported, particularly after the administration of formulations for systemic use. They refer to those detected with the use of flurbiprofen used short term and at doses compatible with the classification of self-medication medicines. When treating chronic conditions and for long periods of time, additional side effects may occur. The side effects associated with the use of flurbiprofen are divided below based on system organ classification and frequency. Frequency is defined as: very common (≥ 1\/10), common (≥1\/100, \u003c1\/10), uncommon (≥1\/1,000, \u003c1\/100), rare (≥1\/10,000, \u003c1\/1,000), very rare (\u003c1\/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders - Frequency: Not known. Adverse reactions: Anemia, thrombocytopenia, aplastic anemia and agranulocytosis.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Common. Adverse reactions: Dizziness, headache, paraesthesia.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Uncommon. Adverse reactions: Drowsiness.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Not known. Adverse reactions: Cerebrovascular accidents, optic neuritis, migraine, confusional states, dizziness.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Rare. Adverse reactions: Anaphylactic reactions.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Not known. Adverse reactions: Angioedema, hypersensitivity\u003c\/p\u003e\n\u003cp\u003eEye disorders - Frequency: Not known. Adverse reactions: Visual disturbances.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders - Frequency: Not known. Adverse reactions: Tinnitus.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Frequency: Not known. Adverse reactions: Heart failure, edema.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Frequency: Not known. Adverse reactions: Hypertension.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Common. Adverse reactions: Throat irritation.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Uncommon. Adverse reactions: Asthma, bronchospasm and dyspnea, blisters in the oropharynx, oropharyngeal hypoesthesia.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Common. Adverse reactions: Diarrhoea, mouth ulcers, nausea, oral pain, oral paraesthesia, oropharyngeal pain, oral discomfort (hot or burning sensation, tingling in the mouth).\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Uncommon. Adverse reactions: Abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysesthesia, vomiting.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Adverse reactions: Melena, haematemesis, gastrointestinal haemorrhage, colitis, exacerbation of Crohn's disease, gastritis, peptic ulcer, gastric perforation, ulcer haemorrhage.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Uncommon. Adverse reactions: Rash, itching.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Not known. Adverse reactions: Urticaria, purpura, bullous dermatitis (including Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis and Erythema multiforme).\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Frequency: Not known. Adverse reactions: Nephrotoxicity, tubulointerstitial nephritis and nephrotic syndrome, renal failure (as with other NSAIDs).\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and administration site conditions - Frequency: Uncommon. Adverse reactions: Pyrexia, pain.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and conditions relating to the administration site - Frequency: Not known. Adverse reactions: Discomfort, fatigue.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders - Frequency: Not known. Adverse reactions: Hepatitis.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Uncommon. Adverse reactions: Insomnia.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Not known. Adverse reactions: Depression, hallucination.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eReporting of suspected adverse reactions. \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGiven the reduced content of the active ingredient and its local use, it is unlikely that overdose situations may occur. \u003cb\u003eSymptoms\u003c\/b\u003e The majority of patients who ingest clinically large quantities of NSAIDs develop nausea, vomiting, gastrointestinal irritation, epigastric pain, or more rarely diarrhea. Tinnitus, headache and gastrointestinal bleeding are also possible. In more severe cases of NSAID intoxication, central nervous system toxicity is observed, manifested by drowsiness, occasionally excitability, blurred vision and disorientation or coma. Occasionally patients develop seizures. In case of severe NSAID intoxication, metabolic acidosis may occur and the prothrombin time\/INR may be prolonged, probably due to interference with the action of coagulation factors present in circulation. Acute renal failure and liver damage may occur. An exacerbation of asthma is possible in asthmatic subjects. \u003cb\u003eTreatment\u003c\/b\u003e Treatment should be symptomatic and supportive and should include maintaining a patent airway and monitoring cardiac function and vital signs until stabilization. Oral administration of activated charcoal and, if necessary, correction of serum electrolytes should be considered if the patient presents within one hour of ingesting a potentially toxic amount. Seizures should be treated with intravenous diazepam or lorazepam if they are frequent or prolonged. Administer bronchodilators for asthma. There is no specific antidote for flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003ePregnancy\u003c\/u\u003e \u003c\/i\u003e Flurbiprofen should not be administered during the first and second trimester of pregnancy unless strictly necessary. \u003ci\u003eThe use of flurbiprofen during the third trimester of pregnancy is contraindicated.\u003c\/i\u003e \u003ci\u003e \u003cu\u003eBreastfeeding\u003c\/u\u003e \u003c\/i\u003e In a limited number of studies, flurbiprofen appears in breast milk in very low concentrations and is unlikely to have negative effects on the breastfed infant. However, administration of flurbiprofen is not recommended in breastfeeding mothers. \u003ci\u003e \u003cu\u003eFertility\u003c\/u\u003e \u003c\/i\u003e There is evidence to suggest that cyclooxygenase\/prostaglandin synthesis inhibitors may cause impairment of female fertility through an effect on ovulation. This is reversible upon discontinuation of treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt does not interfere with the ability to drive and use machinery.\u003c\/p\u003e","brand":"Bayer","offers":[{"title":"Default Title","offer_id":51131266040135,"sku":"041513033","price":9.25,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/bayer-spa-aspi-gola-8-75mg-16-pastiglie-gusto-miele-limone-farmacia-dottor-tili-1213792279.jpg?v=1767133110"},{"product_id":"benactiv-gola-0-25-spray-per-mucosa-orale-15ml","title":"Benactiv Gola 0.25% spray for oral mucosa 15ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory conditions also associated with oropharyngeal pain (e.g. gingivitis, stomatitis, pharyngitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e 100 ml of mouthwash contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 250 mg Excipients with known effects: hydrogenated castor oil-40-polyoxyethylene, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene). \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e 100 ml of solution contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 250 mg Excipients with known effects: hydrogenated castor oil-40-polyoxyethylene, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene). \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e One tablet contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 8.75 mg Excipients with known effects: liquid glucose (containing sulphites and wheat starch), liquid sucrose, honey, lemon flavoring and levomenthol (containing butylated hydroxyanisole, citral, citronellol, d-limonene, farfalle, geraniol, linalool). \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e One tablet contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 8.75 mg Excipients with known effects: liquid maltitol (E965), isomalt (E953), orange flavoring and levomenthol (containing citral, citronellol, d-limonene, geraniol, linalool). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e Glycerol, ethanol (96 percent), sorbitol 70, hydrogenated castor oil-40-polyoxyethylene, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene), patent blue V (E131), purified water. \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e Glycerol, ethanol (96 percent), sorbitol 70, hydrogenated castor oil-40-polyoxyethylene, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene), patent blue V (E131), purified water. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e Liquid sucrose, liquid glucose (containing sulphites and wheat starch), macrogol 300, potassium hydroxide, lemon flavoring and levomenthol (containing butylated hydroxyanisole, citral, citronellol, d-limonene, farfalle, geraniol, linalool), honey. \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e Macrogol 300, potassium hydroxide, orange flavor and levomenthol (containing citral, citronellol, dlimonene, geraniol, linalool), acesulfame potassium (E950), liquid maltitol (E965), isomalt (E953).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not use the medicine in children under 12 years of age. Flurbiprofen is contraindicated in patients with known hypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Patients who have previously shown hypersensitivity reactions (e.g. asthma, urticaria, allergy, rhinitis, angioedema, bronchospasm) towards ibuprofen, acetylsalicylic acid (aspirin) or other non-steroidal anti-inflammatory drugs (NSAIDs). Flurbiprofen is also contraindicated in patients with a history of gastrointestinal bleeding or perforation related to previous NSAID treatment. Flurbiprofen should not be taken by patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal haemorrhage (defined as two or more distinct episodes of demonstrated ulceration or bleeding). Flurbiprofen is contraindicated in patients with severe heart failure, severe hepatic failure and renal failure (see section 4.4). Third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.4). \u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: 2-3 rinses or gargles per day with 10 ml (1 scoop) of mouthwash. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Rinse or keep in mouth while gargling for up to 1 minute. Do not ingest. The mouthwash can be used pure or diluted in half a glass of water. \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: apply one dose (2 sprays) 3 times a day, directed directly onto the affected part. Each spray delivers 0.2 ml of solution, equivalent to 0.5 mg of active ingredient. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Direct the nozzle towards the back of the throat and spray on the affected part. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: 1 tablet every 3-6 hours, as needed. Do not exceed the dose of 8 tablets in 24 hours. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Dissolve slowly in your mouth. As with all lozenges, in order to avoid local irritation, flurbiprofen lozenges should also be moved inside the mouth during administration. If mouth irritation occurs, treatment should be discontinued.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenactiv Gola Orange flavored sugar-free lozenges and Benactiv Gola Lemon and Honey flavored lozenges: store at temperatures below 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not cause any harm to the patient, as the dose of flurbiprofen is significantly lower than that commonly used in systemic treatments. Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal haemorrhage and perforation, which may be fatal. \u003ci\u003eRespiratory disorders \u003c\/i\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma or allergies. Flurbiprofen should be used with caution in these patients. \u003ci\u003eOther NSAIDs \u003c\/i\u003e It is advisable not to combine the medicine with other NSAIDs (see section 4.5). \u003ci\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease \u003c\/i\u003e Patients with systemic lupus erythematosus and mixed connective tissue disease may have an increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiac, hepatic and renal impairment \u003c\/i\u003e The medicine should be used with caution in patients with cardiac, renal or hepatic insufficiency. NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID can cause a dose-dependent reduction in the formation of prostaglandins and precipitate renal failure. Patients at highest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; however, this effect is not usually observed with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiovascular and cerebrovascular effects \u003c\/i\u003e Before starting treatment in patients with a positive history of hypertension and\/or heart failure, caution is required (discuss with your doctor or pharmacist), since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). \u003ci\u003eEffects on the central nervous system \u003c\/i\u003e Analgesic-induced headache. In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003ci\u003eGastrointestinal effects\u003c\/i\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. The risk of gastrointestinal haemorrhage, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by haemorrhage and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse reactions can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal reactions. Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2). Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003ci\u003eDermatological effects\u003c\/i\u003e The use of the medicine, especially if prolonged, can give rise to sensitization or local irritation phenomena. In such cases it is necessary to interrupt the treatment and consult a doctor to institute, if necessary, suitable therapy. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003ci\u003eInfections\u003c\/i\u003e Since isolated cases of exacerbation of inflammation related to infections (e.g. development of necrotizing fasciitis) have been described in temporal association with the systemic use of drugs belonging to the NSAID class, patients are recommended to immediately consult a doctor in case of appearance or worsening of signs of a bacterial infection during flurbiprofen-based therapy. A possible indication for starting antibiotic therapy must be taken into consideration. If mouth irritation develops, treatment should be discontinued. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain para-hydroxybenzoates which can cause allergic reactions (even delayed). BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain hydrogenated 40-polyoxyethylene castor oil which may cause localized skin reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain an aroma which in turn contains d-limonene. D-limonene can cause allergic reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain less than 1 mmol (23mg) sodium per 10 ml dose, i.e. essentially \"sodium-free\". BENACTIV GOLA Lemon and Honey flavored lozenges contain liquid glucose, liquid sucrose and honey (invert sugar). Patients suffering from rare problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. To be taken into consideration in people with diabetes mellitus: this medicine contains 1.07 g of glucose and 1.41 g of sucrose per tablet. BENACTIV GOLA Lemon and Honey flavored lozenges contain sulphites. Rarely it can cause serious hypersensitivity reactions and bronchospasm. BENACTIV GOLA Lemon and Honey flavored lozenges contain only a very small amount of gluten (from wheat starch). This medicine is considered “gluten-free” and is very unlikely to cause problems for a celiac patient. One tablet contains no more than 21.38 micrograms of gluten. If a patient is allergic to wheat (condition other than celiac disease) he or she should not take this medicine. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, farfalle, geraniol and linalool. Citral, citronellol, d-limonene, farfalle, geraniol and linalool can cause allergic reactions. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains butylated hydroxyanisole which can cause localized skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. BENACTIV GOLA Sugar-Free Lozenges Orange flavor is instead indicated for those patients who need to control their intake of sugars and calories. BENACTIV GOLA Orange flavored sugar-free lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. BENACTIV GOLA Orange flavored sugar-free lozenges contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. May have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. Do not use for prolonged treatments beyond 7 days. If you do not notice appreciable results after 3 days of treatment, the cause could be a different pathological condition. In these cases it is advisable to consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. However, inform your doctor if you are taking other medicines. Flurbiprofen should be avoided in association with: - Aspirin: unless the intake of low-dose aspirin (not exceeding 100 mg\/day or local prophylactic doses for cardiovascular protection) has been recommended by the doctor; As with other NSAID-containing medicinal products, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased side effects (see section 4.4). - Cox-2 inhibitors and other NSAIDs: concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects and an increased risk of adverse reactions (see section 4.4). Flurbiprofen should be used with caution in association with: - Anticoagulants: NSAIDs can potentiate the effects of anticoagulants such as warfarin (see section 4.4) - Antiaggregating agents: increased risk of gastrointestinal bleeding - Selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding - Antihypertensives (diuretics, ACE inhibitors and angiotensin II antagonists): i NSAIDs can reduce the effect of diuretics. Other antihypertensive drugs may potentiate nephrotoxicity caused by inhibition of cyclooxygenase, especially in patients with impaired renal function (these patients must be adequately hydrated) - Alcohol: may increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract - Cardiac glycosides: NSAIDs may exacerbate heart failure, reduce GFR (glomerular filtration rate) and increase plasma levels of glycosides - Cyclosporine: increased risk of nephrotoxicity - Corticosteroids: increased risk of gastrointestinal ulcer or haemorrhage with NSAIDs (see section 4.4) - Lithium: there is evidence for a possible increase in plasma lithium levels - Methotrexate: there may be an increase in plasma levels of methotrexate - Mifepristone: NSAIDs should not be used for 8-12 days after administration of mifepristone, as NSAIDs may reduce the effect of mifepristone - Quinolone antibiotics: data obtained in animals indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures - Tacrolimus: possible increased risk of nephrotoxicity when NSAIDs are administered together with tacrolimus - Zidovudine: increased risk of haematological toxicity when NSAIDs are administered with zidovudine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis (b) respiratory tract reactivity, e.g. asthma, aggravated asthma, bronchospasm, dyspnoea (c) various skin disorders, including for example skin rashes of different types, pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatosis (including necrolysis epidermal and erythema multiforme). The most commonly observed adverse reactions are gastrointestinal in nature. Local use of the medicine, especially if prolonged, can give rise to local sensitization or irritation phenomena. The dissolution of the medicine in tablet form in the oral cavity may be accompanied by sensations of heat or tingling in the oropharynx. In such cases it is necessary to interrupt treatment and institute, if necessary, suitable therapy. The following side effects have been reported, particularly after the administration of formulations for systemic use. They refer to those detected with the use of flurbiprofen used short term and at doses compatible with the classification of self-medication medicines. When treating chronic conditions and for long periods of time, additional side effects may occur. The side effects associated with the use of flurbiprofen are divided below based on system organ classification and frequency. Frequency is defined as: very common (≥ 1\/10), common (≥1\/100, \u003c1\/10), uncommon (≥1\/1,000, \u003c1\/100), rare (≥1\/10,000, \u003c1\/1,000), very rare (\u003c1\/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eDisorders of the blood and lymphatic system - Frequency: Not known. Adverse reactions: Anemia, thrombocytopenia, aplastic anemia and agranulocytosis.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Common. Adverse reactions: Dizziness, headache, paraesthesia.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Uncommon. Adverse reactions: Drowsiness.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Not known. Adverse reactions: Cerebrovascular accident, optic neuritis, migraine, confusional states, dizziness.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Rare. Adverse reactions: Anaphylactic reaction.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Not known. Adverse reactions: Angioedema, hypersensitivity\u003c\/p\u003e\n\u003cp\u003eEye disorders - Frequency: Not known. Adverse reactions: Vision impairment.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders - Frequency: Not known. Adverse reactions: Tinnitus.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Frequency: Not known. Adverse reactions: Heart failure, edema.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Frequency: Not known. Adverse reactions: Hypertension.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Common. Adverse reactions: Throat irritation.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Uncommon. Adverse reactions: Asthma, bronchospasm and dyspnea, oropharyngeal vesicular rash, oropharyngeal hypoesthesia.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Common. Adverse reactions: Diarrhoea, mouth ulceration, nausea, oral pain, oral paraesthesia, oropharyngeal pain, oral discomfort (hot or burning sensation, tingling in the mouth).\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Uncommon. Adverse reactions: Abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysesthesia, vomiting.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Adverse reactions: Melena, haematemesis, gastrointestinal haemorrhage, colitis, exacerbation of Crohn's disease, gastritis, peptic ulcer, gastric perforation, ulcer haemorrhage.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Uncommon. Adverse reactions: Skin rash, itching.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Not known. Adverse reactions: Urticaria, purpura, bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme).\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Frequency: Not known. Adverse reactions: Toxic nephropathy, tubulointerstitial nephritis and nephrotic syndrome, renal failure (as with other NSAIDs).\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and administration site conditions - Frequency: Uncommon. Adverse reactions: Pyrexia, pain.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and conditions relating to the administration site - Frequency: Not known. Adverse reactions: Discomfort, tiredness.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders - Frequency: Not known. Adverse reactions: Hepatitis.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Uncommon. Adverse reactions: Insomnia.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Not known. Adverse reactions: Depression, hallucination.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGiven the reduced content of the active ingredient and its local use, it is unlikely that overdose situations may occur. \u003cb\u003eSymptoms\u003c\/b\u003e The majority of patients who ingest clinically large quantities of NSAIDs develop nausea, vomiting, gastrointestinal irritation, epigastric pain, or more rarely diarrhea. Tinnitus, headache and gastrointestinal bleeding are also possible. In more severe cases of NSAID intoxication, central nervous system toxicity is observed, manifested by drowsiness, occasionally excitability, blurred vision and disorientation or coma. Occasionally patients develop seizures. In case of severe NSAID intoxication, metabolic acidosis may occur and the prothrombin time\/INR may be prolonged, probably due to interference with the action of coagulation factors present in circulation. Acute renal failure and liver damage may occur. An exacerbation of asthma is possible in asthmatic subjects. \u003cb\u003eTreatment\u003c\/b\u003e Treatment should be symptomatic and supportive and should include maintaining a patent airway and monitoring cardiac function and vital signs until stabilization. Oral administration of activated charcoal and, if necessary, correction of serum electrolytes should be considered if the patient presents within one hour of ingesting a potentially toxic amount. Seizures should be treated with intravenous diazepam or lorazepam if they are frequent or prolonged. Administer bronchodilators for asthma. There is no specific antidote for flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Flurbiprofen should not be administered during the first and second trimester of pregnancy unless strictly necessary. The use of flurbiprofen during the third trimester of pregnancy is contraindicated. \u003cu\u003eBreastfeeding\u003c\/u\u003e In a limited number of studies, flurbiprofen appears in breast milk in very low concentrations and is unlikely to have negative effects on the breastfed infant. However, administration of flurbiprofen is not recommended in breastfeeding mothers. \u003cu\u003eFertility\u003c\/u\u003e There is evidence to suggest that cyclooxygenase\/prostaglandin synthesis inhibitors may cause impairment of female fertility through an effect on ovulation. This is reversible upon discontinuation of treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt does not interfere with the ability to drive and use machinery.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51131271971143,"sku":"033262041","price":11.07,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-benactiv-gola-0-25-spray-per-mucosa-orale-15ml-farmacia-dottor-tili-1213792265.jpg?v=1767133307"},{"product_id":"froben-gola-0-25-collutorio-160ml","title":"Froben Throat 0.25% mouthwash 160ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFroben Gola is indicated for the symptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• \u003cb\u003eFROBEN THROAT 250mg\/100ml Mouthwash\u003c\/b\u003e 100 ml of solution contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: Flurbiprofen 0.25 g \u003cu\u003eExcipients with known effect\u003c\/u\u003e: Ethanol, patent blue V(E131). • \u003cb\u003eFROBEN THROAT 250mg\/100ml Spray for oral mucosa\u003c\/b\u003e 100 ml of solution contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: Flurbiprofen 0.25 g \u003cu\u003eExcipients with known effect\u003c\/u\u003e: Ethanol, patent blue V(E131). For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePurified water, alcohol, patent blue VE 131, glycerol, mint essence, 40-polyoxyethylene hydrogenated castor oil, potassium bicarbonate, sodium saccharinate, sorbitol.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Froben Gola is also contraindicated in: • patients who have previously experienced hypersensitivity reactions (e.g. asthma, urticaria) after taking aspirin or other NSAIDs. • patients with a history of gastrointestinal bleeding or perforation related to previous treatment with NSAIDs. • patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal bleeding (defined as two or more distinct episodes of demonstrated ulceration or bleeding). • patients with severe cardiac, renal or hepatic insufficiency (see section 4.4). Froben Gola is contraindicated during the third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.4). It is recommended to use this medicine for a maximum of three days. \u003cb\u003eDosage:\u003c\/b\u003e • \u003cb\u003eMOUTHWASH\u003c\/b\u003e The recommended dose is two or three rinses or gargles per day with 10 ml of mouthwash. Can be diluted in water • \u003cb\u003eSPRAY FOR ORAL MUCOSA\u003c\/b\u003e The recommended dose is 2 sprays 3 times a day aimed directly at the affected part. \u003ci\u003ePediatric population\u003c\/i\u003e No adequate data are available on the pediatric population; therefore the use of the medicine is not recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMouthwash: this medicine must not be stored above 25 C. Oral mucosa spray: this medicine must not be stored above 25 C; Keep the bottle in the outer carton to protect the medicine from light.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eGeneral precautions \u003c\/b\u003e Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2 and the sections below on gastrointestinal and cardiovascular risks). \u003cb\u003eUse in elderly patients \u003c\/b\u003e Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal. \u003cb\u003e \u003ci\u003e \u003cu\u003eGastrointestinal effects \u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse events can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal events. The risk of gastrointestinal haemorrhage, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by haemorrhage and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low doses of aspirin or other drugs that may increase the risk of gastrointestinal events (see section below and section 4.5). Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. When gastrointestinal bleeding or ulceration occurs in patients taking Froben Gola, treatment should be suspended. \u003cb\u003e \u003ci\u003e \u003cu\u003eRespiratory Disorders\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma. \u003cb\u003e \u003ci\u003e \u003cu\u003eCardiac, renal and hepatic impairment \u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Particular caution must be taken when treating patients with severely compromised renal, cardiac or hepatic function, as the use of NSAIDs can lead to deterioration of renal function. In such patients the dosage should be kept as low as possible and renal function should be monitored. The administration of an NSAID can cause a dose-dependent reduction in the formation of prostaglandins, accelerating renal failure. Patients at highest risk of developing this reaction are those with impaired kidney function, heart failure and liver dysfunction, those taking diuretics and elderly people. Renal function should be monitored in these patients (see also section 4.3). Flurbiprofen should be administered with caution in patients with a history of heart failure or hypertension as cases of edema have been reported in association with the administration of flurbiprofen. \u003cb\u003e \u003ci\u003e \u003cu\u003eCardiovascular and cerebrovascular effects\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Adequate monitoring and appropriate instructions are necessary in patients with a history of hypertension and\/or mild to moderate congestive heart failure since, in association with the administration of flurbiprofen and treatment with NSAIDs, fluid retention and edema have been found. In these patients Froben Gola should be taken with caution. Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). \u003cb\u003e \u003cu\u003eSkin reactions\u003c\/u\u003e \u003c\/b\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs. In the early stages of therapy, patients appear to be at higher risk: the onset of the reaction occurs in most cases within the first month of treatment. Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003cb\u003e \u003ci\u003e \u003cu\u003eRenal effects\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Caution should be used when initiating treatment with NSAIDs such as flurbiprofen in patients with considerable dehydration. \u003cb\u003e \u003ci\u003e \u003cu\u003eHematological effects\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Flurbiprofen, like other NSAIDs, can inhibit platelet aggregation and prolong bleeding time. \u003cb\u003e \u003ci\u003e \u003cu\u003eSystemic lupus erythematosus (SLE) and connective system diseases\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e An increased risk of aseptic meningitis may occur in patients with Systemic Lupus Erythematosus (SLE) and connective system disorders (see section 4.8). The effects reported above have been reported in particular after the administration of formulations based on Flurbiprofen for systemic use. At the recommended doses, swallowing FROBEN GOLA does not cause any harm to the patient as these doses are significantly lower than those of the single dosage of the product systemically. The use of FROBEN GOLA, especially if prolonged, can give rise to local sensitization or irritation phenomena; in such cases it is necessary to interrupt the treatment and consult the doctor to institute, if necessary, a suitable therapy. Flurbiprofen should not be used for prolonged treatments. It is necessary to inform patients to seek medical advice if after short periods of treatment without appreciable results. \u003cb\u003eImpairment of fertility\u003c\/b\u003e The use of flurbiprofen may impair female fertility and is not recommended in women trying to become pregnant. In women who have difficulty conceiving or who are undergoing infertility investigations, discontinuation of treatment with flurbiprofen should be considered. \u003cb\u003e \u003ci\u003e \u003cu\u003eImportant information about some excipients\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e \u003cu\u003eFROBEN THROAT 250mg\/100ml Mouthwash\u003c\/u\u003e contains: • \u003ci\u003eSorbitol (E420)\u003c\/i\u003e. Patients with hereditary fructose intolerance should not be given this medicine. • \u003ci\u003eEthanol\u003c\/i\u003e. This medicine contains 12 vol% ethanol (alcohol), e.g. up to 1 g per dose, equivalent to 24 ml of beer, 10 ml of wine per dose. It can be harmful to alcoholics. To be taken into consideration in pregnant or breastfeeding women, children and high-risk groups such as people with liver disease or epilepsy. For those who carry out sporting activities, the use of medicines containing ethyl alcohol can lead to positive anti-doping tests in relation to the blood alcohol concentration limits indicated by some sports federations. • \u003ci\u003ePatent blue dye V(E131)\u003c\/i\u003e which can cause allergic reactions. \u003cu\u003eFROBEN THROAT 250mg\/100ml Spray for oral mucosa\u003c\/u\u003e contains: • \u003ci\u003eSorbitol\u003c\/i\u003e. The additive effect of co-administration of medicinal products containing sorbitol (or fructose) and daily dietary intake of sorbitol (or fructose) should be considered. The sorbitol content in oral medicinal products may modify the bioavailability of other co-administered oral medicinal products. • \u003ci\u003eEthanol\u003c\/i\u003e. This medicine contains 12 vol% ethanol (alcohol), e.g. up to 40 mg per dose, equivalent to 1 ml of beer, 0.4 ml of wine per dose. For those who carry out sporting activities, the use of medicines containing ethyl alcohol can lead to positive anti-doping tests in relation to the blood alcohol concentration limits indicated by some sports federations. • \u003ci\u003ePatent blue dye V(E131)\u003c\/i\u003e which can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. \u003cb\u003eDiuretics, ACE inhibitors and angiotensin II antagonists\u003c\/b\u003e: NSAIDs can reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of NSAID nephrotoxicity. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Flurbiprofen concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and on a periodic basis thereafter. \u003cb\u003eLithium salts:\u003c\/b\u003e decrease in lithium elimination. \u003cb\u003eMethotrexate: \u003c\/b\u003ecaution is advised in case of concomitant administration of flurbiprofen and methotrexate as NSAIDs can increase the levels of methotrexate and therefore its toxic effects). \u003cb\u003eAnticoagulants, such as warfarin: \u003c\/b\u003eincreased anticoagulant effect. \u003cb\u003eAnti-aggregating agents:\u003c\/b\u003e increased risk of gastrointestinal bleeding \u003cb\u003eSelective serotonin reuptake inhibitors (SSRIs):\u003c\/b\u003e increased risk of gastrointestinal bleeding. \u003cb\u003eAspirin:\u003c\/b\u003e As with other NSAID-containing medicines, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased side effects. \u003cb\u003eCardiac glycosides\u003c\/b\u003e: NSAIDs can exacerbate heart failure, reduce glomerular filtration rate and increase plasma levels of cardiac glycosides. \u003cb\u003eCyclosporins:\u003c\/b\u003e increased risk of nephrotoxicity with NSAIDs. \u003cb\u003eCorticosteroids:\u003c\/b\u003e increased risk of gastrointestinal ulcer or bleeding with NSAIDs. \u003cb\u003eCox-2 inhibitors and other NSAIDs:\u003c\/b\u003e Concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects. \u003cb\u003eMifepristone\u003c\/b\u003e: NSAIDs should not be taken for 8-12 days after administration of mifepristone as NSAIDs may reduce the effects of mifepristone. \u003cb\u003eQuinolone Antibiotics: \u003c\/b\u003eResults from animal studies suggest that NSAIDs may increase the risk of seizures associated with the use of quinolone antibiotics. Patients taking NSAIDs and Quinolones may have an increased risk of developing seizures. \u003cb\u003eTacrolimus\u003c\/b\u003e: possible increased risk of nephrotoxicity in case of co-administration with NSAIDs. \u003cb\u003eZidovudine\u003c\/b\u003e: increased risk of blood toxicity in case of co-administration with NSAIDs. There is evidence of an increased risk of haemarthrosis and haematoma in haemophilia patients affected by HIV in simultaneous treatment with Zidovudine and other NSAIDs. The interactions reported above have been reported in particular after the administration of Flurbiprofen-based formulations for systemic use. At the recommended doses of FROBEN GOLA, no interactions with other medicinal products or of any other nature have been reported. However, inform your doctor if you are taking other medicines.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following adverse reactions, reported in particular after the administration of formulations for systemic use, are reported according to the MedDRA classification. Frequency groupings are classified according to the following convention: very common (≥ 1\/10), Common (≥1\/100 to \u003c1\/10), Uncommon (≥1\/1000 to \u003c1\/100), Rare (≥ 1\/10,000 to \u003c1\/1000), Very rare (\u003c1\/10,000) and Not Known (frequency cannot be estimated).\u003c\/p\u003e\n\u003cp\u003eMedDRA system organ class: Frequency of Adverse Reactions.\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders: Uncommon Anemia.\u003c\/p\u003e\n\u003cp\u003eBlood and lymphatic system disorders: Very rare Leukopenia, agranulocytosis, aplastic anemia, neutropenia, thrombocytopenia, haemolytic anemia.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders: Uncommon Hypersensitivity\u003c\/p\u003e\n\u003cp\u003eImmune system disorders: Rare Anaphylactic reaction.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders: Rare Depression, Confusional state.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders: Very rare Hallucination.\u003c\/p\u003e\n\u003cp\u003eNervous System Disorders: Common Migraine, dizziness.\u003c\/p\u003e\n\u003cp\u003eNervous System Disorders: Uncommon Paraesthesia.\u003c\/p\u003e\n\u003cp\u003eNervous System Disorders: Rare Drowsiness, Insomnia.\u003c\/p\u003e\n\u003cp\u003eNervous System Disorders: Not known Optic neuritis, cerebrovascular accident, headache.\u003c\/p\u003e\n\u003cp\u003eEye disorders: Uncommon Visual disturbances.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders: Uncommon Tinnitus, vertigo.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders: Uncommon Asthma, dyspnoea.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders: Rare Bronchospasm.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Common Dyspepsia, diarrhoea, nausea, vomiting, abdominal pain, flatulence, constipation, melena, haematemesis, gastrointestinal haemorrhage.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Uncommon Gastritis, duodenal ulcer, gastric ulcer, mouth ulcer, gastrointestinal perforation.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Very rare Pancreatitis.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Not known Colitis and Crohn's disease.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders: Very rare Jaundice, cholestatic jaundice, abnormal liver function.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders: Not known Hepatitis.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders: Uncommon Rash, urticaria, pruritus, purpura, angioedema, photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders: Very rare Severe forms of bullous skin reactions (e.g. Erythema Multiforme, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis).\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders: Rare Nephrotoxicity in various forms i.e. interstitial nephritis, nephrotic syndrome, renal failure and acute renal failure. (see paragraph 4.4).\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders: Not known Glomerulonephritis.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and administration site conditions: Common Fatigue, malaise, edema.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders: Uncommon Heart failure.\u003c\/p\u003e\n\u003cp\u003eVascular disorders: Uncommon Hypertension.\u003c\/p\u003e\n\u003cp\u003eInvestigations: Common Liver function test abnormal, bleeding time prolonged.\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders: Common Fluid retention.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e Hypersensitivity reactions have been reported following treatment with NSAIDs. These consist of: a) non-specific allergic reactions and anaphylaxis; b) reactions affecting the respiratory tract including asthma, even severe, bronchospasm or dyspnoea, or c) various skin disorders, such as various types of skin rashes, itching, urticaria, purpura, angioedema and, very rarely, exfoliative and bullous dermatitis (including Toxic Epidermal Necrolysis and erythema multiforme). \u003cb\u003eCardiac and vascular pathologies\u003c\/b\u003e Cases of edema, hypertension and heart failure have been reported in association with treatment with NSAIDs. Clinical studies and epidemiological data suggest that the intake of some NSAIDs (especially if at high doses and in case of long-term treatment) may be associated with an increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4).\u003cb\u003eNervous System Pathologies \u003c\/b\u003e Aseptic meningitis (especially in patients with existing autoimmune disorders such as Systemic Lupus Erythematosus and connective tissue disorders) with symptoms such as stiff neck, headache, nausea, vomiting, fever or disorientation (see section 4.4). \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSymptoms\u003c\/b\u003e Symptoms of overdose may include nausea, vomiting, and gastrointestinal irritation. \u003cb\u003eTreatment\u003c\/b\u003e Treatment should include gastric lavage and, if necessary, correction of the serum electrolyte picture. There is no specific antidote for flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFertility\u003c\/i\u003e The use of FROBEN GOLA may negatively affect fertility and is not recommended in women who are trying to conceive. In women who have difficulty conceiving or who are undergoing fertility investigations, stopping taking FROBEN GOLA should be considered. \u003ci\u003ePregnancy \u003c\/i\u003e Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, flurbiprofen should not be administered unless strictly necessary. If flurbiprofen is used by a woman attempting to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: • Cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); • Renal dysfunction, which may progress to renal failure with oligohydramnios. The mother and the newborn, at the end of pregnancy, to: • Possible prolongation of bleeding time, an anti-aggregating effect which can occur even at very low doses; • Inhibition of uterine contractions resulting in delayed or prolonged labor. \u003cb\u003eConsequently, flurbiprofen is contraindicated during the third trimester of pregnancy (see section 4.3). \u003c\/b\u003e \u003ci\u003eBreastfeeding\u003c\/i\u003e In the few studies available so far, NSAIDs can appear in breast milk in very low concentrations. If possible, NSAIDs should be avoided during breastfeeding. See paragraph \u003ci\u003e4.4 Special warnings and precautions for use\u003c\/i\u003e, regarding fertility in women.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects such as dizziness, drowsiness, fatigue and visual disturbances are possible after taking NSAIDs. If these effects occur, patients should not drive or use machinery.\u003c\/p\u003e","brand":"Viatris","offers":[{"title":"Default Title","offer_id":51131281670471,"sku":"042822015","price":11.72,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/viatris-italia-srl-froben-gola-0-25-collutorio-160ml-farmacia-dottor-tili-1213792246.jpg?v=1767133769"},{"product_id":"oki-gola-1-6-collutorio-150ml","title":"Oki Gola 1.6% mouthwash 150ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 ml of mouthwash contains as active ingredient: Ketoprofen lysine salt 1.6 grams Excipient with known effects: Methyl parahydroxybenzoate, mint flavor (containing d-limonene, linalool) For the complete list of excipients, see paragraph 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGlycerin, Ethanol,\u003cb\u003e Methyl parahydroxybenzoate, Mint flavor (containing d-limonene, linalool)\u003c\/b\u003e, Menthol, Sodium Saccharin, Certosa Green Colourant, Monobasic Sodium Phosphate, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients, listed in paragraph 6.1. Individual hypersensitivity in subjects in whom the use of other non-steroidal anti-inflammatory drugs has caused allergic reactions such as asthma, urticaria or rhinitis. During pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe package includes a measuring cup with a mark corresponding to 10 ml. To open the package you need to firmly press the cap and rotate it counterclockwise at the same time. Two rinses or gargles a day with 10 ml of OKi throat 1.6% mouthwash diluted in approximately 100 ml of water. Any involuntary swallowing of the solution used for rinsing and gargling does not cause any particular harm to the patient as it is equivalent to the expected systemic dose (160 mg of ketoprofen lysine salt).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of topical drugs, especially if prolonged, could give rise to sensitization phenomena, in which case it is necessary to suspend the treatment and adopt suitable therapeutic measures. In prolonged and high-dose therapies, keep in mind the possibility of competition between absorbed ketoprofen and other drugs with high binding to plasma proteins. This medicine contains methyl parahydroxybenzoate, known to cause allergic reactions (including delayed reactions). This medicine contains mint flavouring, which in turn contains d-Limonene and linalool which may cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt present, no negative interactions with other drugs have emerged.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal irritation phenomena and angioneurotic edema have been reported, especially in subjects with hypersensitivity to NSAIDs, with very rare frequency. There are no known systemic side effects. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have ever been reported with the use of ketoprofen lysine salt solution. In case of improper use or accidental overdose, it is advisable to resort to general therapeutic measures of the type normally adopted in case of poisoning with non-steroidal anti-inflammatory drugs.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e There are no clinical data associated with the use of topical formulations of ketoprofen during pregnancy. Despite the lower systemic exposure compared to oral administration, it is not known whether the systemic exposure of ketoprofen achieved following topical administration could be harmful to an embryo\/fetus. During the third trimester of pregnancy, the systemic use of prostaglandin synthesis inhibitors, including ketoprofen, can induce cardiopulmonary and renal toxicity in the fetus. At the end of pregnancy there may be a prolongation of the bleeding time of the mother and the newborn and labor may be delayed. Consequently, Oki throat is contraindicated during pregnancy (see section 4.3). \u003cu\u003eBreastfeeding\u003c\/u\u003e OKi throat 1.6% mouthwash should not be used during breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known effects on the level of attention\u003c\/p\u003e","brand":"Dompé","offers":[{"title":"Default Title","offer_id":51131293991239,"sku":"041797010","price":11.16,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/dompe-farmaceutici-spa-oki-gola-1-6-collutorio-150ml-farmacia-dottor-tili-1213792218.jpg?v=1767134290"},{"product_id":"fomentil-10-compresse-per-suffumigi","title":"Fomentil 10 tablets for fumigations","description":"\u003cp\u003eFomentil 10 fumigation tablets is a \u003cstrong\u003emedical device\u003c\/strong\u003e Class I, designed to provide relief to the respiratory tract through inhalation of vapors. These non-sterile tablets are ideal for those suffering from \u003cstrong\u003esore throat\u003c\/strong\u003e, \u003cstrong\u003ecold\u003c\/strong\u003e, \u003cstrong\u003esinusitis\u003c\/strong\u003e, \u003cstrong\u003ebronchitis\u003c\/strong\u003e and other inflammations of the respiratory system. Thanks to their formulation, Fomentil acts as an effective \u003cstrong\u003edecongestant\u003c\/strong\u003e, helping to clear the airways and fluidize catarrhal secretions, which are then naturally expelled through coughing.\u003c\/p\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Fomentil 10 fumigation tablets used? What is it for?\u003c\/h3\u003e\u003cp\u003eFomentil 10 fumigation tablets is a \u003cstrong\u003emedical device\u003c\/strong\u003e Class I, designed to provide relief to the respiratory tract through inhalation of vapors. These non-sterile tablets are ideal for those suffering from \u003cstrong\u003esore throat\u003c\/strong\u003e, \u003cstrong\u003ecold\u003c\/strong\u003e, \u003cstrong\u003esinusitis\u003c\/strong\u003e, \u003cstrong\u003ebronchitis\u003c\/strong\u003e and other inflammations of the respiratory system. Thanks to their formulation, Fomentil acts as an effective \u003cstrong\u003edecongestant\u003c\/strong\u003e, helping to clear the airways and fluidize catarrhal secretions, which are then naturally expelled through coughing.\u003c\/p\u003e\u003cp\u003eThe product exploits the beneficial properties of \u003cstrong\u003ementhol\u003c\/strong\u003e and of the\u003cstrong\u003eeucalyptus\u003c\/strong\u003e, which, combined with water vapor, help to decongest the respiratory tract, offering an immediate sense of relief. Fomentil is particularly useful in the presence of \u003cstrong\u003emucosal hypersecretion\u003c\/strong\u003e, acting as an adjuvant in treatments aimed at restoring the normal functioning of the respiratory tract. Its action is also indicated for conditions of \u003cstrong\u003erhinitis\u003c\/strong\u003e, \u003cstrong\u003epharyngitis\u003c\/strong\u003e e \u003cstrong\u003elaryngitis\u003c\/strong\u003e, protecting the nasal and oropharyngeal mucosa.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Fomentil 10 fumigation tablets contain?\u003c\/h3\u003e\u003cp\u003eSodium Bicarbonate, Tartaric Acid, Microcrystalline Cellulose, Bentonite, Glyceryl Distearate, Silica Colloidal Hydrated, Polyvinylpyrrolidone, Talc, Magnesium Stearate, Flavor (Eucaliptus Globulus Leaf Oil, Lavandula Angustifolia Oil, Thymus Vulgaris Flower\/Leaf Oil, Menthol).\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Fomentil 10 fumigation tablets?\u003c\/h3\u003e\u003cp\u003eDissolve 1-2 tablets in approximately half a liter of boiling water and breathe the vapors for 3-4 minutes, collecting them using a special vapor inhaler or with your hands. Repeat this operation 3-4 times a day.\u003cbr\u003eThe water must be boiling for the tablet to dissolve completely. Break the tablets to facilitate their dissolution.\u003cbr\u003eDo not cover your head with a cloth while inhaling and be careful to keep your face at a distance of about 40 cm to prevent the hot water vapor from irritating the skin.\u003cbr\u003eFor children over 30 months: place a basin with boiling water near the child's bed and dissolve 3-4 tablets in it, one at a time. The duration of fumigation treatment should not exceed 3 days.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Fomentil 10 fumigation tablets?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eRead the leaflet carefully. Do not use if package is open or damaged. The product should not be used for children under 30 months of age. Do not administer in case of already known hypersensitivity to the components. For external use, do not swallow the tablets or drink the solution. Use only for fumigations and inhalations. Avoid contact with eyes. There are no known interactions with other products and\/or medicines, however in case of concomitant therapy for the respiratory tract, wait at least 30 minutes between the use of Fomentil and the other treatment. Fomentil is not recommended during pregnancy and in women of childbearing potential who are not using contraceptive measures. Fomentil should not be used during breastfeeding. It is important to report the appearance of side effects to your doctor or pharmacist. Keep out of the sight and reach of children and anyone who may accidentally ingest the tablet or solution. A higher dose than recommended should not be used. Consult your doctor if you suffer from chronic respiratory diseases.\u003cbr\u003eDo not use the product after the expiry date indicated on the package. Do not dispose of in the environment after use.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Fomentil 10 fumigation tablets stored?\u003c\/h3\u003e\u003cp\u003eStore the product in the original packaging, away from direct light and heat, at room temperature.\u003cbr\u003eThe expiry date refers to the intact product, correctly stored.\u003cbr\u003eValidity with intact packaging: 36 months.\u003cbr\u003eValidity after first opening: 18 months.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Fomentil 10 fumigation tablets?\u003c\/h3\u003e\u003cp\u003eTube of 10 tablets.\u003c\/p\u003e","brand":"Sit Laboratorio Farmaceutico","offers":[{"title":"Default Title","offer_id":51131304640839,"sku":"935558039","price":8.84,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sit-laboratorio-farmac-srl-fomentil-10-compresse-per-suffumigi-farmacia-dottor-tili-1213792163.jpg?v=1767134710"},{"product_id":"neo-borocillina-gola-dolore-8-75mg-16-pastiglie-senza-zucchero-gusto-menta","title":"Neo Borocillina Gola Dolore 8.75mg 16 sugar-free mint-flavored tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNEO BOROCILLINA THROAT PAIN mouthwash \/ NEO BOROCILLINA THROAT PAIN spray for oral mucosa is used in the symptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy. NEO BOROCILLINA THROAT PAIN tablets are used in the symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eNEO BOROCILLINA THROAT PAIN 0.25% mouthwash and NEO BOROCILLINA THROAT PAIN 0.25% spray for oral mucosa (all presentations) \u003c\/u\u003e 100 ml of solution contains: \u003cb\u003eActive ingredient:\u003c\/b\u003e Flurbiprofen 0.25 g. \u003cb\u003eExcipients with known effects:\u003c\/b\u003e ethanol 9.60 g; liquid sorbitol (non-crystallizable) 7.00 g; methyl-p-hydroxybenzoate 0.10 g; propyl-p-hydroxybenzoate 0.02 g; glycerol 10 g; sodium 6.8 mg. NEO BOROCILLINA THROAT PAIN 0.25% orange and honey flavor oral mucosa spray and NEO BOROCILLINA THROAT PAIN 0.25% lemon and honey flavor oral mucosa spray also contain the excipient with the known effect sunset yellow (E110): 100 ml of solution contains: sunset yellow (E110): 0.014 g (presentation 0.25% orange and honey flavor oral mucosa spray); 0.006 g (presentation 0.25% lemon and honey flavor oral mucosa spray) For the complete list of excipients, see paragraph 6.1 \u003cu\u003eNEO BOROCILLINA THROAT PAIN 8.75 mg lozenges (all presentations)\u003c\/u\u003e One tablet contains: \u003cb\u003eActive ingredient: \u003c\/b\u003e Flurbiprofen 8.75 mg. \u003cb\u003eExcipients with known effects\u003c\/b\u003e: glycerol 20 mg; isomalt 931.45 mg (orange and honey flavour); 936.45 mg (lemon and honey flavour); 913.25 mg (mint flavour). For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eMint flavored mouthwash and oral mucosa spray\u003c\/u\u003e \u003c\/i\u003e \u003cb\u003eGlycerol\u003c\/b\u003e, ethyl alcohol (\u003cb\u003eethanol\u003c\/b\u003e 96%), \u003cb\u003esorbitol\u003c\/b\u003e liquid (non-crystallizable), \u003cb\u003ecastor oil\u003c\/b\u003e hydrogenated 40 polyoxyethylene, \u003cb\u003esodium\u003c\/b\u003e hydroxide, saccharin \u003cb\u003esodium\u003c\/b\u003e, \u003cb\u003emethyl-p-hydroxybenzoate, propyl-p-hydroxybenzoate,\u003c\/b\u003e tri-rectified mint essential oil, patent blue V (E 131), citric acid, purified water. \u003ci\u003e \u003cu\u003eLemon and honey flavored oral mucosa spray \u003c\/u\u003e \u003c\/i\u003e Glycerol, ethyl alcohol (\u003cb\u003eethanol\u003c\/b\u003e 96%), \u003cb\u003esorbitol\u003c\/b\u003e liquid (non-crystallizable), \u003cb\u003ecastor oil\u003c\/b\u003e hydrogenated 40 polyoxyethylene, \u003cb\u003esodium\u003c\/b\u003e hydroxide, saccharin \u003cb\u003esodium\u003c\/b\u003e, \u003cb\u003emethyl -p-hydroxybenzoate,\u003c\/b\u003e \u003cb\u003epropyl-p-hydroxybenzoate,\u003c\/b\u003e honey flavour, lemon flavour, mint flavour, \u003cb\u003esunset yellow (E110\u003c\/b\u003e), citric acid, purified water. \u003ci\u003e \u003cu\u003eOrange and honey flavored oral mucosa spray \u003c\/u\u003e \u003c\/i\u003e \u003cb\u003eGlycerol\u003c\/b\u003e, ethyl alcohol (\u003cb\u003eethanol\u003c\/b\u003e 96%), \u003cb\u003esorbitol\u003c\/b\u003e liquid (non-crystallizable), \u003cb\u003ecastor oil\u003c\/b\u003e hydrogenated 40 polyoxyethylene, \u003cb\u003esodium\u003c\/b\u003e hydroxide, saccharin \u003cb\u003esodium\u003c\/b\u003e, \u003cb\u003emethyl -p-hydroxybenzoate,\u003c\/b\u003e \u003cb\u003epropyl-p-hydroxybenzoate\u003c\/b\u003e, honey flavour, orange flavour, mint flavour, \u003cb\u003esunset yellow (E110)\u003c\/b\u003e, citric acid, purified water. \u003ci\u003e \u003cu\u003eMint flavored sugar-free lozenges\u003c\/u\u003e \u003c\/i\u003e \u003cb\u003eGlycerol\u003c\/b\u003e dibeenate, acesulfame potassium, balsamic mint aroma, \u003cb\u003eisomalt\u003c\/b\u003e, copovidone. \u003ci\u003e \u003cu\u003eSugar-free lemon and honey flavored lozenges\u003c\/u\u003e \u003c\/i\u003e \u003cb\u003eGlycerol\u003c\/b\u003e dibeenate, acesulfame potassium, lemon honey flavour, \u003cb\u003eisomalt\u003c\/b\u003e, copovidone. \u003ci\u003e \u003cu\u003eOrange and honey flavored sugar-free lozenges\u003c\/u\u003e \u003c\/i\u003e \u003cb\u003eGlycerol\u003c\/b\u003e dibeenate, acesulfame potassium, honey orange flavour, \u003cb\u003eisomalt\u003c\/b\u003e, copovidone.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFlurbiprofen is contraindicated in patients with hypersensitivity (asthma, bronchospasm, urticaria or allergic type) towards flurbiprofen or to any of the excipients, and towards acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Third trimester of pregnancy. The administration of flurbiprofen is not recommended in breastfeeding mothers. Do not use in patients who have peptic ulcers or who have had them in the past. \u003ci\u003e \u003cu\u003eDo not give the tablets to children under the age of 12\u003c\/u\u003e \u003c\/i\u003e \u003ci\u003e \u003cu\u003eyears.\u003c\/u\u003e \u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eMouthwash\u003c\/u\u003e \u003c\/i\u003e The recommended dose is 2-3 rinses or gargles per day with 10 ml of mouthwash (using the appropriate measuring cup), diluted in half a glass of water or pure. \u003ci\u003e \u003cu\u003eSpray for oral mucosa\u003c\/u\u003e \u003c\/i\u003e The recommended dose is 2 sprays 3 times a day aimed directly at the affected part; each spray delivers 0.2 ml of solution, equivalent to 0.5 mg of active ingredient.\u003ci\u003e \u003cu\u003ePads\u003c\/u\u003e \u003c\/i\u003e Adults and children over 12 years of age: 1 tablet to dissolve slowly in the mouth every 3-6 hours, as needed. Do not exceed the dose of 8 tablets in 24 hours. Do not administer to children under 12 years of age. For elderly people, no changes in dosage are necessary.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMouthwash and oral mucosa spray: No particular storage conditions. Tablets: Store at temperatures not exceeding 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not, in itself, cause any harm to the patient, as these doses are widely lower than those commonly used in treatments with flurbiprofen systemically. In patients with renal, cardiac or hepatic insufficiency, the medicine NEO BOROCILLINA THROAT PAIN should be used with caution. It is recommended not to combine the medicine with NSAIDs. Use of the product, especially if prolonged, can give rise to local sensitization or irritation phenomena; in such cases it is necessary to interrupt the treatment and consult the doctor to institute, if necessary, a suitable therapy. Do not use for prolonged treatments. After a short period of treatment without appreciable results, consult your doctor. \u003cb\u003eNEO BOROCILLINA THROAT PAIN mouthwash and NEO BOROCILLINA THROAT PAIN spray for oral mucosa (all presentations) contain:\u003c\/b\u003e - 960 mg of ethanol per 10 ml of mouthwash. May cause burning sensation on damaged skin. - hydrogenated polyoxide castor oil which may cause localized skin reactions. - parahydroxy benzoates which can cause allergic reactions (even delayed). NEO BOROCILLINA THROAT PAIN 0.25% spray for oral mucosa orange and honey flavor and NEO BOROCILLINA THROAT PAIN 0.25% spray for oral mucosa lemon and honey flavor also contain the coloring sunset yellow (E110), which can cause allergic reactions.NEO BOROCILLINA THROAT PAIN 8.75 mg lozenges (all presentations) contains isomalt: patients suffering from rare hereditary problems of intolerance to fructose, you should not take this medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHowever, inform your doctor if you are taking other medicines. As demonstrated in some clinical studies, flurbiprofen may occasionally reduce the diuretic activity of furosemide. Furthermore, flurbiprofen may occasionally interfere with the action of anticoagulant drugs. However, no interaction of flurbiprofen with digoxin, tolbutamide and antacids has been demonstrated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of NEO BOROCILLINA THROAT PAIN, especially if prolonged, can give rise to sensitization or local irritation phenomena; in such cases it is necessary to interrupt the treatment and institute, if necessary, a suitable therapy. The following side effects have been reported, particularly after the administration of higher doses systemically: \u003ci\u003e \u003cu\u003ePathologies of the blood and lymphatic system\u003c\/u\u003e \u003c\/i\u003e Thrombocytopenia, aplastic anemia and agranulocytosis. \u003ci\u003e \u003cu\u003eImmune system disorders\u003c\/u\u003e \u003c\/i\u003e Anaphylaxis, angioedema, allergic reaction. \u003ci\u003e \u003cu\u003eNervous system disorders\u003c\/u\u003e \u003c\/i\u003e Dizziness, cerebrovascular accident, visual disturbances, optic neuritis, migraine, paraesthesia, depression, confusion, hallucination, vertigo, discomfort, fatigue and drowsiness. \u003ci\u003e \u003cu\u003eEar and labyrinth disorders\u003c\/u\u003e \u003c\/i\u003e Tinnitus. \u003ci\u003e \u003cu\u003eRespiratory, thoracic and mediastinal disorders\u003c\/u\u003e \u003c\/i\u003e Reactivity of the respiratory tract (asthma, bronchospasm and dyspnea). \u003ci\u003e \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e \u003c\/i\u003e The most commonly observed adverse events are gastrointestinal in nature. The following have been reported after administration of flurbiprofen: nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melena, haematemesis, ulcerative stomatitis, gastrointestinal haemorrhage and exacerbation of colitis and Crohn's disease. Less frequently, gastritis, peptic ulcer, perforation and ulcer bleeding have been observed. \u003ci\u003e \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e \u003c\/i\u003e Skin disorders including rash, pruritus, urticaria, purpura and very rarely bullous dermatoses (including Stevens-Johnson syndrome, Toxic Epidermal Necrolysis and Erythema multiforme). \u003ci\u003e \u003cu\u003eRenal and urinary disorders\u003c\/u\u003e \u003c\/i\u003e Nephrotoxicity in various forms, including interstitial nephritis and nephrotic syndrome. As with other NSAIDs, rare cases of renal failure have been reported. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWith the use of NEO BOROCILLINA THROAT PAIN it is rare for overdose situations to occur. \u003ci\u003e \u003cu\u003eSymptoms\u003c\/u\u003e \u003c\/i\u003e Symptoms of overdose may include nausea, vomiting, and gastrointestinal irritation. \u003ci\u003e \u003cu\u003eTreatment\u003c\/u\u003e \u003c\/i\u003e Treatment should include gastric lavage and, if necessary, correction of the serum electrolyte picture. There is no specific antidote for flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDuring the first and second trimester of pregnancy, flurbiprofen should not be administered unless strictly necessary. The medicine administered during pregnancy can delay the onset of labor and increase its duration. The administration of flurbiprofen is not recommended in breastfeeding mothers.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine does not alter the ability to drive or use machines.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51131307360583,"sku":"035760040","price":9.77,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-neo-borocillina-gola-dolore-8-75mg-16-pastiglie-senza-zucchero-gusto-menta-farmacia-dottor-tili-1213792156.jpg?v=1767135047"},{"product_id":"licky-caramelle-baby-tosse-gola-fragola","title":"Licky baby cough\/throat strawberry sweets","description":"\u003cp\u003eLe \u003cstrong\u003eLicky baby cough\/throat strawberry sweets\u003c\/strong\u003e they are the ideal solution for the well-being of the throat of the little ones. These candies are formulated with a combination of \u003cstrong\u003emedicinal herbs\u003c\/strong\u003e e \u003cstrong\u003eIcelandic lichen\u003c\/strong\u003e, known for their soothing and emollient properties. The delicious \u003cstrong\u003estrawberry flavour\u003c\/strong\u003e makes these sweets particularly appreciated by children, transforming the moment of relief into a pleasant experience.\u003c\/p\u003e\n\u003cp\u003eThanks to their composition, Licky baby candies are perfect for alleviating discomfort related to \u003cstrong\u003ecough\u003c\/strong\u003e and to \u003cstrong\u003esore throat\u003c\/strong\u003e, offering natural and delicate support. The practical format of 24 sweets is ideal for always carrying with you, guaranteeing immediate relief at any time of the day.\u003c\/p\u003e\n\u003cp\u003eLicky candies are a \u003cstrong\u003esupplement for children\u003c\/strong\u003e which combines effectiveness and taste, making them a precious ally for parents looking for a safe and natural product for the well-being of their children.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy should you use Licky baby cough\/throat strawberry sweets? What is it for?\u003c\/h3\u003e\u003cp\u003eStrawberry flavored sweets based on medicinal herbs and Icelandic lichen, with soothing and emollient properties, designed for the well-being of children's throats in case of irritated throats.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings for Licky baby strawberry cough\/throat sweets?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eLegal warnings\u003c\/strong\u003e\u003cbr\u003eDo not exceed the recommended daily dose.\u003cbr\u003eKeep out of reach of children under three years of age.\u003cbr\u003eSupplements are not intended as substitutes for a varied and balanced diet and a healthy lifestyle.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Licky baby cough\/throat strawberry sweets?\u003c\/h3\u003e\u003cp\u003eCase of 24 candies.\u003c\/p\u003e","brand":"Fitobucaneve","offers":[{"title":"Default Title","offer_id":51131314405703,"sku":"930366137","price":6.7,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/fitobucaneve-srl-licky-caramelle-baby-tosse-gola-fragola-farmacia-dottor-tili-1213792122.jpg?v=1767135869"},{"product_id":"dequadin-0-25mg-20-compresse","title":"Dequadin 0.25mg 20 tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTablets: Topical treatment in angina, stomatitis, pharyngitis and tonsillitis. After tooth extractions DEQUADIN tablets are useful for the prophylaxis of infections. Spray for oral mucosa and solution for oral mucosa: Topical treatment in gingivitis, stomatitis, tonsillitis, pharyngitis. After tooth extractions DEQUADIN spray and solution for oral mucosa are useful for the prophylaxis of infections.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDEQUADIN 0.25 mg tablets Each tablet contains: Active ingredient: dequalinium chloride 0.25 mg. Excipients: sucrose, glucose. DEQUADIN 0.5% solution for oral mucosa 100 ml of solution for oral mucosa contains: Active ingredient: dequalinium chloride 0.5 g. DEQUADIN 0.5% spray for oral mucosa 100 ml of spray for oral mucosa contains: Active ingredient: dequalinium chloride 0.5 g. \u003cu\u003eExcipients with known effects\u003c\/u\u003e: DEQUADIN 0.25 mg tablets contain sucrose and glucose. DEQUADIN 0.5% solution for oral mucosa and DEQUADIN 0.5% spray for oral mucosa contain propylene glycol. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDEQUADIN 0.25 tablets Sucrose, citric acid monohydrate, gelatin, glucose, magnesium stearate, mint essence, lime aroma DEQUADIN 0.5% solution for oral mucosa DEQUADIN 0.5% spray for oral mucosa Propylene glycol, ethyl alcohol, saccharin, purified water, benzyl alcohol, pink aroma, geranium essential oil\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. In children under three years of age, especially if predisposed to laryngospasm or convulsions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDEQUADIN tablets: Adults: slowly dissolve one tablet in the mouth every two or three hours during the initial phase of treatment, at a later time the interval can be increased. Children over three years of age: 3 to 4 tablets per day. DEQUADIN solution for oral mucosa and DEQUADIN spray for oral mucosa: Adults: apply locally every 2–3 hours: use a brush or a cotton ball wrapped around a stick or the appropriate spray nozzle in the 10 ml bottle. Children over three years of age: 2 to 5 local applications per day. To dispense the solution with the spray: a) press the button on the dispensing pump several times until the spray is obtained; b) direct the diffusion tube and apply the product on the area to be treated. In the topical treatment of infections of medium or mild severity, the use of DEQUADIN can be used. Solution for oral mucosa, for gargle or for mouthwash: dilute 10-20 drops of solution in a glass of water and apply 3 times a day. It is advisable to keep your mouth open and not swallow saliva for a few minutes after applying the solution: this will ensure maximum therapeutic effectiveness. Do not exceed the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore at room temperature (8 – 30° C) and in a dry place.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially if prolonged, of products for topical use can give rise to sensitization phenomena; if this occurs, treatment must be suspended and suitable therapy instituted. The same applies in the event of the development of resistant microorganisms. Spray for oral mucosa and solution for oral mucosa: use should be limited to lesions of the mouth and throat.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAvoid the simultaneous use of other antiseptics and detergents.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of the medicine may cause local irritation\u003cb\u003e.\u003c\/b\u003e Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo reports of overdose.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known contraindications.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot applicable.\u003c\/p\u003e","brand":"Eurospital","offers":[{"title":"Default Title","offer_id":51131334066503,"sku":"012235040","price":8.28,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/eurospital-spa-dequadin-0-25mg-20-compresse-farmacia-dottor-tili-1213792052.jpg?v=1767137387"},{"product_id":"neo-borocillina-tosse-10mg-1-2mg-20-pastiglie","title":"Neo Borocillina Cough 10mg + 1.2mg 20 tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCough sedative and oropharyngeal antiseptic.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEvery \u003ci\u003etablet\u003c\/i\u003e contains: - DEXTROMETHORPHAN BROMYDRATE 10 mg (adsorbed on magnesium trisilicate) - 2,4-DICHLOROBENZYL ALCOHOL 1.2 mg \u003ci\u003eExcipients with known effects\u003c\/i\u003e: aspartame (E 951), compressible sugar For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFreshflavor aroma, ammonium glycyrrhizinate, magnesium stearate, aspartame (E 951), copovidone, compressible sugar.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients. Bronchial asthma, COPD, pneumonia, breathing difficulties, respiratory depression, cardiovascular diseases, hypertension, hyperthyroidism, diabetes, glaucoma, prostatic hypertrophy, gastrointestinal and urogenital stenosis, epilepsy, serious liver diseases. Do not administer to children under 12 years of age. Do not use at the same time as or in the two weeks following treatment with MAO inhibitor antidepressant drugs. Pregnancy, particularly in the first trimester, breastfeeding (see section 4.6).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdults and children over 12 years of age: slowly dissolve one tablet in the mouth every 2-3 hours, up to a daily maximum of 8 tablets. Do not exceed the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn case of irritating cough with significant mucus production (e.g. in patients suffering from pathologies such as bronchiectasis and cystic fibrosis) or in patients suffering from neurological diseases associated with a marked reduction of the cough reflex (such as stroke, Parkinson's disease and dementia), treatment with Neo Borocillin Cough Lozenges as a cough sedative should be administered with particular caution and only on medical advice after a careful risk-benefit assessment (see section 4.5). There is limited information on the use of dextromethorphan in patients with impaired hepatic or renal function. Therefore, Neo Borocillin Cough Lozenges should be administered with caution in such patients, especially in patients with severe impairment. Dextromethorphan is metabolised by hepatic cytochrome P450 2D6. The activity of this enzyme is genetically determined. Approximately 10% of the population slowly metabolizes CYP2D6. Exaggerated and\/or prolonged effects of dextromethorphan may occur in poor metabolizers and patients with concomitant use of CYP2D6 inhibitors. Caution is therefore necessary in patients who are poor metabolisers of CYP2D6 or who use CYP2D6 inhibitors (see also section 4.5). Due to the potential release of histamine, the use of Neo Borocillin Cough Lozenges should be avoided in case of mastocytosis. A chronic cough can be an early symptom of asthma and therefore Neo Borocillin Cough Lozenges is not indicated for the suppression of chronic cough, particularly in children. Neo Borocillin Cough Lozenges should be used with caution in patients taking serotonergic drugs (other than MAO inhibitor drugs), such as selective serotonin reuptake inhibitors (SSRIs) (e.g. fluoxetine, paroxetine) or tricyclic antidepressant drugs (see section 4.5). The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt the treatment and consult the doctor for the purposes of instituting any suitable therapy. After 5-7 days of treatment, without appreciable results, consult your doctor. \u003cu\u003eImportant information about some excipients\u003c\/u\u003e Contains 1.386 g of sucrose (sugar) per tablet. To be taken into consideration in people suffering from diabetes mellitus. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. The product contains aspartame, a source of phenylalanine (see paragraph 4.3). It is inadvisable to consume alcohol during therapy. Dextromethorphan may be slightly habit-forming. Following prolonged use (e.g. exceeding the recommended treatment period), patients may develop tolerance to the medicine, as well as mental and physical dependence. Cases of abuse of dextromethorphan have been reported. Particular caution is recommended with adolescents and young adults, as well as with patients with a history of drug or psychoactive substance abuse. Patients with a tendency towards abuse or dependence must take Neo Borocillin Cough for short periods and under close medical supervision.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDextromethorphan has weak serotonergic properties. Dextromethorphan may therefore lead to an increased risk of serotonin toxicity (serotonin syndrome), especially when taken together with other serotonergic agents, such as MAO inhibitor drugs or SSRIs or tricyclic antidepressants. Especially pre-treatment or concomitant treatment with drugs that compromise the metabolism of serotonin, such as antidepressant drugs of the MAO inhibitor type, can induce the development of a serotonin syndrome with the following characteristic symptoms: neuromuscular hyperactivity (e.g. tremor, clonic spasm, myoclonus, increased reflex response and rigidity of pyramidal origin), hyperactivity of the autonomic nervous system (e.g. diaphoresis, fever, tachycardia, tachypnoea, mydriasis) and altered mental status (e.g. agitation, excitation, confusion) (see section 4.3 (MAO inhibitor drugs) and 4.4). Concomitant administration of drugs with an inhibitory effect on the central nervous system such as hypnotics, sedatives or anxiolytics, or the intake of alcohol, may lead to additive effects. If dextromethorphan is used in combination with mucolytics in patients with pre-existing respiratory tract diseases, such as cystic fibrosis and bronchiectasis, suffering from mucus hypersecretion, the reduction of the cough reflex may lead to a (severe) accumulation of mucus. \u003cb\u003eCYP2D6 inhibitors\u003c\/b\u003e Dextromethorphan is metabolised by CYP2D6 and has extensive first pass metabolism. Concomitant use of strong inhibitors of the CYP2D6 enzyme can increase dextromethorphan concentrations in the body to levels many times higher than the normal value. This increases the patient's risk for toxic effects of dextromethorphan (agitation, confusion, tremor, insomnia, diarrhea, and respiratory depression) and for the development of serotonin syndrome. Potent inhibitors of CYP2D6 are fluoxetine, paroxetine, quinidine, terbinafine, cimetidine, ritonavir, berberine. In concomitant use with quinidine, plasma concentrations of dextromethorphan are increased up to 20-fold, resulting in increased adverse central nervous system effects of the agent. Amiodarone, flecainide and propafenone, sertraline, bupropion, methadone, cinacalcet, haloperidol, perphenazine and thioridazine also have similar effects on the metabolism of dextromethorphan. If concomitant use of CYP2D6 inhibitors and dextromethorphan is necessary, the patient should be monitored and the dose of dextromethorphan may need to be reduced.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eThere is insufficient data to establish the frequency of the listed effects\u003c\/u\u003e. \u003cb\u003e \u003ci\u003eImmune system disorders\u003c\/i\u003e \u003c\/b\u003e Hypersensitivity reactions (including anaphylactic reaction, angioedema, urticaria, pruritus, rash and erythema) \u003cb\u003e \u003ci\u003eMetabolism and nutrition disorders\u003c\/i\u003e \u003c\/b\u003e Reduced appetite \u003cb\u003e \u003ci\u003ePsychiatric disorders\u003c\/i\u003e \u003c\/b\u003e Hallucinations Dextromethorphan abuse and dependence \u003cb\u003e \u003ci\u003eNervous system disorders\u003c\/i\u003e \u003c\/b\u003e Drowsiness \u003cb\u003e \u003ci\u003eEar and labyrinth disorders\u003c\/i\u003e \u003c\/b\u003e Dizziness \u003cb\u003e \u003ci\u003eRespiratory, thoracic and mediastinal disorders\u003c\/i\u003e \u003c\/b\u003e Respiratory depression \u003cb\u003e \u003ci\u003eGastrointestinal disorders\u003c\/i\u003e \u003c\/b\u003e Nausea, vomiting, gastrointestinal disorders \u003cb\u003e \u003ci\u003eSystemic pathologies and conditions relating to the administration site\u003c\/i\u003e \u003c\/b\u003e Fatigue \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http:\/\/www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSymptoms\u003c\/b\u003e In case of overdose, the known side effects may occur with greater frequency or severity: nausea, vomiting, visual disturbances and central nervous system disorders such as ataxia, dizziness, excitation, increased muscle tone, states of mental confusion, drowsiness, hypotension and tachycardia. In extreme cases, urinary retention and respiratory depression may occur. \u003cb\u003eTreatment\u003c\/b\u003e If necessary, resort to intensive medical care (in particular intubation, ventilation). Precautions may be necessary to safeguard heat loss and replenish fluids. Intravenous administration of naloxone can antagonize the effects of dextromethorphan on the central nervous system. If necessary, perform gastric lavage with \u003ci\u003estable circulation\u003c\/i\u003e. Do not administer centrally acting emetics.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNeo Borocillin Cough Lozenges should not be used during the first three months of pregnancy; in the following months the drug must be administered only in case of actual need and under the direct supervision of the doctor. Since the excretion of the drug in breast milk is not known and a respiratory depressive effect on the newborn cannot be excluded, Neo Borocillin Cough Lozenges is contraindicated during breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the product can cause drowsiness and\/or dizziness (especially in conjunction with the intake of alcohol or other medicines which can reduce reaction times), this must be taken into account by those who may drive motor vehicles or carry out operations requiring an intact level of vigilance.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51131342225735,"sku":"027081049","price":10.51,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-neo-borocillina-tosse-10mg-1-2mg-20-pastiglie-farmacia-dottor-tili-1213792006.jpg?v=1767149267"},{"product_id":"benactivdol-gola-8-75mg-dose-spray-15ml","title":"Benactivdol Throat 8.75mg\/dose spray 15ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenactivdol Throat is indicated for the short-term symptomatic treatment of acute pain in sore throat in adults.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne spray contains 2.92 mg of Flurbiprofen, three \u003cb\u003edisbursements\u003c\/b\u003e equal to one dose contain 8.75 mg, corresponding to 16.2 mg\/ml of Flurbiprofen Excipients with known effects: Methyl parahydroxybenzoate (E218) 1.18 mg\/dose Propyl parahydroxybenzoate (E216) 0.24 mg\/dose Flavors containing allergens (mint flavor and cherry flavor) For the complete list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBetadex Dibasic sodium phosphate dodecahydrate Citric acid monohydrate Methyl parahydroxybenzoate (E218) Propyl parahydroxybenzoate (E216) Sodium hydroxide Mint flavor Cherry flavor N,2,3-Trimethyl-2-isopropylbutanamide Sodium saccharin (E954) Hydroxypropylbetadex Purified water Qualitative composition of the flavor Mint: Flavoring substances Flavoring preparation Propylene glycol E1520 Glyceryl triacetate (Triacetin) E1518 Qualitative composition of the flavor Cherry: Flavoring substances Flavoring preparation Propylene glycol E1520 Water\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. • Patients who have previously experienced hypersensitivity reactions (e.g. asthma, bronchospasm, rhinitis, angioedema or urticaria) in response to acetylsalicylic acid or other NSAIDs. • Patients with current or previous recurrent peptic ulcers\/haemorrhages (two or more distinct episodes of demonstrated ulceration) and intestinal ulceration. • Patients with a history of gastrointestinal bleeding or perforation, severe colitis, bleeding or haematopoietic disorders related to previous therapy with NSAIDs. • Last trimester of pregnancy (see section 4.6). • Severe heart failure, renal failure or hepatic failure (see section 4.4). • Children and adolescents under the age of 18.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDosage Only for short-term treatments. Indicated for adults over 18 years of age: One dose (3 sprays) directed to the affected part of the throat every 3-6 hours as needed, up to a maximum of 5 doses in a 24-hour period. \u003ci\u003ePediatric population\u003c\/i\u003e The safety and effectiveness of Benactivdol Gola in children or adolescents under 18 years of age have not been established. \u003ci\u003eElderly population\u003c\/i\u003e A general dosing recommendation cannot be given, as clinical experience to date is limited. Elderly people are at increased risk of serious consequences in case of adverse reactions. The lowest effective dose should be administered for the shortest possible duration of treatment to control symptoms (see section 4.4). Method of administration For oromucosal administration Do not inhale during delivery. This medicine should not be used for more than 3 days. Before use, it is necessary to activate the pump 4 times, pointing the nozzle away from your body, until a uniform and consistent mist is released. The pump is then ready for use. Between one use and another, dispense a minimum quantity of product, away from your body, in order to ensure that the nebulization is uniform and consistent. Before using the product, always make sure that the spray is uniform and consistent.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not refrigerate or freeze.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by using the lowest effective dose for the shortest duration of treatment needed to control symptoms. \u003cb\u003eInfections \u003c\/b\u003e Since isolated cases of exacerbation of inflammation related to infections (e.g. development of necrotizing fasciitis) have been described in temporal association with the systemic use of drugs belonging to the NSAID class, patients are recommended to immediately consult a doctor in case of appearance or worsening of signs of a bacterial infection during therapy based on flurbiprofen spray. A possible indication for starting antibiotic therapy must be taken into consideration. In case of purulent bacterial pharyngitis\/tonsillitis, the patient should consult the doctor for a re-evaluation of the treatment. Treatment should not be administered for more than 3 days. Treatment should be reevaluated if symptoms worsen or new symptoms occur. If mouth irritation develops, treatment with flurbirprofen should be discontinued. \u003cb\u003eElderly population \u003c\/b\u003e Elderly people experience an increased frequency of adverse reactions to NSAIDs, especially bleeding and gastrointestinal perforation, which can be fatal. \u003cb\u003eRespiratory disorders \u003c\/b\u003e Bronchospasm can be precipitated in patients suffering from or with a history of bronchial asthma or allergic disease, Flurbiprofen spray should be used with caution in these patients. \u003cb\u003eOther NSAIDs \u003c\/b\u003e The use of flurbiprofen spray should be avoided concomitantly with other NSAIDs, including selective cyclooxygenase-2 inhibitors (see section 4.5). \u003cb\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease \u003c\/b\u003e Patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease may be at increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for short-term use such as flurbiprofen spray. \u003cb\u003eCardiovascular, renal and hepatic impairment \u003c\/b\u003e NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and precipitate renal failure. Patients at highest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; this effect is not usually observed with products intended for short-term use such as flurbiprofen spray. \u003cb\u003eHepatic effects\u003c\/b\u003e Mild to moderate hepatic dysfunction (see sections 4.3 and 4.8). \u003cb\u003eCardiovascular and cerebrovascular effects \u003c\/b\u003e Before starting treatment in patients with a positive history of hypertension and\/or heart failure, caution is required (contact your doctor or pharmacist) since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Data from clinical and epidemiological studies suggest that the use of some NSAIDs (particularly at high doses and in long-term treatments) may be associated with a slight increase in the risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude this risk with flurbiprofen when administered at a daily dosage of less than 5 times (3 actuations for each dose). \u003cb\u003eEffects on the central nervous system \u003c\/b\u003e Headache induced by analgesics - In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003cb\u003eGastrointestinal disorders \u003c\/b\u003e NSAIDs should be administered with caution to patients with a history of gastrointestinal disorders (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Gastrointestinal bleeding, ulceration or perforation, which may be fatal, have been reported with all NSAIDs at any time during treatment, in the presence or absence of warning symptoms or a history of serious gastrointestinal events. The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing doses of NSAIDs, in patients with a history of ulcer, especially if complicated with the presence of haemorrhage or perforation (see section 4.3) and in the elderly; this effect is not usually observed with products intended for short-term use such as flurbiprofen spray. Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) to their healthcare provider. Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003cb\u003eHematological effects \u003c\/b\u003e Flurbiprofen, like other NSAIDs, can inhibit platelet aggregation and prolong bleeding time. Flurbiprofen spray should be used with caution in patients with potential bleeding abnormalities. \u003cb\u003eDermatological effects \u003c\/b\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen spray should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. This product contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions (sometimes even delayed). This medicine contains flavors containing citral, d-limonene, eugenol and linalool. Citral, d-limonene, eugenol and linalool can cause allergic reactions. This medicinal product contains less than 1 mmol sodium (23mg) per dose, i.e. essentially 'sodium-free'.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFlurbiprofen should be avoided in association with:\u003c\/p\u003e\n\u003cp\u003eOther NSAIDs including selective cyclooxygenase-2 inhibitors: Avoid concomitant use of two or more NSAIDs, as this may increase the risk of adverse effects (especially gastrointestinal adverse events such as ulcers and bleeding) (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eAcetylsalicylic acid (at low doses): Unless the intake of acetylsalicylic acid at low doses (not exceeding 75 mg\/day) has been recommended by the doctor (see section 4.4), since the potential risk of adverse events may increase.\u003c\/p\u003e\n\u003cp\u003eFlurbiprofen should be used with caution in association with:\u003c\/p\u003e\n\u003cp\u003eAnticoagulants: NSAIDs may potentiate the effects of anticoagulants such as warfarin (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eAntiplatelet agents: There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eAntihypertensive drugs (Diuretics, ACE inhibitors, Angiotensin II antagonists): NSAIDs can reduce the effect of diuretics. Other antihypertensive drugs may potentiate nephrotoxicity caused by cyclooxygenase inhibition, especially in patients with impaired renal function.\u003c\/p\u003e\n\u003cp\u003eAlcohol: May increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract.\u003c\/p\u003e\n\u003cp\u003eCardiac glycosides: NSAIDs can exacerbate heart failure, reduce VGR (glomerular filtration rate) and increase plasma levels of glycosides - adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003eCyclosporine: There is an increased risk of nephrotoxicity.\u003c\/p\u003e\n\u003cp\u003eCorticosteroids: There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eLithium: There may be an increase in serum lithium levels - adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003eMethotrexate: The administration of NSAIDs within 24 hours before or after the administration of methotrexate can lead to high concentrations of methotrexate and an increase in its toxic effects.\u003c\/p\u003e\n\u003cp\u003eMifepristone: NSAIDs should not be used for 8 - 12 days following administration of mifepristone, as NSAIDs may reduce the effect of mifepristone.\u003c\/p\u003e\n\u003cp\u003eOral antidiabetics: Alterations in blood glucose levels have been reported (increasing the frequency of checks is recommended).\u003c\/p\u003e\n\u003cp\u003ePhenytoin: Serum levels of phenytoin may increase - adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003ePotassium-sparing diuretics: Concomitant use may cause hyperkalemia.\u003c\/p\u003e\n\u003cp\u003eProbenecid and Sulfinpyrazone: Medicines containing probenecid and sulfinpyrazone may delay the excretion of flurbiprofen.\u003c\/p\u003e\n\u003cp\u003eQuinolone antibiotics: Animal data indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may be at increased risk of developing seizures.\u003c\/p\u003e\n\u003cp\u003eSelective serotonin reuptake inhibitors (SSRIs): There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eTacrolimus: An increased risk of nephrotoxicity is possible when NSAIDs are administered concomitantly with tacrolimus.\u003c\/p\u003e\n\u003cp\u003eZidovudine: There is an increased risk of hematological toxicity when NSAIDs are administered with zidovudine.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePediatric population \u003c\/b\u003e No additional information is available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis (b) respiratory tract reactivity, e.g. asthma, asthma aggravated, bronchospasm, dyspnoea (c) various skin reactions, e.g. pruritus, urticaria, angioedema and, more rarely, exfoliative and bullous dermatosis (including epidermal necrolysis and erythema multiforme). Edema, hypertension and heart failure have been reported in association with treatment with NSAIDs. Data are insufficient to exclude this risk following the use of flurbiprofen oral mucosal spray, solution. \u003cb\u003eThe list of adverse effects reported below refers to the clinical evaluation carried out with flurbiprofen, used short term and at doses compatible with the OTC classification.\u003c\/b\u003e (Very common (≥1\/10), Common (≥1\/100 to \u003c1\/10), Uncommon (≥1\/1000 to \u003c1\/100), Rare (≥1\/10000 to \u003c1\/1000), Very rare (\u003c1\/10000), not known (frequency cannot be estimated from the available data)). \u003ci\u003ePathologies of the blood and lymphatic system\u003c\/i\u003e Not known: Anemia, Thrombocytopenia. \u003ci\u003eCardiac and vascular pathologies\u003c\/i\u003e Not known: Edema, Hypertension, Heart failure. \u003ci\u003eNervous system disorders\u003c\/i\u003e Common: Dizziness, Headache, Paraesthesia. Uncommon: Drowsiness. \u003ci\u003eRespiratory, thoracic and mediastinal disorders\u003c\/i\u003e Common: Throat irritation. Uncommon: exacerbation of asthma and bronchospasm, dyspnoea, wheezing, formation of blisters at the oropharyngeal level, pharyngeal hypoesthesia. \u003ci\u003eGastrointestinal disorders\u003c\/i\u003e Common: Diarrhoea, Mouth ulceration, Nausea, Oral pain, Oral paraesthesia, Oropharyngeal pain, Oral discomfort (hot or burning sensation, tingling in the mouth). Uncommon: Abdominal distension, Abdominal pain, Constipation, Dry mouth, Dyspepsia, Flatulence, Glossodynia, Dysgeusia, Oral dysesthesia, Vomiting. \u003ci\u003ePathologies of the skin and subcutaneous tissue\u003c\/i\u003e Uncommon: Skin rashes of various types, Itching. Not known: Severe skin reactions such as bullous reactions, including Stevens-Johnson Syndrome and Toxic Epidermal Necrosis. \u003ci\u003eSystemic pathologies and conditions relating to the administration site\u003c\/i\u003e Uncommon: Pyrexia, Pain. \u003ci\u003eImmune system disorders\u003c\/i\u003e Rare: Anaphylactic reaction. \u003ci\u003ePsychiatric disorders\u003c\/i\u003e Uncommon: Insomnia. \u003ci\u003eHepatobiliary disorders\u003c\/i\u003e Not known: Hepatitis \u003cb\u003eReporting of suspected adverse reactions \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioniavverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSymptoms\u003c\/b\u003e The majority of patients who have ingested clinically large quantities of NSAIDs will develop nausea, vomiting, epigastric pain, or more rarely diarrhea. Tinnitus, headache and gastrointestinal bleeding are also possible. In more severe cases of NSAID intoxication, central nervous system toxicity is observed, manifested by drowsiness, occasionally excitability, blurred vision and disorientation or coma. Occasionally patients develop seizures. In case of severe NSAID intoxication, metabolic acidosis may occur and the prothrombin time\/INR may be prolonged, probably due to interference with the action of coagulation factors present in circulation. Acute renal failure and liver damage may occur. An exacerbation of asthma is possible in asthmatic subjects. \u003cb\u003eTreatment \u003c\/b\u003e Treatment should be symptomatic and supportive and should include maintaining a patent airway and monitoring cardiac function and vital signs until stabilization. Oral administration of activated charcoal or gastric lavage and, if necessary, correction of serum electrolytes should be considered if the patient presents within one hour of ingesting a potentially toxic amount. Seizures should be treated with intravenous diazepam or lorazepam if they are frequent or prolonged. Administer bronchodilators for asthma. There is no specific antidote for flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy \u003c\/b\u003e Inhibition of prostaglandin synthesis can negatively influence pregnancy and\/or embryonic\/fetal development. Data obtained from epidemiological studies suggest an increased risk of miscarriage, cardiac malformations and gastroschisis following the use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiovascular malformations was increased from less than 1% to approximately 1.5%. The risk is thought to increase with the dose and duration of therapy. In animals, the administration of a prostaglandin synthesis inhibitor has been shown to cause an increase in pre- and post-implantation losses and embryo-foetal lethality. In addition, an increased incidence of several malformations, including cardiovascular ones, has been reported in animals administered a prostaglandin synthesis inhibitor during the organogenetic period. Flurbiprofen must not be administered during the first and second trimester of pregnancy. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose • the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction which may progress to renal failure with oligo-hydramnios. • the mother and newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, an anti-aggregating effect which can occur even at very low doses. - inhibition of uterine contractions resulting in a delay or prolongation of labor. Consequently, flurbiprofen is contraindicated during the third trimester of pregnancy (see section 4.3). \u003cb\u003eBreastfeeding \u003c\/b\u003e In a limited number of studies, flurbiprofen appears in breast milk at very low concentrations and is unlikely to have negative effects on the breastfed infant. However, due to the possible adverse effects of NSAIDs on breast-fed infants, the use of flurbiprofen spray by breastfeeding mothers is not recommended. \u003cb\u003eFertility \u003c\/b\u003e There is evidence to suggest that cyclooxygenase\/prostaglandin synthesis inhibitors may cause impairment of female fertility through an effect on ovulation. This is reversible upon discontinuation of treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo studies on the effects on the ability to drive and use machines have been performed. Dizziness, drowsiness and visual disturbances are side effects that can arise following the intake of NSAIDs. If these effects occur, patients should not drive or use machinery.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51131346420039,"sku":"043050018","price":12.93,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-benactivdol-gola-8-75mg-dose-spray-15ml-farmacia-dottor-tili-1213791987.jpg?v=1767149609"},{"product_id":"sedo-calcio-soluzione-100ml","title":"Sedo Calcium solution 100ml","description":"\u003cp\u003e\u003cstrong\u003eSedo Calcium solution 100ml\u003c\/strong\u003e is an innovative product designed to keep the upper respiratory tract clean through the mechanical removal of catarrhal secretions. Thanks to its unique formulation, this solution not only lubricates and cleans the oropharyngeal cavity, but also creates a protective film that offers a barrier against irritants such as fine dust, smoke and smog. This makes it especially useful during times of flu and colds, when the airways are most vulnerable.\u003c\/p\u003e\n\n\u003cp\u003eThe composition of \u003cstrong\u003eSedo Football\u003c\/strong\u003e includes ingredients such as glycerin, sucrose, sodium benzoate, calcium lactate, EDTA, menthol, anise essence and cinnamon, which work synergistically to ensure effective and gentle action. Menthol and anise and cinnamon essences give the solution a pleasant and refreshing aroma, improving the experience of use.\u003c\/p\u003e\n\n\u003cp\u003eIdeal for \u003cstrong\u003efumigate\u003c\/strong\u003e, steam inhalations and gargles, Sedo Calcio solution 100ml is a precious ally for those looking for a natural and safe method to relieve the symptoms of congested airways. Its versatility makes it suitable for different modes of use, offering quick and long-lasting relief. Available in a handy 100ml bottle, it is perfect for home use and easy to take with you wherever you go.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy use Sedo Calcium solution 100ml? What is it for?\u003c\/h3\u003e\u003cp\u003eSolution for cleaning and lubricating the oropharyngeal cavity and upper respiratory tract, indicated for the mechanical removal of catarrhal secretions; it forms a protective film against fine dust, smoke and smog, particularly useful during periods of flu and colds.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Sedo Calcium solution 100ml contain?\u003c\/h3\u003e\u003cp\u003eGlycerin, sucrose, sodium benzoate, calcium lactate, EDTA, menthol, anise essence, cinnamon essence, purified water.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Sedo Calcium solution 100ml?\u003c\/h3\u003e\u003cp\u003e- Fuments\/fumigations: the prepared solution must not be used for subsequent applications.\u003cbr\u003eAdults: dilute three tablespoons of calcium sedum in 1 liter of hot water, inhale the vapors for about 5 minutes; maximum four applications daily.\u003cbr\u003e- Steam inhalations:\u003cbr\u003eAdults: three tablespoons of sedo calcium diluted in 500 ml of hot water; maximum two applications daily.\u003cbr\u003e- Gargling:\u003cbr\u003eAdults: one tablespoon in half a glass of water; maximum four\/five applications daily.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Sedo Calcium solution 100ml?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eDo not use the product without first diluting it. Do not use if hypersensitive or allergic to any of the components. Contact a doctor if there is hypersensitivity to the components. Keep out of reach of children. Avoid contact with eyes. In case of accidental contact, wash eyes with plenty of water. Do not ingest. Do not use for more than 3 consecutive days. Do not administer to children.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Sedo Calcium solution 100ml stored?\u003c\/h3\u003e\u003cp\u003eStore at room temperature, in a cool, dry place and away from heat sources. Do not use the device after the expiry date indicated on the packaging. The expiry date refers to the product in intact packaging, correctly stored.\u003cbr\u003eValidity with intact packaging: 36 months.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Sedo Calcium solution 100ml?\u003c\/h3\u003e\u003cp\u003e100 ml bottle.\u003c\/p\u003e","brand":"Deca Laboratorio Chimico","offers":[{"title":"Default Title","offer_id":51131362935111,"sku":"938989288","price":16.84,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/deca-laboratorio-chimico-srl-sedo-calcio-soluzione-100ml-farmacia-dottor-tili-1213791925.jpg?v=1767141730"},{"product_id":"neo-borocillina-gola-dolore-8-75mg-32-pastiglie-senza-zucchero-gusto-menta","title":"Neo Borocillina Gola Dolore 8.75mg 32 sugar-free mint-flavored tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNEO BOROCILLINA THROAT PAIN mouthwash \/ NEO BOROCILLINA THROAT PAIN spray for oral mucosa is used in the symptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy. NEO BOROCILLINA THROAT PAIN tablets are used in the symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eNEO BOROCILLINA THROAT PAIN 0.25% mouthwash and NEO BOROCILLINA THROAT PAIN 0.25% spray for oral mucosa (all presentations) \u003c\/u\u003e 100 ml of solution contains: \u003cb\u003eActive ingredient:\u003c\/b\u003e Flurbiprofen 0.25 g. \u003cb\u003eExcipients with known effects:\u003c\/b\u003e ethanol 9.60 g; liquid sorbitol (non-crystallizable) 7.00 g; methyl-p-hydroxybenzoate 0.10 g; propyl-p-hydroxybenzoate 0.02 g; glycerol 10 g; sodium 6.8 mg. NEO BOROCILLINA THROAT PAIN 0.25% orange and honey flavor oral mucosa spray and NEO BOROCILLINA THROAT PAIN 0.25% lemon and honey flavor oral mucosa spray also contain the excipient with the known effect sunset yellow (E110): 100 ml of solution contains: sunset yellow (E110): 0.014 g (presentation 0.25% orange and honey flavor oral mucosa spray); 0.006 g (presentation 0.25% lemon and honey flavor oral mucosa spray) For the complete list of excipients, see paragraph 6.1 \u003cu\u003eNEO BOROCILLINA THROAT PAIN 8.75 mg lozenges (all presentations)\u003c\/u\u003e One tablet contains: \u003cb\u003eActive ingredient: \u003c\/b\u003e Flurbiprofen 8.75 mg. \u003cb\u003eExcipients with known effects\u003c\/b\u003e: glycerol 20 mg; isomalt 931.45 mg (orange and honey flavour); 936.45 mg (lemon and honey flavour); 913.25 mg (mint flavour). For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eMint flavored mouthwash and oral mucosa spray\u003c\/u\u003e \u003c\/i\u003e \u003cb\u003eGlycerol\u003c\/b\u003e, ethyl alcohol (\u003cb\u003eethanol\u003c\/b\u003e 96%), \u003cb\u003esorbitol\u003c\/b\u003e liquid (non-crystallizable), \u003cb\u003ecastor oil\u003c\/b\u003e hydrogenated 40 polyoxyethylene, \u003cb\u003esodium\u003c\/b\u003e hydroxide, saccharin \u003cb\u003esodium\u003c\/b\u003e, \u003cb\u003emethyl-p-hydroxybenzoate, propyl-p-hydroxybenzoate,\u003c\/b\u003e tri-rectified mint essential oil, patent blue V (E 131), citric acid, purified water. \u003ci\u003e \u003cu\u003eLemon and honey flavored oral mucosa spray \u003c\/u\u003e \u003c\/i\u003e Glycerol, ethyl alcohol (\u003cb\u003eethanol\u003c\/b\u003e 96%), \u003cb\u003esorbitol\u003c\/b\u003e liquid (non-crystallizable), \u003cb\u003ecastor oil\u003c\/b\u003e hydrogenated 40 polyoxyethylene, \u003cb\u003esodium\u003c\/b\u003e hydroxide, saccharin \u003cb\u003esodium\u003c\/b\u003e, \u003cb\u003emethyl -p-hydroxybenzoate,\u003c\/b\u003e \u003cb\u003epropyl-p-hydroxybenzoate,\u003c\/b\u003e honey flavour, lemon flavour, mint flavour, \u003cb\u003esunset yellow (E110\u003c\/b\u003e), citric acid, purified water. \u003ci\u003e \u003cu\u003eOrange and honey flavored oral mucosa spray \u003c\/u\u003e \u003c\/i\u003e \u003cb\u003eGlycerol\u003c\/b\u003e, ethyl alcohol (\u003cb\u003eethanol\u003c\/b\u003e 96%), \u003cb\u003esorbitol\u003c\/b\u003e liquid (non-crystallizable), \u003cb\u003ecastor oil\u003c\/b\u003e hydrogenated 40 polyoxyethylene, \u003cb\u003esodium\u003c\/b\u003e hydroxide, saccharin \u003cb\u003esodium\u003c\/b\u003e, \u003cb\u003emethyl -p-hydroxybenzoate,\u003c\/b\u003e \u003cb\u003epropyl-p-hydroxybenzoate\u003c\/b\u003e, honey flavour, orange flavour, mint flavour, \u003cb\u003esunset yellow (E110)\u003c\/b\u003e, citric acid, purified water. \u003ci\u003e \u003cu\u003eMint flavored sugar-free lozenges\u003c\/u\u003e \u003c\/i\u003e \u003cb\u003eGlycerol\u003c\/b\u003e dibeenate, acesulfame potassium, balsamic mint aroma, \u003cb\u003eisomalt\u003c\/b\u003e, copovidone. \u003ci\u003e \u003cu\u003eSugar-free lemon and honey flavored lozenges\u003c\/u\u003e \u003c\/i\u003e \u003cb\u003eGlycerol\u003c\/b\u003e dibeenate, acesulfame potassium, lemon honey flavour, \u003cb\u003eisomalt\u003c\/b\u003e, copovidone. \u003ci\u003e \u003cu\u003eOrange and honey flavored sugar-free lozenges\u003c\/u\u003e \u003c\/i\u003e \u003cb\u003eGlycerol\u003c\/b\u003e dibeenate, acesulfame potassium, honey orange flavour, \u003cb\u003eisomalt\u003c\/b\u003e, copovidone.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFlurbiprofen is contraindicated in patients with hypersensitivity (asthma, bronchospasm, urticaria or allergic type) towards flurbiprofen or to any of the excipients, and towards acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Third trimester of pregnancy. The administration of flurbiprofen is not recommended in breastfeeding mothers. Do not use in patients who have peptic ulcers or who have had them in the past. \u003ci\u003e \u003cu\u003eDo not give the tablets to children under the age of 12\u003c\/u\u003e \u003c\/i\u003e \u003ci\u003e \u003cu\u003eyears.\u003c\/u\u003e \u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eMouthwash\u003c\/u\u003e \u003c\/i\u003e The recommended dose is 2-3 rinses or gargles per day with 10 ml of mouthwash (using the appropriate measuring cup), diluted in half a glass of water or pure. \u003ci\u003e \u003cu\u003eSpray for oral mucosa\u003c\/u\u003e \u003c\/i\u003e The recommended dose is 2 sprays 3 times a day aimed directly at the affected part; each spray delivers 0.2 ml of solution, equivalent to 0.5 mg of active ingredient.\u003ci\u003e \u003cu\u003ePads\u003c\/u\u003e \u003c\/i\u003e Adults and children over 12 years of age: 1 tablet to dissolve slowly in the mouth every 3-6 hours, as needed. Do not exceed the dose of 8 tablets in 24 hours. Do not administer to children under 12 years of age. For elderly people, no changes in dosage are necessary.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMouthwash and oral mucosa spray: No particular storage conditions. Tablets: Store at temperatures not exceeding 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not, in itself, cause any harm to the patient, as these doses are widely lower than those commonly used in treatments with flurbiprofen systemically. In patients with renal, cardiac or hepatic insufficiency, the medicine NEO BOROCILLINA THROAT PAIN should be used with caution. It is recommended not to combine the medicine with NSAIDs. Use of the product, especially if prolonged, can give rise to local sensitization or irritation phenomena; in such cases it is necessary to interrupt the treatment and consult the doctor to institute, if necessary, a suitable therapy. Do not use for prolonged treatments. After a short period of treatment without appreciable results, consult your doctor. \u003cb\u003eNEO BOROCILLINA THROAT PAIN mouthwash and NEO BOROCILLINA THROAT PAIN spray for oral mucosa (all presentations) contain:\u003c\/b\u003e - 960 mg of ethanol per 10 ml of mouthwash. May cause burning sensation on damaged skin. - hydrogenated polyoxide castor oil which may cause localized skin reactions. - parahydroxy benzoates which can cause allergic reactions (even delayed). NEO BOROCILLINA THROAT PAIN 0.25% spray for oral mucosa orange and honey flavor and NEO BOROCILLINA THROAT PAIN 0.25% spray for oral mucosa lemon and honey flavor also contain the coloring sunset yellow (E110), which can cause allergic reactions.NEO BOROCILLINA THROAT PAIN 8.75 mg lozenges (all presentations) contains isomalt: patients suffering from rare hereditary problems of intolerance to fructose, you should not take this medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHowever, inform your doctor if you are taking other medicines. As demonstrated in some clinical studies, flurbiprofen may occasionally reduce the diuretic activity of furosemide. Furthermore, flurbiprofen may occasionally interfere with the action of anticoagulant drugs. However, no interaction of flurbiprofen with digoxin, tolbutamide and antacids has been demonstrated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of NEO BOROCILLINA THROAT PAIN, especially if prolonged, can give rise to sensitization or local irritation phenomena; in such cases it is necessary to interrupt the treatment and institute, if necessary, a suitable therapy. The following side effects have been reported, particularly after the administration of higher doses systemically: \u003ci\u003e \u003cu\u003ePathologies of the blood and lymphatic system\u003c\/u\u003e \u003c\/i\u003e Thrombocytopenia, aplastic anemia and agranulocytosis. \u003ci\u003e \u003cu\u003eImmune system disorders\u003c\/u\u003e \u003c\/i\u003e Anaphylaxis, angioedema, allergic reaction. \u003ci\u003e \u003cu\u003eNervous system disorders\u003c\/u\u003e \u003c\/i\u003e Dizziness, cerebrovascular accident, visual disturbances, optic neuritis, migraine, paraesthesia, depression, confusion, hallucination, vertigo, discomfort, fatigue and drowsiness. \u003ci\u003e \u003cu\u003eEar and labyrinth disorders\u003c\/u\u003e \u003c\/i\u003e Tinnitus. \u003ci\u003e \u003cu\u003eRespiratory, thoracic and mediastinal disorders\u003c\/u\u003e \u003c\/i\u003e Reactivity of the respiratory tract (asthma, bronchospasm and dyspnea). \u003ci\u003e \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e \u003c\/i\u003e The most commonly observed adverse events are gastrointestinal in nature. The following have been reported after administration of flurbiprofen: nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melena, haematemesis, ulcerative stomatitis, gastrointestinal haemorrhage and exacerbation of colitis and Crohn's disease. Less frequently, gastritis, peptic ulcer, perforation and ulcer bleeding have been observed. \u003ci\u003e \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e \u003c\/i\u003e Skin disorders including rash, pruritus, urticaria, purpura and very rarely bullous dermatoses (including Stevens-Johnson syndrome, Toxic Epidermal Necrolysis and Erythema multiforme). \u003ci\u003e \u003cu\u003eRenal and urinary disorders\u003c\/u\u003e \u003c\/i\u003e Nephrotoxicity in various forms, including interstitial nephritis and nephrotic syndrome. As with other NSAIDs, rare cases of renal failure have been reported. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWith the use of NEO BOROCILLINA THROAT PAIN it is rare for overdose situations to occur. \u003ci\u003e \u003cu\u003eSymptoms\u003c\/u\u003e \u003c\/i\u003e Symptoms of overdose may include nausea, vomiting, and gastrointestinal irritation. \u003ci\u003e \u003cu\u003eTreatment\u003c\/u\u003e \u003c\/i\u003e Treatment should include gastric lavage and, if necessary, correction of the serum electrolyte picture. There is no specific antidote for flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDuring the first and second trimester of pregnancy, flurbiprofen should not be administered unless strictly necessary. The medicine administered during pregnancy can delay the onset of labor and increase its duration. The administration of flurbiprofen is not recommended in breastfeeding mothers.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine does not alter the ability to drive or use machines.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51131368603975,"sku":"035760065","price":12.93,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-neo-borocillina-gola-dolore-8-75mg-32-pastiglie-senza-zucchero-gusto-menta-farmacia-dottor-tili-1213791892.jpg?v=1767150251"},{"product_id":"gastrotuss-sciroppo-500ml","title":"Gastrotuss syrup 500ml","description":"\u003cp\u003eThe \u003cstrong\u003eGastrotuss syrup 500ml\u003c\/strong\u003e is a CE medical device designed for the treatment of \u003cstrong\u003egastroesophageal reflux\u003c\/strong\u003e and\/or pharyngolaryngeal. This anti-reflux syrup is formulated to relieve symptoms associated with reflux, such as \u003cstrong\u003eacid or basic regurgitation\u003c\/strong\u003e, the \u003cstrong\u003eheartburn\u003c\/strong\u003e (heartburn), the feeling of \u003cstrong\u003ehypopharyngeal globe\u003c\/strong\u003e (foreign body in the throat), and the \u003cstrong\u003ecough\u003c\/strong\u003e. Furthermore, it is useful in cases of \u003cstrong\u003edysphonia\u003c\/strong\u003e (voice alteration) e \u003cstrong\u003enasopharyngeal inflammation\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThanks to its mechanical action, Gastrotuss helps to reduce the residence time of gastric contents in the stomach, favoring the re-epithelialization processes of the gastroesophageal and pharyngolaryngeal mucosa. Its formulation includes ingredients such as \u003cstrong\u003emagnesium alginate\u003c\/strong\u003e e \u003cstrong\u003esimethicone\u003c\/strong\u003e, known for their beneficial properties in treating reflux. The product is free of \u003cstrong\u003egluten and lactose\u003c\/strong\u003e, making it also suitable for those with food intolerances.\u003c\/p\u003e\n\n\u003cp\u003eGastrotuss syrup is available in a practical \u003cstrong\u003e500 ml bottle\u003c\/strong\u003e with measuring spoon, ideal for prolonged use and to ensure precise dosing. This product is particularly suitable for those looking for an effective and safe treatment for the symptoms of gastroesophageal reflux, improving the quality of daily life. Choose Gastrotuss for quick and long-lasting relief from the discomfort of reflux.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy use Gastrotuss syrup 500ml? What is it for?\u003c\/h3\u003e\u003cp\u003eThe \u003cstrong\u003eGastrotuss syrup 500ml\u003c\/strong\u003e is a CE medical device designed for the treatment of \u003cstrong\u003egastroesophageal reflux\u003c\/strong\u003e and\/or pharyngolaryngeal. This anti-reflux syrup is formulated to relieve symptoms associated with reflux, such as \u003cstrong\u003eacid or basic regurgitation\u003c\/strong\u003e, the \u003cstrong\u003eheartburn\u003c\/strong\u003e (heartburn), the feeling of \u003cstrong\u003ehypopharyngeal globe\u003c\/strong\u003e (foreign body in the throat), and the \u003cstrong\u003ecough\u003c\/strong\u003e. Furthermore, it is useful in cases of \u003cstrong\u003edysphonia\u003c\/strong\u003e (voice alteration) e \u003cstrong\u003enasopharyngeal inflammation\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Gastrotuss syrup 500ml contain?\u003c\/h3\u003e\u003cp\u003eMagnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis and Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, sodium methyl p-oxybenzoate, sodium propyl p-oxybenzoate, natural flavors, erythrosine (E127), purified water.\u003c\/p\u003e\u003cp\u003eWithout \u003cstrong\u003egluten and lactose\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Gastrotuss syrup 500ml?\u003c\/h3\u003e\u003cp\u003eShake vigorously before use. Adults and children over 12 years: 20 ml after main meals and at bedtime or according to different medical advice.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Gastrotuss syrup 500ml?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eDo not use the product in case of known hypersensitivity to the components of the product.\u003cbr\u003eTo take it during pregnancy or during the breastfeeding period, consult your doctor.\u003cbr\u003eThe product can be more or less viscous, without any deterioration in its quality.\u003cbr\u003eThe presence of natural substances can affect the organoleptic characteristics of the product; variations in color and\/or flavor can therefore be detected without any deterioration in its quality.\u003cbr\u003eIn case of adverse reactions, discontinue use of the product and consult your doctor.\u003cbr\u003eDo not exceed the recommended doses, follow the instructions for use.\u003cbr\u003eIt is advisable to leave an interval of at least one hour between taking Gastrotuss and taking medications.\u003cbr\u003eDo not use the product if the packaging is not intact or has been tampered with. Tampering and\/or lack of integrity of the packaging could compromise the safety requirements of the product itself.\u003cbr\u003eDo not use the product after the expiry date indicated on the package.\u003cbr\u003eKeep out of the sight and reach of children.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Gastrotuss syrup 500ml stored?\u003c\/h3\u003e\u003cp\u003eStore at temperatures not exceeding 30°C.\u003cbr\u003eClose the bottle tightly after use.\u003cbr\u003eThe expiry date refers to the product in intact packaging, correctly stored.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Gastrotuss syrup 500ml?\u003c\/h3\u003e\u003cp\u003e500 ml bottle with measuring spoon.\u003c\/p\u003e","brand":"Dmg Italia","offers":[{"title":"Default Title","offer_id":51131382923591,"sku":"900489360","price":18.1,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/d-m-g-italia-srl-gastrotuss-sciroppo-500ml-farmacia-dottor-tili-1213791701.png?v=1767144469"},{"product_id":"faringotricina-2-5-mg-20-compresse-orosolubili","title":"Faringothricin 2.5 mg 20 buccal tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTopical therapy of stomatitis of bacterial origin.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne orodispersible tablet contains: thyrothricin 2.5 mg. Excipients with known effects: glucose 20 mg, lactose 275 mg and sucrose 467 mg. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMenthol – Corn starch – Gum arabic – Glucose – Lactose – Magnesium stearate – Sucrose.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e Allow 1 tablet to slowly dissolve in your mouth every ½ – 1 hour. Continue treatment for two or more days. Do not exceed the daily dosage of 10 tablets.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUse of the product, especially if prolonged, can give rise to sensitization phenomena. In this case it is necessary to interrupt the treatment and institute adequate therapy: similar treatment must be observed in the event of the development of infections caused by non-susceptible germs. \u003cu\u003ePediatric population\u003c\/u\u003e In very early childhood the product should be administered in cases of actual need, under the direct supervision of the doctor. \u003cb\u003ePHARYNGOTRICIN\u003c\/b\u003e \u003cb\u003econtains glucose, lactose and sucrose. \u003c\/b\u003ePatients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known interactions with other medicines.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince thyrothricin is poorly absorbed by the mucous membranes, the possibility of allergic reactions is reduced. Rarely, blackening of the tongue, glossitis, sensitization reactions may occur. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo phenomena of overdose are known as the poor absorption of thyrothricin through the mucous membranes reduces the possibility of toxic phenomena at the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn pregnant and breastfeeding women, the product should be administered in cases of actual need, under the direct supervision of a doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePHARYNGOTRICIN does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Sit Laboratorio Farmaceutico","offers":[{"title":"Default Title","offer_id":51730207211847,"sku":"022801017","price":8.55,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sit-laboratorio-farmac-srl-faringotricina-2-5-mg-20-compresse-orosolubili-farmacia-dottor-tili-1213791099.jpg?v=1767140267"},{"product_id":"benactivdolmed-8-75-mg-dose-15-ml-spray-orale-limone-e-miele","title":"BenactivDolMed 8.75 mg\/dose 15 ml lemon and honey oral spray","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenactivdolmed is indicated for the short-term symptomatic treatment of acute pain in sore throat in adults.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne spray contains 2.92 mg of Flurbiprofen, a dose equal to three sprays contains 8.75 mg of Flurbiprofen, corresponding to 16.2 mg\/ml of Flurbiprofen. \u003cu\u003eExcipients with known effect:\u003c\/u\u003e Methyl parahydroxy benzoate (E218) 1.181 mg\/dose Propyl parahydroxy benzoate (E216) 0.2362 mg\/dose Flavorings contain allergens (lemon flavoring and honey flavouring) For the complete list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBetadex, Disodium phosphate dodecahydrate, Citric acid monohydrate, Methyl parahydroxybenzoate (E218), Propyl parahydroxybenzoate (E216), Sodium hydroxide, Honey flavouring, Lemon flavouring, N,2,3-Trimethyl-2-isopropylbutanamide, Sodium saccharin (E954), Hydroxypropylbetadex, Purified water. Qualitative composition of Honey aroma: Flavoring substance(s), Flavoring preparation(s), Propylene glycol (E1520). Qualitative composition of the Lemon flavour: Flavoring substance(s), Flavoring preparation(s), Propylene glycol (E1520).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. • Patients who have previously experienced hypersensitivity reactions (e.g. asthma, bronchospasm, rhinitis, angioedema or urticaria) in response to acetylsalicylic acid or other NSAIDs. • Current or previous peptic ulcer\/recurrent hemorrhage (two or more distinct episodes of demonstrated ulceration) and intestinal ulceration. • History of gastrointestinal bleeding or perforation, severe colitis, bleeding or haematopoietic disorders related to previous therapy with NSAIDs. • Last trimester of pregnancy (see section 4.6). • Severe heart failure, severe renal failure or severe hepatic failure (see section 4.4). • Children and adolescents under the age of 18.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e: Only for short-term treatments. Adults aged 18 and over: one dose (3 sprays) administered to the back of the throat every 3-6 hours as needed, up to a maximum of 5 doses in a 24-hour period. \u003cb\u003ePediatric population\u003c\/b\u003e: The safety and effectiveness of Benactivdolmed in children or adolescents under 18 years of age have not been established. \u003cb\u003eElderly patients\u003c\/b\u003e: A general dosage recommendation cannot be given, as clinical experience to date is limited. Elderly people are at increased risk of serious consequences in case of adverse reactions. The lowest effective dose should be administered for the shortest duration of treatment needed to control symptoms (see section 4.4). \u003cu\u003eMethod of administration\u003c\/u\u003e: For oromucosal administration. Do not inhale while dispensing. This medicine should be used for a maximum of 3 days. Before first use, activate the pump, pointing the nozzle away from your body and spraying at least four times, until a fine, uniform mist is released. The pump is then activated and ready for use. Between uses, point the nozzle away from your body and dispense a minimum amount of product, in order to ensure that the atomization is fine and uniform. Before using the product, always make sure that the spray is fine and uniform.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not refrigerate or freeze.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by using the lowest effective dose for the shortest duration of treatment needed to control symptoms. \u003cu\u003eInfections\u003c\/u\u003e: Since an exacerbation of infectious inflammations (e.g. development of necrotizing fasciitis) has been described in isolated cases in temporal association with the systemic use of drugs belonging to the NSAID class, the patient is recommended to immediately consult a doctor in the event of the appearance or worsening of signs of a bacterial infection during therapy with flurbiprofen spray. Consideration should be given to whether initiation of antibiotic therapy is indicated. In case of purulent bacterial pharyngitis\/tonsillitis, the patient is advised to consult the doctor for a re-evaluation of the treatment. Treatment should be administered for a maximum of 3 days. If symptoms worsen or new symptoms appear, treatment should be reevaluated. If mouth irritation occurs, treatment with flurbirprofen should be discontinued. \u003cu\u003eElderly population\u003c\/u\u003e: Elderly people experience an increased frequency of adverse reactions to NSAIDs, especially bleeding and gastrointestinal perforation, which may be fatal. \u003cu\u003eRespiratory effects\u003c\/u\u003e: Bronchospasm may be precipitated in patients with or with a previous history of bronchial asthma or allergic disease. Flurbiprofen spray should be used with caution in these patients. \u003cu\u003eOther NSAIDs\u003c\/u\u003e: The use of flurbiprofen spray should be avoided concomitantly with other NSAIDs, including selective cyclooxygenase-2 inhibitors (see section 4.5). \u003cu\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease\u003c\/u\u003e: Patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease may have an increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for limited and short-term use such as flurbiprofen spray. \u003cu\u003eCardiovascular, renal and hepatic impairment\u003c\/u\u003e: NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and precipitate renal failure. Patients at greatest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; however, this effect is not usually seen with products intended for limited, short-term use such as flurbiprofen spray. \u003cu\u003eHepatic effects\u003c\/u\u003e: Mild to moderate hepatic dysfunction (see sections 4.3 and 4.8). \u003cu\u003eCardiovascular and cerebrovascular effects\u003c\/u\u003e: Before starting treatment in patients with a history of hypertension and\/or heart failure, caution is required (contact your doctor or pharmacist) since fluid retention, hypertension and edema have been reported in association with NSAID therapy. Clinical studies and epidemiological data suggest that the use of some NSAIDs (particularly at high doses and in long-term treatment) may be associated with a slight increase in the risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude this risk with flurbiprofen when administered at a daily dose not exceeding 5 doses (3 actuations for each dose). \u003cu\u003eEffects on the nervous system\u003c\/u\u003e: Headache induced by analgesics - In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003cu\u003eGastrointestinal effects\u003c\/u\u003e: NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Gastrointestinal bleeding, ulceration or perforation, which may be fatal, have been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a prior history of serious gastrointestinal events. The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing doses of NSAIDs, in patients with a history of ulcer, especially if complicated by haemorrhage or perforation (see section 4.3) and in the elderly; however, this effect is not usually observed with products intended for short-term limited use such as flurbiprofen spray. Patients with a history of gastrointestinal toxicity, particularly if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) to their doctor. Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). If gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003cu\u003eHematological effects\u003c\/u\u003e: Flurbiprofen, like other NSAIDs, can inhibit platelet aggregation and prolong bleeding time. Flurbiprofen spray should be used with caution in patients with potential for abnormal bleeding. \u003cu\u003eDermatological effects\u003c\/u\u003e: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen spray should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. This product contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions (sometimes delayed). This product contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially “sodium-free”. Flavors containing allergens: This product contains flavors containing anisilic alcohol, citral, citronellol, d-Limonene, geraniol and linalool. Anisilic alcohol, citral, citronellol, d-Limonene, geraniol, linalool can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFlurbiprofen should be avoided in association with:\u003c\/p\u003e\n\u003cp\u003eOther NSAIDs including selective cyclooxygenase-2 inhibitors: Avoid concomitant use of two or more NSAIDs, as this may increase the risk of adverse effects (especially gastrointestinal adverse events such as ulcers and bleeding) (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eAcetylsalicylic acid (low doses): Unless taking low doses of aspirin (not exceeding 75 mg\/day) has been recommended by your doctor, as the risk of adverse events may increase (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eFlurbiprofen should be used with caution in association with:\u003c\/p\u003e\n\u003cp\u003eAnticoagulants: NSAIDs may potentiate the effects of anticoagulants such as warfarin (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eAntiplatelet agents: There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eAntihypertensive drugs (Diuretics, ACE inhibitors, angiotensin II antagonists): NSAIDs can reduce the effect of diuretics and other antihypertensive drugs can potentiate the nephrotoxicity caused by the inhibition of cyclooxygenase, especially in patients with impaired renal function.\u003c\/p\u003e\n\u003cp\u003eAlcohol: May increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract.\u003c\/p\u003e\n\u003cp\u003eCardiac glycosides: NSAIDs can exacerbate heart failure, reduce VGR (glomerular filtration rate) and increase plasma levels of glycosides - adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003eCyclosporine: There is an increased risk of nephrotoxicity.\u003c\/p\u003e\n\u003cp\u003eCorticosteroids: There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eLithium: There may be an increase in serum lithium levels - adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003eMethotrexate: The administration of NSAIDs within 24 hours before or after the administration of methotrexate can lead to high concentrations of methotrexate and an increase in its toxic effects.\u003c\/p\u003e\n\u003cp\u003eMifepristone: NSAIDs should not be used for 8 - 12 days after administration of mifepristone, as NSAIDs may reduce the effect of mifepristone.\u003c\/p\u003e\n\u003cp\u003eOral antidiabetics: Alterations in blood glucose levels have been reported (increasing the frequency of checks is recommended).\u003c\/p\u003e\n\u003cp\u003ePhenytoin: Serum levels of phenytoin may increase - adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003ePotassium-sparing diuretics: Concomitant use may cause hyperkalemia.\u003c\/p\u003e\n\u003cp\u003eProbenecid and Sulfinpyrazone: Medicines containing probenecid and sulfinpyrazone may delay the excretion of flurbiprofen.\u003c\/p\u003e\n\u003cp\u003eQuinolone antibiotics: Animal data indicate that NSAIDs may increase the risk of seizures associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may be at increased risk of developing seizures.\u003c\/p\u003e\n\u003cp\u003eSelective serotonin reuptake inhibitors (SSRIs): There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eTacrolimus: An increased risk of nephrotoxicity is possible when NSAIDs are administered concomitantly with tacrolimus.\u003c\/p\u003e\n\u003cp\u003eZidovudine: There is an increased risk of haematological toxicity when NSAIDs are administered concomitantly with zidovudine.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePediatric population\u003c\/u\u003e: No additional information available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis; (b) respiratory tract reactivity, e.g. asthma, aggravated asthma, bronchospasm, dyspnoea; (c) various skin reactions, e.g. pruritus, urticaria, angioedema and, more rarely, exfoliative and bullous dermatosis (including epidermal necrolysis and erythema multiforme). Edema, hypertension and heart failure have been reported in association with treatment with NSAIDs. Data are insufficient to exclude this risk with the use of flurbiprofen oral mucosal spray, solution. \u003cb\u003eThe list of adverse effects reported below refers to those recorded with flurbiprofen, used at doses compatible with the OTC classification and for a short period\u003c\/b\u003e. (Very common (≥1\/10), Common (≥1\/100 to \u003c1\/10), Uncommon (≥1\/1,000 to \u003c1\/100), Rare (≥1\/10,000 to \u003c1\/1,000), Very rare (\u003c1\/10,000), Not known (cannot be estimated from the available data)). \u003ci\u003ePathologies of the blood and lymphatic system\u003c\/i\u003e. Not known: anemia, thrombocytopenia. \u003ci\u003eCardiovascular and cerebrovascular diseases\u003c\/i\u003e. Not known: edema, hypertension, heart failure. \u003ci\u003eNervous system disorders\u003c\/i\u003e. Common: dizziness, headache, paraesthesia; Uncommon: drowsiness. \u003ci\u003eRespiratory, thoracic and mediastinal disorders\u003c\/i\u003e. Common: throat irritation; Uncommon: exacerbation of asthma and bronchospasm, dyspnoea, wheezing, oropharyngeal vesicular rash, hypoesthesia of the pharynx. \u003ci\u003eGastrointestinal disorders\u003c\/i\u003e. Common: diarrhoea, mouth ulceration, nausea, oral pain, oral paraesthesia, oropharyngeal pain, oral discomfort (warm or burning sensation, tingling in the mouth); Uncommon: abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysesthesia, vomiting. \u003ci\u003ePathologies of the skin and subcutaneous tissue\u003c\/i\u003e. Uncommon: various types of skin rashes, itching; Not known: severe forms of skin reactions such as bullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrosis. \u003ci\u003eGeneral pathologies and conditions relating to the administration site\u003c\/i\u003e. Uncommon: pyrexia, pain. \u003ci\u003eImmune system disorders\u003c\/i\u003e. Rare: anaphylactic reaction. \u003ci\u003ePsychiatric disorders\u003c\/i\u003e. Uncommon: insomnia. \u003ci\u003eHepatobiliary disorders\u003c\/i\u003e. Not known: hepatitis. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSymptoms\u003c\/b\u003e The majority of patients who have ingested clinically significant quantities of NSAIDs will no longer develop nausea, vomiting, epigastric pain, or more rarely diarrhea. Tinnitus, headache, and gastrointestinal bleeding are also possible. In cases of more severe NSAID intoxication, central nervous system toxicity is observed, manifested by drowsiness, occasionally excitation, blurred vision and disorientation or coma. Occasionally patients develop seizures. In severe NSAID intoxication, metabolic acidosis may occur and the prothrombin time\/INR may be prolonged, probably due to interference with the action of circulating coagulation factors. Acute renal failure and liver damage may occur. An exacerbation of asthma is possible in asthmatic subjects. \u003cb\u003eTreatment\u003c\/b\u003e Treatment should be symptomatic and supportive and should include maintaining a patent airway and monitoring cardiac function and vital signs until stabilization. Oral administration of activated charcoal or gastric lavage and, if necessary, correction of serum electrolytes should be considered if the patient presents within one hour of ingesting a potentially toxic amount. Seizures, if they are frequent or prolonged, should be treated with intravenous diazepam or lorazepam. Administer bronchodilators for asthma. There is no specific antidote for flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e: Inhibition of prostaglandin synthesis may negatively influence pregnancy and\/or embryonic\/fetal development. Data obtained from epidemiological studies suggest an increased risk of miscarriage, cardiac malformation and gastroschisis following the use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiovascular malformation was increased from less than 1% to approximately 1.5%. The risk is thought to increase with the dose and duration of therapy. In animals, it has been shown that the administration of a prostaglandin synthesis inhibitor causes an increase in pre- and post-implantation losses and embryo-foetal lethality. In addition, an increased incidence of several malformations, including cardiovascular ones, has been reported in animals administered a prostaglandin synthesis inhibitor during the organogenetic period. Flurbiprofen should not be administered during the first and second trimester of pregnancy. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose • the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction which may progress to renal failure with oligo-hydramnios; • the mother and newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, an anti-aggregating effect which can occur even at very low doses. - inhibition of uterine contractions resulting in a delay or prolongation of labor. Consequently, flurbiprofen is contraindicated during the third trimester of pregnancy (see section 4.3). \u003cu\u003eBreastfeeding\u003c\/u\u003e: In a limited number of studies, flurbiprofen appears in breast milk at very low concentrations and is unlikely to have adverse effects on the breastfed infant. However, due to the possible adverse effects of NSAIDs on breast-fed infants, the use of flurbiprofen spray by breastfeeding mothers is not recommended. \u003cu\u003eFertility\u003c\/u\u003e: There is some evidence to suggest that cyclooxygenase\/prostaglandin synthesis inhibitors may cause impairment of female fertility through an effect on ovulation. This is reversible upon discontinuation of treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo studies on the effects on the ability to drive and use machines have been performed. Dizziness, drowsiness and visual disturbances are possible side effects following the intake of NSAIDs. If these occur, the patient should not drive or use machinery.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51730210324807,"sku":"048231017","price":12.93,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-benactivdolmed-8-75-mg-dose-15-ml-spray-orale-limone-e-miele-farmacia-dottor-tili-1213791050.jpg?v=1767154809"},{"product_id":"pino-caramelle-balsamiche-60-g-tosse","title":"Pine balsamic cough sweets 60 g","description":"\u003cp\u003e\n\u003cstrong\u003ePino balsamic sweets 60 g cough\u003c\/strong\u003e they are the ideal solution for those looking for a \u003cstrong\u003equick relief from cough\u003c\/strong\u003e and come on \u003cstrong\u003ecooling disorders\u003c\/strong\u003e. These \u003cstrong\u003ebalsamic candies\u003c\/strong\u003e are formulated with a mixture of \u003cstrong\u003eherbal extracts\u003c\/strong\u003e e \u003cstrong\u003enatural flavours\u003c\/strong\u003e, including essential oil of pumilio pine, myrtle, hyssop, juniper, eucalyptus, chamomile, menthol, benzoin and hawthorn. Theirs \u003cstrong\u003enormalizing functionality\u003c\/strong\u003e helps soothe irritated throat and promote the well-being of the respiratory tract, offering a \u003cstrong\u003eintense balsamic taste\u003c\/strong\u003e which gives a pleasant sensation of freshness.\n\u003c\/p\u003e\n\u003cp\u003e\nIdeal in case of \u003cstrong\u003ecold\u003c\/strong\u003e, \u003cstrong\u003esore throat\u003c\/strong\u003e, \u003cstrong\u003ebronchitis\u003c\/strong\u003e e \u003cstrong\u003einfluence\u003c\/strong\u003e, Pino balsamic sweets are suitable for both adults and teenagers and children, thanks to their natural composition and no colourings. Perfect to always carry with you, these sweets represent a valid help for \u003cstrong\u003erelieve cough\u003c\/strong\u003e and donate \u003cstrong\u003eimmediate throat relief\u003c\/strong\u003e during the cold season or in the presence of temperature changes. Choose Pino balsamic sweets to take care of your throat in a natural and tasty way.\n\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Pino balsamic sweets 60 g cough contain?\u003c\/h3\u003e\u003cp\u003esugar, glucose syrup, flavourings: essential oil of pumilio pine, myrtle, hyssop, juniper, eucalyptus, chamomile, menthol, benzoin tincture, hawthorn extract, natural flavourings, without colourings.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Pino balsamic sweets 60 g cough?\u003c\/h3\u003e\u003cp\u003eadults: 4-8 tablets per day;\u003cbr\u003eboys: 3-6 tablets per day;\u003cbr\u003echildren: 2-4 tablets per day.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Pino balsamic sweets 60 g cough?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eLegal warnings\u003c\/strong\u003e\u003cbr\u003eDo not exceed the recommended daily dose.\u003cbr\u003eKeep out of reach of children under three years of age.\u003cbr\u003eSupplements are not intended as substitutes for a varied and balanced diet and a healthy lifestyle.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Pino balsamic sweets 60 g cough?\u003c\/h3\u003e\u003cp\u003e60 g\u003c\/p\u003e","brand":"Fitobucaneve","offers":[{"title":"Default Title","offer_id":51749064212807,"sku":"900596432","price":6.88,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/fitobucaneve-srl-pino-caramelle-balsamiche-60-g-tosse-farmacia-dottor-tili-1213791120.jpg?v=1767161509"},{"product_id":"neoborocillina-mal-di-gola-senza-zucchero-20-pastiglie","title":"NeoBorocillina Sore Throat Without Sugar 20 Tablets","description":"\u003cp\u003e\u003cstrong\u003eNeoBorocillina Sore Throat Without Sugar 20 Tablets\u003c\/strong\u003e it's a \u003cstrong\u003eantiseptic medicine for the oropharyngeal cavity\u003c\/strong\u003e in \u003cstrong\u003etablets\u003c\/strong\u003e to slowly dissolve in the mouth. Each tablet contains two active ingredients: \u003cstrong\u003e2,4-dichlorobenzyl alcohol\u003c\/strong\u003e \u003cstrong\u003e1.2 mg\u003c\/strong\u003e e \u003cstrong\u003esodium benzoate\u003c\/strong\u003e \u003cstrong\u003e20 mg\u003c\/strong\u003e, the latter equivalent to 17 mg of benzoic acid.\u003c\/p\u003e\u003cp\u003eThe\u003cstrong\u003e2,4-dichlorobenzyl alcohol\u003c\/strong\u003e is a surface antiseptic from the chlorophenol group, used in formulations for the oral cavity for its action on the bacterial load of the mucous membranes of the mouth and throat. The \u003cstrong\u003esodium benzoate\u003c\/strong\u003e it is the sodium salt of benzoic acid and supports the first with its own antiseptic activity: there are 20 mg in the tablet, corresponding to 17 mg of benzoic acid.\u003c\/p\u003e\u003cp\u003eThe wording \u003cstrong\u003esugar free\u003c\/strong\u003e this is what distinguishes these tablets from the traditional version of the range: instead of sucrose they are there \u003cstrong\u003emannitol\u003c\/strong\u003e e \u003cstrong\u003easpartame\u003c\/strong\u003e as sweeteners. They complete the formula \u003cstrong\u003ementhol\u003c\/strong\u003e, \u003cstrong\u003emint essence\u003c\/strong\u003e, \u003cstrong\u003eeucalyptol\u003c\/strong\u003e e \u003cstrong\u003ecitral\u003c\/strong\u003e, which give the tablet the fresh and balsamic note characteristic of the product.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eNeoBorocillin\u003c\/strong\u003e is a brand of \u003cstrong\u003eAlphasigma\u003c\/strong\u003e. The packaging is from \u003cstrong\u003e20 tablets\u003c\/strong\u003e in PVC, PE and PVDC blisters heat-sealed to aluminium, and the product belongs to the field of medicines for \u003cstrong\u003esore throat\u003c\/strong\u003e and for the antiseptic hygiene of \u003cstrong\u003eoropharyngeal cable\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy should you use NeoBorocillina Sore Throat Without Sugar 20 Tablets? What is it for?\u003c\/h3\u003e\u003cp\u003eAntiseptic of the oropharyngeal cavity.\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of NeoBorocillina Sore Throat Without Sugar 20 Tablets?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eActive ingredients\u003c\/strong\u003e\u003cbr\u003eEach tablet contains 2,4-dichlorobenzyl alcohol 1.2 mg and sodium benzoate 20 mg, equivalent to 17 mg of benzoic acid.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eExcipients\u003c\/strong\u003e\u003cbr\u003eMagnesium stearate, precipitated silica, menthol, mint essence, eucalyptol, citral, naefco peppermint, aspartame, polyvinylpyrrolidone K30, mannitol.\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow to take NeoBorocillin Sore Throat Without Sugar 20 Tablets?\u003c\/h3\u003e\u003cp\u003eSlowly dissolve one lozenge in your mouth every 2-3 hours, up to a daily maximum of 8 lozenges.\u003c\/p\u003e\u003cp\u003eDo not exceed the recommended doses.\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should NeoBorocillin Sore Throat Without Sugar 20 Tablets be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eContraindications\u003c\/strong\u003e\u003cbr\u003eHypersensitivity to the active substances or to any of the excipients. Contraindicated in children under two years of age, with a predisposition to laryngospasm and convulsions. Due to the presence of aspartame, the product is contraindicated in cases of phenylketonuria.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSide effects\u003c\/strong\u003e\u003cbr\u003eVery rarely: hypersensitivity reactions, feeling of dizziness, respiratory failure, glottis edema, vomiting, malaise, sweating, arm edema, pulmonary edema, eyelid edema, face edema, urticaria, haemolytic anaemia, jaundice.\u003c\/p\u003e\n\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003eWhich medicines or foods can modify the effect of NeoBorocillina Sore Throat Without Sugar 20 Lozenges?\u003c\/h3\u003e\u003cp\u003eAvoid the simultaneous use of other antiseptics.\u003c\/p\u003e\n\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003eCan NeoBorocillina Sore Throat Without Sugar 20 Lozenges be used during pregnancy and breastfeeding?\u003c\/h3\u003e\u003cp\u003eIn pregnant and breastfeeding women, the product should be administered in case of real need and under the direct supervision of a doctor.\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of NeoBorocillina Sore Throat Without Sugar 20 Tablets?\u003c\/h3\u003e\u003cp\u003eDue to the presence of menthol, the product is contraindicated in children under two years of age with a predisposition to laryngospasm and convulsions.\u003c\/p\u003e\u003cp\u003eEach tablet contains 3.22 mg of sodium, equal to 25.76 mg at the maximum daily dose.\u003c\/p\u003e\u003cp\u003eProlonged use may give rise to sensitization phenomena.\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is NeoBorocillin Sore Throat Sugar Free 20 Tablets stored?\u003c\/h3\u003e\u003cp\u003eStore at temperatures not exceeding 30 degrees centigrade.\u003c\/p\u003e\u003cp\u003eThe validity period is 5 years.\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of NeoBorocillina Sore Throat Without Sugar 20 Tablets?\u003c\/h3\u003e\u003cp\u003e20 sugar-free tablets in PVC, PE and PVDC blisters opaque with titanium dioxide, heat-sealed to aluminum foil.\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":54137676300615,"sku":"022632107","price":11.2,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-1-2-mg-20-mg-pastiglie-senza-zucchero-20-pastiglie-in-blister-pvc-pe-pvdc-al-farmacia-dottor-tili-1244017771.jpg?v=1781246021"}],"url":"https:\/\/www.dottortili.com\/en-eu\/collections\/farmaci-e-pastiglie-per-il-mal-di-gola.oembed?page=2","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}